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des-Formylflustrabromine (dFBr), isolated from the marine organism Flustra foliacea, is the first
selective, positive allosteric modulator (PAM) of α4β2 nicotinic acetylcholine receptors that
potentiates the action of the neurotransmitter acetylcholine (ACh). Most agonists for this
receptor population are not selective and can activate other nACh receptors. A selective PAM,
which activates α4β2 nACh receptors only in the presence of ACh, might find application in the
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treatment of of various neurological diseases such as Alzheimer’s disease or autism. dFBr was
examined and found to produce a biphasic dose-response curve over a wide concentration range
(i.e., potentiation at low concentration, but inhibition of the ACh-induced response at high
concentrations). Our goal was to examine various structural features of dFBr required for
potentiation; a secondary goal was to examine the same for inhibition. To understand the
structural requirements of dFBr, a systematic ‘deconstruction-reconstruction-elaboration’
approach was employed to determine the contribution of various structrual components of dFBr
to its activity at α4β2 nACh receptors. Novel compounds were synthesized and characterized.
Human α4β2 nACh receptors were expressed in Xenopus oocytes and the actions of dFBr and its
analogs were measured using a two-electrode voltage clamp technique. Dose-response curves
were obtained for the compounds in the absence and presence of 100 μM ACh. Structural
features of dFBr optimal and/or required for PAM action at 42 nACh receptors were
identified. A novel reconstructed analog with all the essential features for PAM action was
synthesized and submitted for biological testing. Elaborated analogs of dFBr further helped in
identification of various structural features important for PAM action and the inhibition of
action of ACh. The ‘deconstruction-reconstructio-elaboration’ approach identified important
structural features of dFBr that modify its actions as a PAM or an antagonist (NAM? or channel
blocker?) at α4β2 nACh receptors. This information should be useful for the subsequent design
of novel analogs to evaluate their potential for the treatment of neurological disorders associated
with ACh.

1. Introduction

Homeostasis is essential to the day-to-day biological functions of all living organisms. For
example simple ions (e.g., Na+, K+, Ca2+, Cl) play a vital role in the regulation of water inside
and outside a cell. The phenomenon of transfer of ions across the cell membrane occurs through
ion channels. The concept of ion channels evolved because of the discovery of two natural
phenomena: the discovery of the Torpedo fish and its electrofiring capabilities, and the discovery
of -bungarotoxin, a venom (found in the Taiwanese krait snake).1 These two spectacular
discoveries were the events that attracted the attention of the scientific community to ion channel
research. Ion channels are essential for the survival of all organisms including mammals.
Malfunction occurs when the normal flow of ions is disrupted which can directly affect the
reaction time of the organism to its environment.
Nicotinic acetylcholine receptors are the oldest known ion channels and have been a model for
the study of other ligand-gated ion channels.2 The nicotinic acetylcholine receptors are
pentameric in nature with varying subunits (1-10, 1-4, ,  and ) located both in the central
nervous system and the peripheral nervous system.3 The neuronal acetylcholine (nACh)
receptors are found to play a modulatory role in the brain where 42 and 7 nACh receptors
predominate, and have been implicated in various neurological disorders.4 On binding of the
neurotransmitter acetylcholine to the extracellular surface of the ion channel a conformational
change in the receptor protein occurs and enables the opening of the channel pore through which
1

ions pass.2 The long exposure of the neurotransmitter or agonist causes desensitization of the
nACh receptor.5 The desensitized receptor is the state where the affinity of the neurotransmitter
is high but the channels are closed. Problems of desensitization of the receptors and the nonselectivity of various agents across various subtypes of the nACh receptors still pose a
considerable challenge to develop agents that can modulate ACh action.6
Allosteric agents are compounds that bind to the protein/receptor and stabilize the protein in a
given conformation. Monod, Wyman and Changeux proposed the allosteric model in 1965 and
the concept has been widely investigated since then.7 Allosteric molecules can be positive
allosteric modulators (PAMs) or negative allosteric modulators (NAMs) depending on whether
they activate or inhibit neurotransmitter action.8
desFormlyflustrabromine (dFBr) was one of 22 alkaloids isolated from the marine bryozoan
Flustra foliacea and was found to be a selective PAM at the 42 nACh receptors; that is, it was
inactive alone, but potentiated the effect of ACh.9 Thus, dFBr serves as a unique lead for
structure-activity relationship studies to understand what structural features are important for its
potentiation and/or inhibition of ACh action.
The present investigation is aimed at understanding why dFBr is a PAM of ACh action at 42
nACh receptors.
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II. Background

A. RECEPTORS

1. Definition
John Newport Langley, a Cambridge physiologist, was a pioneer in the field of ‘receptor
research’ and was the first to conceptualize the idea of receptors in 1905.10 He defined the
‘receptor’ (a receptive substance) as a site where an agonist or antagonist competes with the
vehicle for the transmission of a stimulus (transduction) which brings about a physiologic
response.10 Until the 1960s the concept of drug-receptor interactions was a hypothetical scenario.
The 1965 development of the receptor-subtype specific -adrenergic receptor antagonist
propranolol established the acceptance of receptors in the pharmacological community.11

3

2. General classification
Now, according to the International Union of Pharmacology (IUPHAR) Committee on Receptor
Nomenclature and Drug Classification, a receptor is defined as “a cellular macromolecule, or an
assembly of macromolecules, that is concerned directly and specifically in chemical signaling
between and within cells”.12 A change in cell function is initiated upon interaction of a hormone,
neurotransmitter, drug, or intracellular messenger, with its receptor(s).12
The IUPHAR database classifies receptors as:
1.

G protein-coupled receptors (GPCRs)

2.

Ligand-gated ion channels (LGICs)

3.

Voltage-gated ion channels (VGICs)

4.

Nuclear hormone receptors (NHRs)

5.

Enzymes

3. Classification of ligand-gated ion channels
The concept of ion channels can be dated back to the late 1800s and the early 1900s. Prof.
Langley first observed a twitch in the muscle of a dead frog on the application of nicotine and
referred to this as fibrillar twitching.13 Hodgkin and Huxley,14,15 independently, were the first to
study nerve impulses on the neuron of the giant squid (Loligo) which is approximately 100 to
1000 times larger than the human neuron in diameter. Later, they also showed that nerve
4

conductance depends on specific ions outside and inside the nerve cell. They showed that during
nerve impulse, or the spike phase, Na+ ion inflow increases the positive potential in the cell and
causes a response while the falling phase involves K+ ions outflow.15 LGICs are transmembrane
proteins that carry out a physiological response by an ion channel which opens on binding of a
ligand.16 These are termed ‘ionotropic’ which refers to the ion-channel nature of the receptors.
The whole process of channel opening and ion-flow is a display of speed and size. The channel is
open for a few milliseconds in which thousands of ions flow through. The channel is a dynamic
pore that allows passage of ions. The pore can be a few atoms thick at its narrowest point but still
functions as a speedway for ions to go through.17 LGICs mediate action at the synapse and in a
matter of microseconds the neurotransmitter released from the nerve terminal interacts with the
target protein, and binds and triggers a physiologic response. LGIC receptors are comprised of
the following superfamilies:17,18
1.

The superfamily that resembles the nicotinic receptors.

2.

The ionotropic glutamate receptor superfamily (GluR).

3.

Adenosine triphosphate (ATP)-gated purine receptors (P2X).

The classification of LGIC receptor superfamilies is based on molecular architecture, functional
behavior, and sequence homology.19 All of the LGIC receptors share common features, such as
their location in the cell membrane, and the three key structural domains that each of them
possesses.19 The superfamily that resembles the nicotinic receptor is distinct because of the
presence of a cysteine-loop (Cys-loop) in the extracellular domain of the receptor conserved
across all the receptor populations and includes the:
5

1.

Glycine receptors (GlyRs)

2.

-Amino butyric acid receptors (GABAA and GABAC)

3.

Serotonin type 3 receptors (5-HT3 Rs)

4.

Nicotinic acetylcholine receptors (AChRs)

B. ACETYLCHOLINE AND ITS RECEPTORS

1. Acetylcholine
In 1865 Oscar Liebreich (according to Gamgee) isolated and identified a mixture of chemicals
from animal brain that was characterized for its elemental content and referred to it as
‘protagon’.20 This finding had a major impact for the next couple of decades and researchers
around the world were intrigued and started to study it more closely so as to figure out more
about this mystery chemical composite.20 Later Liebreich21,22 was able to identify neurin/choline
by treating the protagon with a barium hydroxide solution. The finding of Liebreich was
consistent with those of Baeyer who had independently synthesized choline.22 In 1914, Ewins23,24
synthesized acetylcholine which was also isolated and found to be the major component in the
extract of ergot fungus which produced an inhibitory effect on heart muscle and a stimulating
effect on intestinal muscle; both responses were abolished by atropine.24 Henry Dale25 was
responsible for identifying acetylcholine (ACh) in ergot fungus extract. Later, an extensive study
was carried out with various ethers and ester of choline and it was found that ACh was the most
6

active chemical entity that produced the effect.26 Thus, from this initial literature, it can be seen
that ACh was studied and investigated long before it was known to be a neurotransmitter. It was
only in the early 1900s that Otto Loewi identified ACh as the first neurotransmitter.26 Both
Henry Dale and Otto Loewi received the Nobel Prize in the field of Physiology or Medicine in
1936.23,25-27 Acetylcholine is, chemically, 2-acetoxy-N,N,N-trimethylethanamanium (1), which is
an acetyl derivative of choline.

Acetylcholine (1)
The cholinergic system is, phylogenetically, one of the oldest nervous pathways. The neurons
that synthesize, store, and release ACh as a neurotransmitter are called cholinergic neurons.28

2. Biosynthesis and Metabolism of ACh
In the peripheral nervous system, ACh is involved in smooth and cardiac muscle regulation as
well as skeletal muscle movement. In the central nervous system ACh is involved in chemoelectrical transduction in cholinergic synapses. ACh is synthesized (Figure 1) in the cytosol of
nerve terminals and stored in synaptic vesicles prior to exocytotic release.28 Choline
acetyltransferase is an enzyme involved in the synthesis of ACh. Choline is taken up from the
synapse by the Na+-dependent choline transporter.28 Acetyl-CoA, which is present in the nerve
terminal, along with choline, forms ACh in the presence of choline acetyltransferase. CoA is
taken up in the mitochondria and is acetylated to acetyl-CoA which is available for ACh
synthesis and the cycle continues.29 The ACh is taken up to the synaptic vesicles by the vesicular
7

ACh transporter, where it is stored.29 Upon excitation of the neuron, vesicular fusion occurs and
ACh is released into the synapse.29 The concentration of ACh in the synaptic cleft rises to around
0.1 to 1 mM for less than 1 msec.28 The released ACh interacts with postsynaptic cholinergic
receptors and triggers the relevant physiological response. ACh is metabolized in the synaptic
cleft.29 Acetylcholine esterase (AChE) is the enzyme present in the synapse that metabolizes
ACh to choline and acetate.29 Choline is taken up by the choline transporter present at the
presynaptic nerve terminal which is utilized to synthesize ACh.28 Metabolism, along with
reuptake of ACh by diffusion, rapidly allows normal physiological levels of around 10-9 M to be
attained.28,29
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Figure 1. Synthesis and metabolism of ACh adapted from a review by Niewiadomska et al.30
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3. Classification of ACh receptors
It was in the early 1900s that physiologists were able to identify that not all responses to the ACh
stimulus were identical. They then hypothesized that ACh interacts differently with the so-called
muscarinic receptors on some receptors and nicotinic receptors on others.31 These two receptor
classes were perceived to have different pharmacological properties along with different
interactions with ACh and associated postsynaptic properties.31 The early classification of ACh
receptors involved what ACh imitated, namely, the actions of muscarine and nicotine. This
finding was further confirmed with the discovery of selective agents for the two subtypes of ACh
receptors. These included nicotinic receptor-selective agents (e.g. tetramethylammonium (TMA),
dimethyl-4-phenylpiperazinium (DMPP), phenyltrimethylammonium (PTMA), suxamethonium,
and decamethonium) and muscarinic receptor-selective agents (e.g. acetyl-β-methylcholine,
oxotremorine, pilocarpine and arecoline).32 Later, it was found that nicotinic receptors could be
classified further as autonomic, which show a preferential affinity towards DMPP, and skeletal
muscle, which are more responsive to PTMA. Antagonists for ACh receptors were also
investigated to confirm the presence of three different receptor populations.32 Atropine
selectively blocked the effect of muscarinic receptors, whereas hexamethonium and
decamethonium differentiated between the autonomic and the skeletal nicotinic receptors.32
Currently, several receptor subtypes of classical ACh receptor populations have been identified.
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The ACh receptors now are classified as shown in Figure 2.

Figure 2. Classification of the ACh receptors.33,34

Muscarinic receptors are present in the central nervous system (CNS) and the peripheral nervous
system (PNS).33 The natural ligand that activates these receptor subtypes is muscarine (2) which
is a plant alkaloid found in various species of mushrooms.33 The classification of the muscarinic
receptors is based on their location and their pharmacological effect.33 All the subtypes consist of
7 transmembrane-spanning -helices and are G-protein coupled.33 The CNS effects associated
with muscarinic receptors include motor control, temperature regulation, cardiovascular
regulation, and memory.33 Peripheral effects include smooth muscle contraction, glandular
secretion, and modulation of cardiac rate and force.33 Nicotinic receptors belong to the LGIC
receptor superfamily and are ionotropic in nature.34 The natural ligand that mimics ACh is
nicotine (3) which is a plant alkaloid found in the tobacco plant,34 Nicotiana tabacum. Nicotinic
11

receptors are broadly classified on the basis of their location.34 Nicotinic receptors are present
throughout the body and are found, for example, in the PNS, CNS, skeletal muscle, lymphocytes,
and fibroblasts.34 Based on their location, they are broadly classified into neuronal and skeletal
subtypes.34 Nicotinic receptors play a vital role in mediating excitatory neurotransmission at the
neuromuscular junction, and modulation of neurotransmitter release.34

Muscarine (2)

(-)Nicotine (3)

In general, nicotinic receptors (Figure 3) are pentameric in nature consisting of 5 subunits
arranged in a bundle that forms a channel in the center.34 Upon activation by the neurotransmitter
ACh, the channel opens to allow ions to flow through. The common feature across all nicotinic
receptor subtypes is the extensive N-terminal region of around 200 amino acid residues in the
extracellular region.34 They are all comprised of four transmembrane domains (M1–M4), with
the M2 domain lining the ion pore.34 The M2 domain consists of amino acids lining the pore
which is essential for ion transport.34 A unique intracellular loop between the M3 and M4
subunits consists of 100-200 amino acids, and an extracellular C-terminus.34 The most prominent
feature of all the nicotinic receptors is a loop of 13 amino acids between two cysteine residues
forming a disulfide bridge in the N-terminal domain; thus, the name cys-loop LGIC receptors.34
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Figure 3. Schematic representation of a subunit of the nicotinic receptor adapted from Lukas et
al.34

4. Nicotinic ACh receptors
Nicotinic ACh receptors were the first neurotransmitter receptors to be characterized, purified,
and cloned.35 Elliott36 observed that a hormone present in the motor nerve ending in crossstriated muscle can activate nerve impulses in a manner comparable to adrenaline’s action on
non-striated muscle. Herring37 was able to support Elliott’s findings in the electric fish, Torpedo
mormorata, that had a high concentrations of motor nerve endings in their electrical organs that
caused an electrical firing caused by ACh due to its depolarizing action at the motor end plates.38
Also, a very high concentration of AChE was observed at the site of the electrical organ
13

implicating the presence of ACh.38 It was found that the fish contain a very high concentration of
ACh, around 40-100 g/g of fresh tissue.38

a. Types and sub-types
Unwin reported the first-ever crystal structure of a nicotinic receptor in a closed conformation at
9 Å-resolution using electron microscopy of a tubular crystal from the postsynaptic membrane of
Torpedo mormorata.39 Initially, four different skeletal muscle type subunits of nicotinic
receptors were identified, namely: 1, 1,  and  based on increasing molecular weights of the
various subunits.40 The  subunit is converted to the  subunit from the fetal to the adult
subtype.40 Cloning and purification of various nicotinic receptors have revealed many additional
subtypes.40 Neuronal ACh receptors can consist of 2-10 and 2-4 subtypes with varying
combinations possible between  and  subunits.40 The  subunit consists of Cys 192 and 193,
which is a characteristic and has been shown to be important for ACh binding in all  subunits, a
feature not observed in the  subunit.41 Thus, the  subunit was not able to bind ACh or various
agents. To date nine other  subunits have been identified; 2-10 along with four other 
subunits; 2-4.41
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C. Neuronal ACh (nACh) receptors
nACh receptors consist of various combinations of 1-10 and 2-4 subunits arranged in a
pentameric structure (Figure 2).42 Functional receptors are a result of the assembly of 5-subunits
around a pseudosymmetric axis.42 Various combinatorial associations of different  and 
subunits are possible, and these form functional nACh receptor subtypes of a large variety.43 It is
known that the principal component of the nACh receptor is associated with the 2, 3, 4, 6,
7, 8 or 9 subunits.42 The principal component consists of two adjacent Cys residues, and
contributes towards the binding of ligands with three loops from discontinuous sections.41,44 The
complementary component of the nACh receptor consists of 2, 4, 7, 8, or 9 subunits.
The complementary component provides an additional three discontinuous loops for binding of
the ligands.44 The 10 subunit, although classified as an -type subunit, can only function as a
principal component at the binding site in nACh receptors in conjunction with the 9 subunit.45
The stoichiometry of (x)2(y)3 is, in general, seen with most of the subunits except the 7, 8,
10 subunits that form homopentameric functional receptors when studied by expressing the
subunits in Xenopus laevis oocytes.46 The ACh binding site, and the transmembrane (TM)
spanning regions, are highly conserved across the various subtypes of nACh receptors, whereas
the intra-cellular loop between M3 and M4 (Figure 3) is conserved across various species.46 The
various subunits of the nACh receptors share a very high homology (91-99%) amongst
themselves.46 Thus, a single amino acid change in the extra-cellular amino terminal (Figure 3)
may affect the property of the nACh receptors.
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1. Distribution of nACh receptors
Various techniques, such as in situ hybridization using a subunit mRNA probe, ligand binding
studies by means of autoradiography, immunohistochemistry, immunoprecipitation, radioligand
binding assays using various ligands such as nicotine, -bungarotoxin to name a few, and nACh
receptor gene knock-out studies, have been performed to map the tissue distribution of nACh
receptors.47

a. Peripheral Tissues
It is accepted that nACh receptors are located in the ganglionic synapse of the PNS along with
broader locations in peripheral tissues.42 The 3, 5, 7, 2 and 4 subunits are the major
subunits identified in peripheral tissue.48 Chick ganglia and cromaffin cells have 3-, 7-, and
4-containing subtypes of nACh receptors.48,49 Developing muscles show the presence of the 7containing subtype.50 Various subunits, such as 3, 5, 7, 2 and 4, are expressed in
keratinocytes,51 bronchial epithelial cells,52 and arterial endothelium.43 Nicotinic receptors have
also been found on lymphocytes and polymorphonuclear cells of human blood, and very little is
known about their function.53 Functional nACh receptors containing 3, 5, 2 and 4 subunits
are found in endothelial cells lining blood vessels and are quite similar in their channel-open
time and, in general, functioning, found in the CNS.43 6-Containing nACh receptors are present
in the optic pathway which oligomerizes with 4, 2, 3, and 3 subunits to form functional
nACh receptors.54
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b. Central nervous system
The distribution of nACh receptors in primates is less well known when compared to rodents,
which have been far more extensively studied to map the distribution of the nACh receptors and
the subunits involved.47 In rodents the most abundant subunits expressed in whole brain are the
4, 7, and 2 subunits (Figure 4). 2-Containing nACh receptors are highly expressed in the
caudate, putamen, and the hippocampal regions of the CNS.55 The 4 subunit is highly expressed
in the cortex, whereas the 7 is expressed in the lateral and medial geniculate nucleus along with
the reticular thalamic nucleus.56 In rodents, as well in humans, 42 nACh receptors are the
most abundant and widespread in the human brain all along the hippocampus, basal ganglia, and
cerebellum.47 Recent studies have suggested that there is an incorporation of the 5 or 6
subunit in some 42 nACh receptors.47 In rodents, 34 nACh receptors are present in the
autonomic ganglia, pineal gland, medial habenula, and interpeduncular nucleus,57 to name a few.
6-Containing nACh receptors are present in the locus coereuleus along with the dopaminergic
neurons of the mesolimbic system which control dopamine release.57 The homopentameric 7
nACh receptors are particularly found in the hippocampus, hypothalamus, cortex, and motor
nucleus of the vagus.47 nACh receptors are anatomically and functionally located in pre- and
post-synaptic sites in the CNS where they perform various functions such as, pre-synaptically,
regulating the release of various neurotransmitters such as norepinephrine, glutamate and
GABA, while post-synaptically, bringing about various voltage-dependent downstream
responses.47,57

17

Figure 4. Regional distribution of various receptor subtypes in a rodent CNS adapted from Gotti
et al.57

2. Importance of 7 and 42 nACh receptors in the brain
The two main classes of nACh receptors widely distributed in the brain are the 7 and the 42
subtypes.4 They are thought to be involved in various pathophysiological states such as
schizophrenia, Alzheimer’s disease (AD), autism, nicotine addiction, attention deficit
hyperactivity disorder (ADHD), depression, Parkinson’s disease (PD), and pain. Also, nonneuronal nACh receptors present in certain tissues and cells are implicated in various disease
states such as lung cell carcinoma, blood pressure, and, inflammatory bowel disease. Due to the
vastness of the various disease states, only neuronal disorders are considered here.
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a. Schizophrenia
Schizophrenia is a neuropsychiatric disorder associated or characterized by delusions,
hallucinations, disorganized speech, and catatonic behavior.58 A high prevalence of an almost 3fold increase of smoking in schizophrenic patients led to investigations of the possible
involvement of nACh receptors in schizophrenia.59 Also, the fact that neuroleptic neuronal side
effects were fewer among smokers, and a negative correlation between smoking and the
symptoms of schizophrenia, established definite involvement of nACh receptors in the
pathophysiology of schizophrenia.60,61 Sensory gating, which is an involuntary process to
selectively sense a stimulus, is impaired in schizophrenic patients, was restored to some extent in
heavy smokers.62 It was found that heteromeric nACh receptors are not involved in the
pathophysiology of schizophrenia.63 Experimental studies were unable to show a difference
between controls and schizophrenic patients in terms of [3H]-nicotine binding and the levels of
4, 3, and 2 subunits in the hippocampus, thalamus, cortex and caudate putamen where most
heteromeric nACh receptors are located.63,64 The homomeric 7 nACh receptors, on the other
hand, were significantly involved in the pathophysiology of schizophrenia, which was shown by
-bungarotoxin administration to induce sensory gating defects in mice.65 -Bungarotoxin was
also seen to have reduced binding in temporal lobes along with 7 nACh receptor
immunoreactivity in the hippocampus,66,67 reticular nucleus of the thalamus and cingulated
frontal cortex of the schizophrenic patients, where 7 nACh receptors predominate.63 Agents
approved by the FDA for the treatment of schizophrenia include various atypical antipsychotics
such as clozapine, olanzapine and others. Clozapine has been shown to improve gating deficits,
and, thus, improve sensory stimulus.68 The improvement can also be attributed to clozapine19

induced increased levels of ACh in the hippocampus.68 This observation was experimentally
demonstrated when -bungarotoxin was shown to block clozapine’s effects.69 Clozapine is not a
preferred choice for the treatment of schizophrenia due to its severe toxicity profile.68 Thus,
various 7 nACh receptor agonists have been examined as potential therapeutic candidates for
the treatment of schizophrenia.68

b. Alzheimer’s disease (AD)
AD is the most common form of dementia in the elderly population.70 It is characterized by
neuronal cell loss due to the presence of β amyloid (Aβ1-42) and progressive accumulation of
neurofibrillary tangles caused by aggregates of hyperphosphorylated tau proteins in the neurons
and amyloid fibers in senile plaques and in the walls of the blood vessels.70 To test the
neurotoxicity of Aβ, Jay et al.71 were able to demonstrate that the mortality rates of transgenic
animals that overexpressed Aβ were doubled compared to control so as to determine that
overexpression of Aβ is sufficient to induce neurotoxicity. This degeneration affects many types
of neurons and may account for the numerous neurobiological deficiencies that patients
experience with the disease onset. The most notable degeneration occurs in the hippocampus,
cerebral cortex, and amygdala.71 These are the regions that play a major role in memory,
cognition and behavior.71 The vast majority of the people with AD have a late-onset form of the
disease in which memory loss occurs at the age of 60 years or more.70 There are few cases where
people are diagnosed with an inherited form of AD at an age as early as 30 or 40 years.70 In AD
patients it has been found that 4 nACh subunits are decreased in the hippocampus and the
cortical areas of the brain.72 Also since the 2 nACh subunit, together with 4, forms the most
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abundant heteromeric nACh receptors, a relationship was established between nACh receptors
and AD.73 This relationship was further supported by genetic polymorphism studies of the 4
and 2 subunits in AD patients.73 The Aβ1-42 is seen to inhibit the 42 and 7 nACh receptor
subtypes acutely at nM and pM concentrations, respectively, which could contribute to the
memory and cognitive impairments associated with AD patients.74 It has been shown that Aβ1-42
is a non-competitive antagonist of the 42 subtype of nACh receptors. It has been
experimentally shown that the β2 subunit isn’t affected, suggesting an alternate site of action for
the Aβ1-42.75 The Aβ1-42 inhibition is not mediated through an open channel block and
pretreatment with Aβ1-42 is necessary to induce convincing inhibition.54,75 To combat AD there
are two strategies that can help increase cholinergic transmission in the brain: firstly by
increasing the amount of ACh at the synapse that could be achieved by blocking acetylcholine
esterase (AChE) activity, and secondly by potentiating the action of ACh at nACh receptors.
Galantamine, tacrine, memantine, donepezil and rivastigmine are commonly used AChE
inhibitors for the treatment of mild to moderate cognitive symptoms of AD of which
galantamine, in addition, allosterically potentiates 42 and 7 nACh receptors present in the
brain.76 Thus, drugs selectively targeting the nACh receptor subtypes can increase cholinergic
tone in the diseased brain and, hence, provide therapeutic potential for the treatment of AD.

c. Autism
Autism is characterized by impaired social and communications skills along with odd and
stereotypical behavior. It is also associated with impaired planning and attention. Autism is also
considered as a spectral disorder with severe developmental defects that are apparent beginning
21

in early childhood.77 A decreased level of 4 mRNA in the parietal cortex and cerebellum as
well as decreased levels of 42 nACh receptors with unchanged levels of 7 nACh subtypes
can be seen in autistic patients.78 ‘Nicotinic tone’ which refers to the overall activation of
synapses by nicotine is considered as a factor that could be contributing towards the changes in
the etiology of autism.78 Thus agents that can restore the ‘nicotinic tone’ and potentiate the 42
nACh receptors might play a crucial role in providing therapeutic options for autism. Selective
42 nACh receptor potentiators can provide important insight into some of the cellular and
molecular mechanisms that can help understand the etiology and pharmacology of autism, which
is still unclear.

d. Attention deficit hyperactivity disorder (ADHD)
ADHD is a psychiatric disorder characterized by hyperactivity, inattentiveness and impulsivity
symptoms.79 Factors such as academic, employment and marital difficulties, psychiatric
disorders, substance abuse, depression, anxiety and personality disorders can be a result from
ADHD in adults.80 nACh receptors have been implicated and studied for their role in the disease
state; and it was found that nicotine and its analogs were efficient in treating ADHD symptoms.79
42 nACh receptor activation by ABT-089 (4), a selective weak agonist, was found to alleviate
the symptoms of ADHD in rodents and primates and humans by improving attention, learning
and memory.81 Drugs targeting selectively at the 42 nACh receptors subtypes can tackle
cognitive disturbances and hence provide therapeutic potential for the treatment of ADHD.
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ABT-089 (4)

(-)Nicotine (3)

e. Nicotine addiction
Nicotine (3), a plant alkaloid, is an active constituent of the leaves of nicotiana tabacum that
interacts with all the nACh receptor subtypes distributed in the CNS as well as the PNS.82
Nicotine is the chief component of tobacco, which is widely abused by smoking and chewing of
the dried and cured leaf. There is an immediate need in understanding the mechanism of nicotine
addiction due to the extreme health risk associated with nicotine abuse.83 Prolonged exposure to
nicotine causes a gradual decrease of the ionic responses called as the high affinity, super-open
desensitized state of nACh receptors that is of key importance to understanding nicotine
addiction.84 The brain areas involved in addiction are the dopaminergic neurons in the ventral
tegmental area (VTA), the prefrontal cortex, the nucleus accumbens (NA), extended amygdala,
hippocampus, and the habenulo-interpeduncular system.82 Activation followed by desensitization
by nicotine causes an alteration in the synaptic response that, in turn, alters synaptic signaling.82
The dopaminergic system in the VTA and its projections in the NA reinforce the nicotine reward
function and nicotine addiction.85 Presynaptic 42 nACh receptors on the dopaminergic
neurons cause the release of dopamine which is strongly attributed to the addictive properties on
nicotine.86
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f. Depression
A direct correlation exists between smoking and depression with an almost 3-fold increase in
nicotine dependence in depressed patients verses nondepressed.87 Similar ratios can be found for
the population who attempts to quit nicotine consumption, where depressed individuals are 2-3
times less prone to quit versus the nondepressed. This clearly indicates a nicotine component
involved in depression and mood.87,88 The 42 nACh receptor subtype has been considered as
an important therapeutic target for the potential treatment of depression due to its widespread
presence in the brain.89 42 nACh receptors have been implicated to modulate the levels of
dopamine which is an important neurotransmitter involved in reward and reinforcement
regulation in the brain through direct actions as well as indirectly through the excitatory
glutamatergic and the inhibitory GABAergic neurons.1,57 The neuronal component of nACh
receptors is involved in depression, and not the peripheral nACh receptor subtypes.90 Smoking
has been known to decrease depression through desensitization of nACh receptors; thus, an
antagonist at nACh receptors could have antidepressant effects.90,91

This correlation was

observed in studies involving mecamylamine (5), a non-selective, non-competitive antagonist at
nACh receptors that showed antidepressant-like effects in behavioral tests performed in mice.92
Cytisine (6), a partial agonist at nACh receptors with low efficacy at 42 nACh receptors and
full agonist action at ganglionic 34 ACh receptor and 7 nACh receptors, is used as a
smoking cessation agent and was also tested for its antidepressant effect.93 A partial agonist at
the nACh receptor will increase the activity of the nACh receptor but limits the ability of ACh to
activate receptors.94 Hence, if high levels of ACh lead to depression-like effect, a partial agonist
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might provide therapeutic benefit towards depression. Studies with cytisine (6) in mice have
supported this theory.95

Mecamylamine (5)

Cytisine (6)

Veranicline (7)

Sezetidine-A (8)

Similar studies were performed with veranicline (7), which is also a partial agonist at nACh
receptors with low efficacy at 42 nACh receptors, with higher efficacy than cytisine and is a
full agonist at ganglionic 34 ACh receptors and 7 nACh receptors. Veranicline (7) has a
similar profile as that of cytisine.96 The 7 nACh receptor agonist effect in the above drugs could
be a possible reason for the antidepressant like effect. This theory was eliminated when
sezetidine-A (8), a selective 42 nACh receptor partial agonist, was able to cause
antidepressant-like effect in mice.97-99 Future directions towards depression and nicotinic
receptors as potential targets requires a bidirectional approach where various factors including
different receptor subtypes, different brain areas where the ligands might act, and different
neurotransmitters that could be influenced by ACh along with different levels of mood, stress
and depression levels in patients. Drugs selectively targeting the 42 nACh receptor subtype
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can potentially target the depressed state of the patient and hence provide therapeutic treatment
for depression.

g. Parkinson’s disease (PD)
PD is a neurodegenerative disorder marked by tremor, rigidity, postural instability and
bradykinesia.100 The pharmacology involves the degeneration of the nigrostriatal dopaminergic
pathway (NDP) which involves neuronal loss in the CNS and PNS. Various neurotransmitters
are thought to be affected, but to a lesser extent compared to the NDP. Collectively there is
impairment of motor function, cognition/memory and autonomic functions.100 Currently,
dopamine replacement therapy is the preferred treatment for PD with L-DOPA along with other
dopamine agonists. These agents are effective for the motor function deficit for the disease state,
while ineffective for the nonmotor symptoms in PD.101 This led to other therapeutic avenues
being explored and it was found that nicotine was able to protect the NDP pathway, thus
encouraging researchers to explore the cholinergic systems. It has been shown that 46(2)23
and 42 nACh receptors are predominantly present in the corpus striatum with their projections
in the substantia nigra region controlling dopaminergic firing.101 The 62*-containing nACh
receptors are almost exclusively expressed on the presynaptic dopaminergic neuronal terminals,
whereas 42*-containing nACh receptors are widely distributed on presynaptic dopaminergic
and postsynaptic glutamatergic, GABAergic and serotonergic neurons.44,102,103 Researchers were
able to show that the 42* and 62* nACh receptors present on dopaminergic neurons
modulate dopamine release and are important for NDP functioning, thus posing as attractive
targets for development of selective agents for the treatment of PD.101
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3. Agents of nACh and other receptors in disease state
nACh receptor subtypes have been validated as critical drug targets due to their roles in the
muscle and ganglionic functions. This has stimulated a wide interest in the research for
generation of synthetic analogs for the various nACh receptor subtypes. However there is still a
major void in subtype selective agents. Listed below in Table 1 are a few examples of analogs
which have been implicated and approved for the use of the various disease states.

Table 1. List of agents implicated in various disease state.
Agents

Targets

Disease state

Additional
information

42, 7
agonist

AD,104 ADHD81

Phase trials;
discontinued
for AD

AD105

Phase IIb;
discontinued

ADHD

Phase II106

AD

Phase II107

ABT-418 (9)

AZD-3480/Ispronicline/
TC-1734 (10)

42, 7
partial
agonist

42
agonist
AZD-1446 (11)
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AChE
inhibitor,
42 and 7
agonist

AD108

FDA
approved

AChE
inhibitor

AD109

FDA
approved

AChE
inhibitor

AD110, dementia
related to PD111

FDA
approved

NMDA
antagonist,
7 noncompetitive
antagonist

AD112,113

FDA
approved

AChE
inhibitor

AD114

FDA
approved

Galantamine (12)

Tacrine (13)

Rivastigmine (14)

Memantine (15)

Donepezil (16)
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A-85380 (17)

42
7, 11
agonist

Pharmacological
probe115

nicotinic
receptor
antagonist

Antidepressant,116
smoking
cessation117

FDA
approved

62
agonist

PD118

Preclinical
development

7 agonist

AD,
schizophrenia119,120

Phase trials;
discontinued

7 partial
agonist

schizophrenia

Phase II121

Bupropion (18)

TC-2429 (19)

ABT-107 (20)

DMXB-A/GTS-21 (21)
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7 partial
agonist

ADHD,
schizophrenia122

Phase II;123
discontinued

TC-5619 (22)

4. Desensitization of nACh receptors
Desensitization means decrease of the response in the presence of a stimulus. Katz and Thesleff5
first noted that continuous application of ACh on frog muscle end-plate resulted in a decreased
cell response and almost abolished the response that was quickly recovered upon removal of
ACh from the system.124,125 This phenomenon was thus termed as ‘desensitization’ and was
hypothesized to have resulted from the transition of the receptor into a refractory state.125 It was
also shown that animals exposed to nicotine resulted in an increased density of nACh receptors.
This phenomenon allowed scientists to propose a two-state model of nACh receptor
desensitization which involved activation and desensitization by nicotine (or any agonist) at the
same time.126 Various factors together provide the net effect of nicotine on nACh receptors such
as drug concentration, exposure length, and the state of the receptor.127 nACh receptors have a
complex pharmacology and this can be mostly attributed to the activation and desensitization of
the nACh receptors over a short time course of nicotine exposure.127 The various biological
events associated with nACh receptor are initiated by the binding of the ACh, which brings about
a conformational change in the receptor shape.128 As previously discussed the nACh receptors
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exist in four states; the closed, the open, the intermediate transition state and the high-affinity
channel-inactive desensitized state (Figure 5).128,129

Figure 5. Multiple conformation states of nACh receptors and their transition from one state to
the other in the presence of ACh (adapted from Arias128).
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The closed state is the low-affinity resting state of the receptor and, in the absence of the
agonist/ACh, consists of around 80% of the receptor population while the remaining 20% exists
in the desensitized state.130,131 Desensitization of the nACh receptors has been found to be
modulated by the activation of protein kinases and receptor phosphorylation.132 It can be noted
that the agonist-induced desensitization of the nACh receptor occurs rapidly. Experiments were
performed on the membrane of Torpedo species and intrinsic fluorescence measurements
showed that the t1/2 was 1.9 sec for agonist induced desensitization.133 The time frame for the
activation cycle of the nACh receptor consists of sec to msec for the fast activation of the
receptor from the closed to the open state upon ACh binding. Prolonged presence of agonist/ACh
causes the receptor to convert to the intermediate transition state which takes around msec and
finally inducing into a high-affinity channel-inactive desensitized state which occurs in a sec to
min time frame.128 Desensitization of the homomeric 7 nACh receptor is associated with a
structural change of the binding sites at the orthosteric site and the ion pore.134,135 Also, mutation
of Leu247 in the pore-lining M2 domain of the TM region of the nACh receptor was shown to
destabilize the conformation of the desensitized receptor making it conducive to channel
opening, thus causing ions to flow through and considerably slow the rate of desensitization of
the rapidly fast-desensitizing 7 nACh receptor.134,136 Desensitization experiments of various
heteromeric nACh receptors have shown that the rate of desensitization is faster for the 2
containing than the 4 containing subtypes.135 The N-terminal region of the  subunit has been
shown to confer the different rate of desensitization of the -containing heteromeric nACh
receptors.134
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D. Allosterism
Receptors are proteins that can adopt multiple tertiary conformations. Receptors can also interact
with other cellular proteins that can function as downstream messengers of the signal
transduction pathway. The origin of allosterism is in the Greek literature where allos means
‘other’ and stereos mean ‘solid shapes’. The concept of allosterism was first proposed by Monod
and Jacob in 19617,137 when it was found that certain bacterial enzymes were feedback inhibited
by the end product or regulatory ligand of the biosynthesis pathway, even though they had no
structural similarity with the starting material or the substrate.138 Further experiments were able
to demonstrate that the interaction between the substrate and the regulatory ligand were the result
of distinct binding sites at which the molecules bind. The binding of the regulatory ligand brings
about a change in the conformation of the protein that reversibly modifies the conformation of
the active site indirectly.138 The concept was studied and adopted by Monod, Wyman and
Changeux (MWC) in 1965139 where they showed that allosteric effects do not fit general
enzymatic theories, and that a molecular transition, also called the allosteric transition, occurs
when an allosteric ligand binds to stabilize the protein.137 Henceforth, the allosteric model of
ligand interaction was also called the MWC model.

1. Theory
In an allosteric modulation various factors play a role such as the dynamic conformational
change of the protein in the absence of the ligand, and stabilization of the protein upon ligand
binding in a preferred conformation. Thus, in theory, a nACh receptor agonist will preferentially
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stabilize the active open state conformation and a nACh receptor competitive antagonist will
stabilize the resting or the closed state conformation. As mentioned earlier, different states of the
receptor possess different affinity for a ligand (Figure 5). Transition between the different states
can be brought about either by ligand binding or a free energy change between the states (L0-L2)
(Figure 5) that involves transition from one state to another. A three-state model for the allosteric
properties of the nACh receptor has been proposed that involves the resting state, open state, and
the desensitized state of the receptor. Generally the allosteric system involves quaternary protein
structures that can cause alteration in the bonding of the subunits of the receptor. Allosteric
effects can be broadly classified into two types; homotropic and heterotropic.137 A homotropic
effect occurs when the second molecule of the endogenous ligand (ACh) can bring about an
allosteric modulation for ACh binding at the orthosteric site. In the case of the heterotropic
effect, the allosteric modulator binds at a site distinct from the orthosteric site and modulates the
binding of the orthosteric ligand. Agents that stabilize the open state of the receptor, thus
potentiating the effect of the endogenous ligand and further shifting the equilibrium towards the
open state, are called as positive allosteric modulators (PAMs) (Figure 6).139 Whereas, on the
other hand, ligands that bind at an allosteric site and increase the energy barrier along with
shifting the equilibrium to the resting state are called negative allosteric modulators (NAMs).
PAMs on their own are inactive and don’t activate the ion channel. A ligand that binds at an
allosteric site and activates the receptor on its own is called an allosteric potentiating ligand or
allosteric non-competitive agonist.140

34

Figure 6. Schematic representation of positive allosteric modulation where the pentameric nACh
receptor is depicted in blue (adapted from Bertrand and Gopalakrishnan139).

Cooperativity is an important phenomenon where binding of two or more ligands on the same
protein at distinct sites generally increases or decreases the rate of binding of the second ligand
onto the protein and is termed positive or negative cooperativity, respectively. Cooperativity is
measured using a Hill coefficient (n) which provides a quantifiable measure of the same. A
coefficient of n >1 indicates a positive cooperativity while n < 1 indicates negative cooperativity.
Kinetic models of the ACh response show that two molecules of ACh are required for the
activation of the receptor and that n = 1.5 to 2.2, which suggests a homotropic effect.141 The
unbinding of the ACh from the receptor is slow enough to allow the receptor to activate the
channel opening more than once, thus suggesting that the channel opens and closes with ACh
remaining bound to the receptor.142 Thus, the allosteric model of ACh binding should include the
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unliganded, single liganded and double liganded state of the receptor. The model (Figure 7)
shows the complexity of the transition of the ACh receptor from one state to the other. At resting
state, the closed conformation (R) of the receptor is predominant. The closed channel (R) has
low affinity for the ligand but possesses a fast rate constant to go to the open state (AR) of the
receptor.143 Once the receptor is bound by 2 molecules of ACh (A2R), the probability of channel
opening is almost a million times more when compared to the closed unliganded state (R) of the
receptor. Once in the activated state, the receptor desensitizes (A2RD) rapidly; thus, eventually,
the burst fades away. Thermodynamically, the desensitized state of the receptor is the highaffinity state with a 100-fold higher affinity for the ACh. With equilibrium favoring the closed
state (R) of the receptor, the desensitized receptor (A2RD and ARD) and the receptor reverts to the
closed state and the cycle is ready to repeat.142
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Figure 7. Allosteric model of the various transition states of the nACh receptors. R= Receptor in
the open state, AR= 1 molecule of ACh bound to the receptor, A2R= 2 molecules of ACh bound
to the receptor, *= open state of the receptor, D= desensitized state of the receptor.142

2. Advantage of allosteric modulators over traditional orthosteric ligands
There are various advantages of allosteric modulators over orthosteric ligands for receptor
activation. First, the orthosteric ligand binds to the orthosteric site and activates the receptor; on
the other hand, the allosteric modulator doesn’t have any intrinsic activation, thus the natural
state of the receptor along with the physiological stimulus produced by the endogenous ligand
can be maintained. This phenomenon could possibly reduce the likelihood of receptor
desensitization even when an allosteric modulator is continuously present, thus providing a tool
to escape tolerance.144 A second major problem associated with the orthosteric ligands is the
overdose/toxicity aspect. The allosteric modulators are saturable; thus once all the binding sites
for the allosteric modulators are occupied it cannot produce any additional effect and, thus, can
be a safer alternative in cases of overdose.145 The third advantage tries to tackle the most
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problematic aspect of drug discovery, i.e., selectivity of the ligands across various receptor
subtypes. In the case of nACh receptors the orthosteric site is highly conserved providing very
little room for designing selective agents for various nACh receptor subtypes. An allosteric site
could be found anywhere on the receptor surface and thus can be specific for a particular
receptor subtype population and provide selectivity.144

3. Allosteric modulators of nACh receptors
Due to the broad implication of nACh receptors in various neurodegenerative disorders, PAMs
can play crucial role in restoration of nicotinic tone.54 Ivermectin, an anthelminthic agent, was
the first agent to be identified as a PAM at 7 nACh receptors. The compound was able to
decrease the EC50 and increase the slope of the dose response curve, thus potentiating the effect
of ACh.146 Since then, various other agents have come to light as potential PAMs at the 7 nACh
receptor subtype.139 Galantamine, which is an AChE inhibitor, was shown to activate 7 and
42 nACh receptors along with other subtype populations, through binding at a site distinct
from the orthosteric site for ACh.147 Thus, co-application of galantamine with ACh in Xenopus
oocytes expressed with 42 nACh receptors was shown to potentiate the effect of ACh.147 The
neuro-steroid 17-estradiol was shown to potentiate ACh-induced responses by increasing
channel opening probability at 42 nACh receptors.148 It was found that the C-terminal region
of the 4 subunit was involved in 17-estradiol binding and that the site was different from other
progesterone inhibitions.148 Various cations, such as zinc (Zn2+)149 and calcium (Ca2+),150 seem to
play a crucial role in the modulation of the various nACh receptor subtype populations in the
brain. Zinc co-application (50 M) with a saturating ACh concentration was shown to potentiate
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ACh-evoked currents by 260%. Also, it was observed that zinc potentiates at low concentrations
(EC50=16 M) and inhibits at high concentrations (IC50=440 M).151 Through mutagenesis
studies it was observed that the Zn2+ potentiates low-affinity (4)3(2)2 receptors that have a
4+/4- phase while inhibiting both the low- and high-affinity stoichiometry of 42 nACh
receptor that have a 2+/4- phase that is required for Zn2+ binding.149,152
PAMs have different qualitative effects on the ACh response.153 They are classified into two
types namely, Type I and Type II PAMs. Type I PAMs are agents that increase the receptor
sensitivity by increasing the magnitude of the current produced by ACh without affecting the
decay rates of the current.153 Type I PAMs do not affect the onset and the basic decay kinetics of
the response. On the other hand Type II PAMs increased the apparent peak current by rapid
onset of action and weak current decay kinetics.154 In the case of 7 nACh receptors Type II
PAMs were able to reactivate the desensitized receptors which are considered to be the reason of
the prolonged decay rates for the ACh currents.153 Table 2 summarizes various agents that have
been shown to be PAMs at the two major nACh receptor populations in the human brain: the 7
and 42 subtypes.
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Table 2. A list of agents and their selectivity profile at various nACh receptor subtypes.
Agent

Target

Type

7 nACh receptor,153
tyrosine kinase inhibitor

PAM type I

Non-specific at nACh
receptors155

PAM type I

7 nACh receptor156-158

PAM type II

7 nACh receptor153

PAM type II

Genistein (23)

NS-1738 (24)

PNU-120596 (25)

TQS (26)
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AChE inhibitor,140
7 and 42 nACh
receptor 159

PAM type II

42 nACh receptor148
and various nuclear
receptors

PAM type II

7 nACh receptor,160
endogenous ligand

PAM type I

42 nACh receptor161

PAM type II

7 and 42 nACh
receptor162

PAM type I

Galantamine (27)

17-Estradiol (28)

5-Hydroxyindole (29)

A-998679 (30)

LY-2087101 (31)
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4. des-Formylflustrabromine (dFBr)
Marine biology has been for years a great source of novel creatures and a part of the research to
identify novel agents for drug discovery. Flustra foliacea is a marine bryozoan species found
commonly in the North Sea and is now known to biosynthesize a variety of indole-containing
natural products as metabolites.163 To date, about 22 alkaloids and monoterpenes have been
isolated from the bryozoan species.163,164 One of the indolic compounds is dFBr (32). Peters et
al.165 performed binding experiments with dFBr (32) at 42 and 7 nACh receptors and it
showed low (Ki = 3,400 nM and >50,000 nM, respectively) affinity compared to (-)nicotine (3)
(Ki = <1 nM).165 Some of the metabolites were shown to possess muscle relaxant properties.166
Several of the Flustra metabolites were tested for their biological activity against 32, 34,
42, 44 and 7 nACh receptors expressed in oocytes and only dFBr (32) showed any
significant activity at the 42 nACh receptor subtype.166 dFBr (32) was shown to potentiate
ACh-induced responses in Xenopus oocytes expressed with 42 nACh receptors, while a
statistically insignificant inhibitory response was measured at the 7 nACh receptor subtype.166
Various experiments were conducted by Sala et al.166 and dFBr (32) was found to potentiate
ACh’s effects through a mechanism that does not involve direct activation of α4β2 nicotinic
receptors at the orthosteric site. Rather than behaving as an orthosteric agonist, dFBr is a positive
allosteric modulator that can potentiate the actions of ACh at 42 nACh receptors.166 It was
shown that the action of dFBr (32) was not on the pore properties but kept the channel open for a
longer time following ACh binding, along with reopening the channel faster, hence increasing
the potency and efficacy of the ACh-induced response.166 The potentiation caused by dFBr on
ACh-induced currents was also found to be reversible and concentration-dependent. dFBr was
42

the first compound shown to possess selectivity for 42 receptors as a PAM and could
potentially be of great benefit for further understanding the importance of 42 nACh receptors
in various disease states. Biological testing was performed using the various Flustra metabolites
as their free bases, which required using DMSO for solubilizing the compounds.166 Joshi et al.167
were able to modify the conventional oocyte electrophysiological experiments and incorporated
a vertical flow system that was shown to have extended oocyte stability, drug exposure to the
complete oocyte surface, and that can be attached to an HPLC autosampler for high throughput
style assays. The vertical oocyte chamber was also able to provide a faster exposure thus
providing more accurate determination of the results compared to the conventional flow oocyte
chamber.167

des-Formylflustrabromine (dFBr) (32)
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III. Specific aims

With the advent of allosteric modulation as a novel route for activation of nACh receptors it is
important to identify agents that act selectively so that nACh receptors and their subtypes can be
studied in greater detail. The major limiting factor with allosteric modulators is that they are
impossible to design a priori. Thus, the only way to identify such compounds is through
serendipity or through high-throughput screening methodology. Sala et al.166 were fortunate to
find dFBr as a novel agent that was able to potentiate 42 nACh receptors allosterically and it,
thus, provided a novel lead for further drug development. The previous studies of dFBr (32)
involved the use of DMSO solutions of the water-insoluble free base for all the biological studies
employed. Also, researchers relied on the natural source for obtaining dFBr (32) and, hence, its
availability was limited. Our laboratory (i.e., Kim et al.)9 and Lindel et al.168 independently
identified convenient synthetic routes for the synthesis of dFBr (32), which was synthesized as a
water-soluble HCl salt. The water-soluble HCl salt was tested for its action at the 42 and 7
nACh receptor subtypes. It was shown that the potentiating effects of the HCl salt of dFBr was
greatly improved over that of its free base.9 This could be because of better water solubility
while performing the biological testing, or due to the non-necessity of using DMSO as solvent.
Interestingly, it was observed that contrary to results published by Sala et al.166 the HCl salt of
dFBr (32) produced a biphasic response at the 42 nACh receptor (Figure 8) with an EC50 of
120 nM for the potentiation component and an IC50 of 150,000 nM for the inhibitory component
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of the dose-response curve when co-applied with 100 M ACh.9 dFBr (32) potentiated the
maximal ACh response to almost 300%.9 The inhibition profile at relatively higher
concentrations was hypothesized to be due to an open channel blockade mechanism with further
studies required to prove it. At 7 nACh receptors, dFBr (32) produced only an inhibitory
response with an IC50 of 44,000 nM (Figure 9).9
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Figure 8. Potentiation and response curve for dFBr at 42 nACh receptors. (A) A typical trace
of the potentiation of the ACh-evoked response for dFBr (32) from a single oocyte expressing
human 42 nACh receptors. (B) A biphasic dose-response curve for dFBr (32) co-applied with
100 M ACh on human 42 nACh receptors.9
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Figure 9. Potentiation and response curve for dFBr at 7 nACh receptors. (A) A typical trace of
potentiation of the ACh-evoked response by dFBr (32) from a single oocyte expressing human
7 nACh receptors. (B) An inhibitory dose-response curve for dFBr (32) co-applied with 100
M ACh on human 7 nACh receptors.9
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Few, if any, allosteric ligands show selectivity for 42 nACh receptors. dFBr (32) is the first
selective allosteric modulator that potentiates the actions of ACh at 42 nACh receptors.
Unfortunately, dFBr (32), at high concentrations, will eventually behave (possibly as a channel
blocking agent) to reverse its effects on the ACh receptor activation profile at 42 nACh
receptors.9 Thus, it would be important to determine what structural requirements are responsible
for: a) allosteric activation of 42 nACh receptors, and b) antagonism. A study will be
undertaken to understand structure-activity relationships (SAR) with dFBr (32) as a starting
point.

To perform the SAR studies that might lead to identification of a possible pharmacophore for
PAM action at the 42 nACh receptor subtype a ‘deconstruction-reconstruction-elaboration’
approach will be employed. This approach involves single structural changes being made to a
compound and the subsequent evaluation of the new compounds for biological activity.169 Thus,
any change in activity can be associated with a single change in the structure of a molecule, and
a rational SAR can be established. The process involves three phases to determine the necessity
or contribution to activity of various structural components of the parent molecule. The first
phase is the ‘deconstruction’ phase where the key structural features in the parent molecule are
removed one at a time and the new compounds are biologically evaluated to measure the
importance of that particular functional group. Also, this might identify the minimum structural
features that are required to retain the activity of the parent compound, providing a
pharmacophore for designing future analogs. The process of ‘deconstruction’ is also beneficial in
identifying analogs that retain action and simultaneously provide a simpler synthetic procedure
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which might ease the scale-up synthesis of a desired final ligand. Once a thorough understanding
of the importance of various structural features of the parent molecule is established, the process
can move to a ‘reconstruction’ phase where an analog with all essential structural features is
synthesized and biologically evaluated to compare to the parent molecule. The third phase is the
‘elaboration’ phase where the important structural features are further elaborated to understand
their role in producing the action. In this phase, principles of classical medicinal chemistry are
applied and an SAR is developed where various substituent parameters, such as electronic, steric,
and lipophilic can be studied. A rational approach using the Topliss decision-tree170 or the Craig
Plot171 can be implemented to minimize the vast number of possible substituents that might be
introduced, and the total number of compounds that will be required for synthesis and evaluation.
The ‘elaboration’ phase generally involves lead optimization and allows an understanding of
‘why’ a particular substituent is important. It also might provide a drug-like molecule with novel
structural features.
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The specific aims of the current investigation are:
1. Elucidation of critical structural features of dFBr (32) required for potentiation of ACh at
42 nACh receptors.
2. Determination of what structural features of dFBr (32) contribute to the potentiation and
inhibition profile of the biphasic dose-response curve of dFBr (32) (Figure 8) which will
eventually help better understand the true potentiation potential of dFBr (32) analogs at 42
nACh receptors.
3. Identification of structurally-simpler PAMs that might result in greater ease of synthesis for
scale-up (e.g. for purpose of in vivo studies).
4. Synthesis of a radiolabeled ligand as a selective PAM at 42 nACh receptors that might
facilitate binding experiments to determine binding profiles along with efficacy studies.
The general goal of this work is to prepare dFBr (32) analogs that can help provide an
understanding of various structural features and their effects towards 42 nACh receptor
action. Specifically, the compounds considered for synthesis and evaluation are shown in Figure
10.
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Figure 10. Deconstructed analogs of dFBr (32) proposed for synthesis and evaluation. For
example, compound 33 can provide information on the necessity of the 6-bromo group of 32,
whereas 34 can provide information on the need for unsaturation. Each structure can provide
important information on the contribution of specific substituents.

It might be noted that one of the first studies conducted in our laboratory showed that the 6bromo substituent of dFBr was an important, but not necessary, contributor to activity (see
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discussion to follow). Consequently, compounds 41-45 (Figure 11) will be prepared and
evaluated, to determine the contribution of the 2-position chain substituents to 42 PAM
action. The reason for this is because of the difficulty in preparing 2-alkyl-6-bromotryptamines.
The intent is to identify an optimal 2-position substituent, and to then prepare the 6-bromo
analog of this compound (i.e., reconstruction).

Figure 11. Deconstructed analogs of 6-desbromo dFBr (33) proposed for synthesis and
evaluation.
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IV. Results and discussion of deconstruction of dFBr

A. Drug-like properties of dFBr (32)
The drug-like properties of a compound are related to its structure which, in turn, is essential for
absorption, distribution, metabolism and elimination (ADME) in humans. The physicochemical
properties of a compound, such as its lipophilicity and solubility, might be related to various
ADME properties. Medicinal chemists generally engage in the process of structure-activity
relationship (SAR) and/or structure-property relationship (SPR) studies to increase the potency
and selectivity towards a drug target, to reduce the undesirable effects, and to improve the druglike properties of a compound. During SAR studies the molecular properties of the compound,
such as molecular weight and logP, along with solubility and molecular volume, to name a few,
are considered and a multi-dimensional optimization approach is carried out. Lipinski’s rule of 5
is a widely accepted guide for understanding the drug’s bioavailability, generally for an orally
active drug. The rule states that an orally active drug should consist of: 1) no more than 5
hydrogen bond donors; 2) no more than 10 hydrogen bond acceptors; 3) molecular weight under
500 Daltons; and 4) a logP not greater than 5.172 There are exceptions to these rules and various
other parameters such as the polar surface area and number of rotatable bonds in a compound are
considered to better predict the oral bioavailability of a drug.173 Table 3 summarizes the various
physical properties of dFBr (32) which were calculated using the OSIRIS property explorer (a
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web-based molecule editor predicting various drug-relevant properties) and MOLSOFT
molecular property calculator.

Table 3. Physicochemical properties of dFBr (32) versus ideal values
Physicochemical properties

Predicted values

Ideal values

logP

4.24

5

solubility

-4.36

 -4.0

Molecular weight (MW)

320

 500

Hydrogen bond acceptors

0

 10

Hydrogen bond donors

3

5

Drug likeness

-6.18

High positive value

Drug score

0.26

High positive value

According to the Lipinksi’s rule of 5, the molecular weight, logP, hydrogen bond acceptor and
hydrogen bond donor are within the requirements, thus dFBr (32) can qualify as a potential drug.
The drug likeness and the drug score is determined by comparing various marketed drugs.174
These scores also consider the various fragments in the compound that can be problematic and
potentially toxic. A positive value for the drug likeness would mean that the fragments of the
compound are what are generally present in commercial drugs. Thus, drug likeness, along with
lipophilicity, molecular weight and potential toxicity, can determine the relative drug-like
attributes of a compound. From Table 3 it can be observed that the drug likeness and the overall
drug score of dFBr (32) is poor which suggest that dFBr (32) is not an ideal drug candidate. Use
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of such tools along with other computational models can help in performing SAR and/or SPR
studies on dFBr which can help in determining the structural features which can improve the
drug-like property of dFBr (32). For example, secondary amines are less lipophilic and more
prone to metabolism than, for example, tertiary amine or -alkyl amines. Hence, such factors
should be investigated.

B. Chemistry
Analogs of dFBr (32) were synthesized in collaboration with others in our laboratory concurrent
with the present investigation. For example the synthesis of compounds 33-36, 38, 41, and 42
were synthesized by German et al.175 and have now been reported. Compound 35 (Figure 10)
was a useful intermediate for analogs where 2-position substitution was introduced as a separate
step. Compound 40 (Scheme 1) was synthesized by performing a modified Henry reaction on an
indole nucleus instead of the Speeter-Anthony glyoxylamide synthesis because the reaction and
the yield of primary glyoxylamide was poor compared to the secondary glyoxylamide. 6Bromoindole (46) (Scheme 1) was allowed to react with 1-dimethylamino-2-nitroethylene in the
presence of TFA to yield 3-[(E)-2-nitroethenyl]-6-bromo-1H-indole (47), which, upon reduction
with NaBH4 in the presence of a Lewis acid, yielded the known 6-bromotryptamine (48) in fairly
good yield.176,177 The tryptamine was used for a further reaction where it was protected with ditert-butyl dicarbonate in the presence of Et3N to yield tert-butyl-2-(6-bromo-1H-indol-3yl)ethylcarbamate (49). The compound was known as a glassy solid,178 but a melting point had
not been reported. Because of the non-polar nature of the carbamate, it was relatively easy to
purify by column chromatography. The Boc-protected tryptamine 49 was subjected to a
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prenylation reaction to obtain the 2-substituted indole with freshly prepared prenyl 9-BBN179 in
the presence of tert-butyl hypochlorite and Et3N, which yielded tert-butyl-2-(6-bromo-2-(1,1dimethylallyl)-1H-indol-3-yl)ethylcarbamate (50). This was one of the only reactions that was
able to provide the 2-dimethylallyl substitution in the presence of 3- and 6-substitution on the
indole nucleus (see below for other routes). Deprotection, along with conversion to an HCl salt,
yielded 6-bromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (40).

Scheme 1. Synthesis of compound 40a

a

Reagent: (a) 1-dimethylamino-2-nitroethylene, TFA, CH2Cl2, room temperature, 1 h; (b)
NaBH4, BF3·Et2O, THF, reflux, 2 h; (c) di-tert-butyl dicarbonate, Et3N, DMF, room temperature,
24 h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room
temperature, 2 h; (3) NaOH, H2O2, 1 h; (e) HCl, EtOAc, 0 °C, 24 h, recrystallized from
MeOH/EtOAc.

Scheme 2 summarizes the various des-bromo analogs, 43-45, that were synthesized. o-Toludine
(51) was treated with pivaloyl chloride in the presence of base to yield the corresponding amide
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52180 which underwent cyclization in the presence of n-butyllithium to yield the known 2-tertbutyl-1H-indole (55).181 This is a more convenient synthetic scheme for 2-substituted indoles
though the drawback is that halogens are susceptible to lithium exchange so it cannot be used
when a 6-bromo substituent is present. The Speeter-Anthony glyoxylamide reaction was
performed on 2-tert-butyl-1H-indole (55), followed by LiAlH4 reduction and salt formation, to
yield N-methyl-2-tert-butyltryptamine oxalate (43). A similar synthetic route was followed with
2-methylbutanoyl chloride and acetyl chloride to yield 44 and 45, respectively. The synthesis of
compound 44 and 45 was reported by German et al.175 (a postdoctoral fellow 2007-11 in Dr.
Glennon’s Lab).
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Scheme 2. Synthesis of compounds 43-45a

a

Reagent: (a) trimethylacetyl chloride (for 43)/2-methylbutanoyl chloride (for 44)/acetyl chloride
(for 45), Et3N, CH2Cl2; (b) n-butyllithium, THF; (c) (1) oxalyl chloride, Et2O, 0 °C; (2)
methylamine, room temperature, overnight; (d) LiAlH4, THF, reflux; (e) oxalic acid, THF, Et2O,
recrystallized from i-PrOH.

Various synthetic routes were attempted for the synthesis of compounds 37 and 39. It was
relatively difficult to incorporate the 6-bromo and 2-alkyl substituents while synthesizing the
indole scaffold. All trials involved routes that can provide 6-bromo analogs with varying 2position alkyl substituents. Some of the attempts are shown in the following schemes (Scheme 358

7). The route shown in Scheme 3 was attempted based on the synthesis of 3-alkyl indoles.180 We
tried to use a N-protected tryptamine, 61, reacting it with 2-iodobutane in the presence of zinc
triflate, which assists in removal of the proton from the indole nucleus. No product (i.e., 62) was
formed suggesting that 2-position alkylation is not possible even with the 3-position being
blocked.

Scheme 3. Attempt to achieve synthesis of 37 by alkylation of the N-protected tryptamine 61a

a

Reagent: (a) di-tert-butyl dicarbonate, Et3N, THF; (b) zinc triflate, TBAB, DIPEA, 2iodobutane, toluene; (c) (1) oxalyl chloride, Et2O; (2) methylamine, THF, H2O; (3)
BH3·S(CH3)2, THF; (4) salt formation.
Scheme 4 represents a Fischer indole synthetic route for the synthesis of 2-substituted indoles. It
is one of the oldest methods of indole synthesis and involves a rearrangement reaction of a
Schiff’s base to give 2-substitued indoles. This route, however, is not favorable for obtaining
ring-substituted indoles as intra-molecular ring closure can affect the final position of the ring
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substituents. Attempts to perform intra-molecular ring closure of intermediate 64 were not
successful and only starting material was recovered. We expected some sort of cyclization to
occur but, with the recovery of starting material, we are unable to offer any possible explanation.

Scheme 4. Fischer indole syntheses for the attempted synthesis of compound 37a

a

Reagent: (a) 3-methylpentan-2-one, HOAc, MeOH; (b) 10% P2O5, CH3SO3H; (c) (1) oxalyl
chloride, Et2O; (2) methylamine, THF, H2O; (d) BH3·S(CH3)2, THF; (4) salt formation.
Another attempt to synthesize 39 was carried out by modifying the Leimgruber-Batcho indole
synthesis as shown in Scheme 5. In this route the 2-nitrostyrene intermediate 70 should undergo
hydrolysis to yield the phenyl ketone intermediate which can further undergo cyclization by
reduction with Zn/HOAc. To introduce the 2-position alkyl group of 39, we subjected 69 to
alkylation with pivaloyl chloride but the reaction was unsuccessful.183 A possible reason for the
failure to synthesize 70 could be that a bulky substituent cannot be attached to the -styrene
portion of 69.
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Scheme 5. Modified Leimgruber-Batcho indole syntheses for the attempted preparation of 39a

a

Reagent: (a) (1) NaNO2, HBr; (2) CuBr, HBr; (b) DMF.DMA, pyrrolidine, DMF; (c)
trimethylacetyl chloride, Et3N; (d) (1) H2O, reflux; (2) Zn, HOAc; (e) (1) oxalyl chloride, Et2O;
(2) methylamine, THF, H2O; (3) BH3·S(CH3)2, THF; (4) salt formation.
Direct bromination was attempted to achieve regioselective bromination of the indole ring. Burm
et al.178 reported the total synthesis of ()-arborescidine, a marine alkaloid in which 61 (see
Scheme 4) was a key intermediate. Intermediate 61 was synthesized by direct bromination of the
glyoxylamide, followed by reduction, N-protection and chromatographic separation of the 5- and
6-bromo mixture.178 Scheme 6 summarizes the direct bromination route for the synthesis of 39.
Bromination of 58 resulted in a mixture of 5- and 6-bromo compounds (73 and 72, respectively).
Separation techniques, including flash column chromatography and preparative TLC, failed to
separate the two isomers. A possible explanation could be because the 2-postion alkyl
substitution makes the compounds quite lipophilic, resulting in very little difference in polarity
of the compounds, making chromatographic separation nearly impossible.
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Scheme 6. Direct bromination route for the attempted synthesis of 39a

a

Reagent: (a) Br2, HOAc; (b) (1) oxalyl chloride, Et2O; (2) methylamine, THF, H2O; (3)
BH3·S(CH3)2, THF; (4) salt formation.
Scheme 7 shows an attempt to achieve the synthesis of 39 using a Grignard-based reaction for
the cyclization. Pei at al.184 successfully achieved a synthetic route for the synthesis of 2substituted

indoles

with

ring

substitution by a

[1,2]-aryl

migration

shift

in

-

chloroacetophenones. Intermediate 75 was synthesized using 3-bromoaniline (74) by reacting it
with chloroacetonitrile in the presence of a Lewis acid, AlCl3 and BCl3. The substituted chloroacetophenone 75 was reacted with tert-butyl magnesium bromide to obtain 6-bromo-2tert-butyl-1H-indole, but here the reaction yielded total degradation indicated by numerous spots
upon the TLC analysis with consumption of the starting material 75. The Grignard reagent route
was successful in the synthesis of the 2-methylpropyl analog (65) (see Scheme 8). This suggests
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that the tert-butyl Grignard reagent might be unstable in the presence of the aromatic halogens,
especially bromine, which is very reactive with the Grignard reagent. There was loss of starting
material and no product (i.e., 71) was formed; hence, finding modified routes for the synthesis of
6-bromo-2-alkyl indoles were explored.

Scheme 7. Grignard reagent route for the attempted synthesis of 39a

a

Reagent: (a) chloroacetonitrile, AlCl3, BCl3, CH2Cl2; (b) tert-butyl magnesium bromide, Et2O;
(c) ) (1) oxalyl chloride, Et2O; (2) methylamine, THF, H2O; (d) BH3·S(CH3)2, THF; (4) salt
formation.

We were finally successful in achieving the synthesis of 37 and 39 through a relatively long, but
simple, route as shown in Scheme 8. This involved a Sonagashira coupling reaction to synthesize
6-bromo-2-subsituted analogs. Scheme 8 summarizes the synthesis of N-methyl-6-bromo-2-tertbutyltryptamine hydrochloride (39) and N-methyl-6-bromo-2-sec-butyltryptamine hydrochloride
(37). Compound 37 was synthesized in collaboration with Dr. German.
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2-Nitroaniline (76) was brominated with N-bromosuccinamide to yield 4-bromo-2-nitroaniline
(77)185 which, on diazotization and reaction with KI and I2, yielded 4-bromo-2-nitroiodobenzene
(78).185,186 This was further reduced with Fe and HCl to yield 5-bromo-2-iodoaniline (79).187
Sonagashira coupling in the presence of the corresponding alkyne with ligand-based palladium
catalysts was performed on 79 to yield 5-bromo-2-(3,3-dimethylbut-1-yn-1-yl)aniline (80). The
corresponding alkyne was treated with ZnI2 to render cyclization to 6-bromo-2-tert-butyl-1Hindole (71). Various Lewis acids can be used to perform the cyclization reaction, such as ZnBr2,
ZnCl2, CuI, CuBr and many others.188 The synthesis of compound 37 was achieved via the
Grignard reagent route where the corresponding indole was reacted with oxalyl chloride and
methylamine via a Speeter-Anthony glyoxylamide reaction to yield N-methyl-6-bromo-2-tertbutyl-1H-indol-3-glyoxylamide

(72)

and

N-methyl-6-bromo-2-sec-butyl-1H-indol-3-yl-

glyoxylamide (66), which followed by reduction and formation of an HCl salt, yielded N-methyl6-bromo-2-tert-butyltryptamine

hydrochloride

(39)

and

N-methyl-6-bromo-2-sec-

butyltryptamine hydrochloride (37). The above routes have provided a versatile method for the
synthesis of various 2-substituted indoles in the presence of a halogen in the indole nucleus.
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Scheme 8. Synthesis of compounds 37 and 39a

a

Reagents: (a) N-bromosuccinamide, EtOH, 40-50 °C, 5 h; (b) (1) BF3·Et2O, t-BuONO, THF, 30 °C to room temperature, 1 h; (2) KI, I2, CH3CN, room temperature, 1 h; (3) Na2S2O3; (c) Fe,
HOAc, EtOH, reflux, 1.5 h; (d) 3,3-dimethylbut-1-yne, CuI, PdCl2(PPh3)2, Et3N, THF, room
temperature, 5 h; (e) ZnI2, toluene, reflux, 41 h; (f) (1) oxalyl chloride, Et2O, reflux, overnight;
(2) methylamine, THF, H2O, room temperature, 15 h; (g) (1) BH3·S(CH3)2, THF, reflux, 6 h; (2)
HCl, Et2O, 0 °C, recrystallized from i-PrOH; (h) chloroacetonitrile, AlCl3, BCl3, CH2Cl2, 12 h
reflux; (i) oxalyl chloride, Et2O, -5 °C, 30 min; (j) methylamine, THF, H2O, room temperature,
overnight; (k) BH3·S(CH3)2, THF, reflux, overnight; (2) oxalic acid, CHCl3, 0 °C, 1.5 h,
recrystallized from i-PrOH.
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Compound 82, which is the des-bromo analog of 40, was also synthesized to compare the effect
of the 6-bromo substituent with/without the N-methyl substituent. Compounds in Figure 12 will
provide further evidence towards the importance of the 6-bromo and the N-methyl substituent of
dFBr (32).

Figure 12. Deconstruction of dFBr (32) at the 6-bromo and the N-methyl substituents.

Scheme 9 summarizes the synthesis of compound 82. Compound 82 was synthesized by a
relatively simple route from commercially available tryptamine (83) which was protected to
obtain the Boc-protected tryptamine (84).189 Compound 84 was prenylated to yield tert-butyl-2(2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (85), that, on deprotection, yielded 2-(1,1dimethylallyl)tryptamine hydrochloride (82) in fairly good yield.

66

Scheme 9. Synthesis of compound 82a

a

Reagents: (a) di-tert-butyl dicarbonate, Et3N, DMF, room temperature, 20 h; (b) (1) tert-butyl
hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 3 h; (3)
NaOH, H2O2, 1 h; (c) HCl, EtOAc, 0 °C, 24 h, recrystallized from i-PrOH/Et2O.

C. Pharmacology
Biological activities of the synthesized compounds were evaluated using two-electrode voltage
clamp techniques employing Xenopus laevis oocytes with expressed human 42 nACh
receptors in the absence or presence of 100 M ACh. A typical dose-response curve for the
compounds tested on human α4β2 nACh receptors shows potentiation at lower concentrations
and inhibitory activation at higher concentrations, but no effect in the absence of ACh. Table 3
provides the biological results of the potentiation or antagonism (i.e., inhibition) of the action of
ACh action at human 42 nACh receptors by dFBr (32) and its analogs.
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Table 4. Effect of dFBr (32) and its deconstructed analogs on the action (potentiation or
antagonism) of ACh action at the human 42 nACh receptors.

32 (dFBr)

+

+

0.33  0.52

Half maximum
inhibition
concentration (IC50)
(M) ( SEM)
150  0.20

33

+

+

7.59  3.50

12.6  3.20

34

+

+

0.14  0.69

NIa

35

-

+

NPb

39.8  0.87

36

-

+

NP

3.55  0.83

37

+

+

60. 5 (0.6-120)

40.7 (0.1-81)

38

-

+

NP

72.4  0.79

DAc

DA

Compound Potentiation

Inhibition

Half maximum
potentiation
concentration (EC50)
(M) ( SEM)

39
40

+

+

0.51  0.58

NI

41

+

+

3.02  0.09

NI

42

-

-

NP

NDd

43

+

+

3.98  0.03

NI

44

-

+

NP

16.6  0.28

45

DA

DA

82

DA

DA

a

NI = Inhibition potency of the action of ACh could not be reliably determined. bNP = No
potentiation of the action of ACh. cDA = Data unavailable. dND = Not determined.  = 95%
confidence limits (CLs). n = 4. In some cases, data were provided as  SEM; in others, data were
provided to us with 95% CLs.
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D. Discussion
The EC50 value obtained for dFBr (32) (0.33 M) (Table 4) in the current investigation is
comparable to a previous report (EC50 = 0.12 M) from our laboratory, and the small difference
might be the result of the large number of determinations carried out with 32 and experimental
variation. Compounds 33-40 represent the first deconstructed analogs of dFBr (32) (Table 4;
Figure 10). Comparing dFBr (32) with its des-bromo analog 33 (EC50 = 7.59 M), it is apparent
that the 6-bromo substituent makes a substantial contribution to activity. Although removal of
the 6-bromo substituent decreased potency by almost 20-fold, compound 33 is still active as a
PAM at 42 nACh receptors. Thus, the 6-bromo substituent is optimal for potency but is not
required for the PAM action of dFBr (32). Removal of the 6-bromo substituent improved the
inhibitory action (IC50 = 12.6 M). It is notable that the removal of the 6-bromo group decreased
the concentration range for the potentiation and the inhibition action at 42 nACh receptors
(Table 4, 0.3 to 150 M for dFBr vs 7.6 to 12.6 M for 33, respectively).
Next, the importance of the 2-position side chain of dFBr (32) was examined. Compounds 34,
35, 36, and 38 were the initial analogs synthesized in our laboratory. Comparing dFBr (32) with
34 (EC50 = 0.14 M), it is evident that chain unsaturation is not required for activity. It was
found, however, that complete removal of the 2-position chain of dFBr (32), affording 35,
resulted in no potentiation of the action of ACh. Compound 35 was, nevertheless, able to
produce an inhibitory action at high concentrations (IC50 = 39.8 M). Evidently the 2-position
substituent, or a portion thereof, is required for the potentiation of ACh action by dFBr at 42
nACh receptors. Because compound 34 was twice as potent as its parent, dFBr (32), unsaturation
of the side chain is not required for the action of ACh. Compound 36, retaining the propenyl side
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chain was unable to potentiate the action of ACh, but produced relatively potent inhibition (IC 50
= 3.55 M). This indicates that at least one of the gem-dimethyl groups of dFBr (32), and not the
unsaturation of the side chain, is important for the potentiating effect of the parent molecule, 32,
as a PAM. Again, supportive of the notion that at least one of the gem-dimethyl groups is
required for PAM activity, compound 38 lacked this action. Compound 37, the monomethyl
counterpart of 34, is more than 400-fold less potent than 34 as a PAM. Hence, the gem-dimethyl
groups seem to play a major role in PAM action.
As in the case of compound 34, which is twice as potent as dFBr (32), compound 38, although an
inhibitor, was almost 24-fold less potent compared to 36 in this regard suggesting a different
mode of binding for the potentiation and antagonism at 42 nACh receptors.
The N-des-methyl analog 40 (EC50 = 0.51 M) was half as potent as dFBr (32) (Table 4) as a
PAM showing that the secondary amine of dFBr (32) is preferred over the primary amine of 40.
Comparing compounds 32, 33, 40 and 82 it can be predicted that compound 82, which lacks the
6-bromo and the N-methyl substituent, will be less potent than 33 and 40 although data have not
yet been obtained for compound 82. It would appear that some steric bulk is tolerated at the
terminal amine. Thus, most of the deconstructed analogs of dFBr (32) to be examined henceforth
will retain the N-methyl group as seen in 32 (Figure 13).
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Figure 13. Initial deconstruction of dFBr (32). Each arrow symbolizes a single structural change.
Data are from Table 4. Certain analogs did not potentiate the effect of ACh at 42 ACh
receptors at their highest concentration evaluated (i.e., 100 M).
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Reconstruction. Up to this point, several structural features were found optimal for PAM action:
a) an N-methyl amine, b) a 6-bromo substituent, and c) a 2-position substituent consisting of a
quaternary carbon (Figure14).

Figure 14. Deconstruction of dFBr (32) revealing the structural requirement for action. a) A
secondary amine is optimal, b), a 6-bromo substituent is required for potency but not action, and
c) a 2-position quaternary carbon is required for activity as a PAM at 42 nACh receptors.

The next goal was a more detailed examination of 2-position substituents. Synthetically, to
incorporate 2-position substituents with a 6-bromo group, is a challenge. Also, the des-bromo
derivative 33 was active; thus, a relatively simpler route for the synthesis of various analogs of
dFBr (32) which will help understand what portion of the 2-position substituent is required for
the potentiation action of ACh was undertaken. The intent was to optimize the 2-position
substituent for a 6-desbromo analog, and then to add a bromo group to the optimized
compound(s). Compound 33 was further deconstructed to compounds 41-45 (Figure 15; Table 4)
of which only compound 41 and 43 showed potentiation of the activity of ACh (41; EC50 = 3.02
M and 43; EC50 = 3.98 M). Comparing compounds 32 and 33 with 34 and 41, respectively, it
was observed that there is a similar trend where the saturated analogs, 34 and 41, are twice as
potent as the parent molecules, 32 and 33, respectively. This information allows us to avoid the
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unsaturation of dFBr which can prove to be a synthetic advantage for synthesizing simpler
analogs. Compounds 42-44 (Table 4) provided information about the gem-dimethyl system of
the 2-position substituent of dFBr (32). It was observed that the gem-dimethyl groups are
important for the potentiation property of dFBr (32). Compound 44, which has a 2-methylpropyl
side chain, was inactive as a PAM, but showed antagonist properties (IC50 = 16.6 M).
Comparing compounds 42, having a 2-iso-propyl side chain, and 43 having a 2-tert-butyl side
chain, it was seen that, although both the analogs possess a gem-dimethyl group, the presence of
a quaternary carbon at the 2-position in 43 is what provides the potentiation property as a PAM
at 42 nACh receptors. In simple terms it can be concluded that, for potentiation, the presence
of a 2-position quaternary carbon atom is required whereas for the inhibitory/antagonistic effect,
a propyl or a mono-substituted propyl substituent is tolerated (Figure 15).
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Figure 15. Deconstruction of 33 to determine the role of the 2-position substituent on the PAM
action of ACh at nACh receptors. Data are from Table 4.

In the reconstruction process, we synthesized compound 39 which bears all the regional features
shown in Figure 14. Although it was expected that the 2-tert-butyl compound 39 would be more
potent than its des-bromo parent 43, data have not yet been obtained for this compound.
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V. Results and discussion of elaboration of dFBr

The elaboration step sought answers to several questions such as, for example: a) is a tertiary
amine tolerated, b) is a quaternary amine tolerated (note: ACh is a quaternary amine) (Figure
16), c) is the indolic N-H a contributor to action (Figure 16), d) what is the specific role of the 6bromo group, e) is the position of attachment of the bromo group important for activity (Figure
17)? That is, the elaboration step introduced substituents not found in dFBr (32).

A. Chemistry
Several analogs of dFBr (32) were synthesized in collaboration with others in our laboratory
concurrent with the present investigation. For example the synthesis of compounds 97-100 were
synthesized in collaboration with Dr. German (a postdoctoral fellow in Dr. Glennon’s lab).
Scheme 10 summarizes the synthesis of 86 and 87. Compound 40 was used as the starting
material which was converted to its free base and subjected to Eschweiler-Clarke reaction with
formic acid and formaldehyde to yield N,N-dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine
(101). The latter was converted to the oxalate salt to yield 86. Compound 101 was further
methylated with iodomethane to yield N,N,N-trimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine
methiodide (87) (Scheme 10). Direct quaternization of 40 resulted in the reaction not going to
completion and yielded a mixture of mono and di-methylated side products under varying
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conditions; from room temperature to reflux and varying equivalence of iodomethane; 3 to 10.
Thus, a 2-step approach was adopted for the synthesis of 87.

Figure 16. Elaborated analogs of dFBr (32) proposed for the synthesis and evaluation. For
example compound 86, 87, 91 and 92 can provide information on the steric bulk tolerated on the
amine, whereas compound 88 and 89 can provide information on the chain length while
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compound 90 can provide information about the -substitution on the tryptamine side chain
required for PAM action at the 42 nACh receptors.

Figure 17. Elaborated analogs of dFBr (32) proposed for the synthesis and evaluation. For
example, compounds 93-96 can provide information on the importance of indolic N-H, whereas
compound 98 can provide information on the position of the bromo substituent and its
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importance towards the activity. Compounds 99 and 100 on the other hand can provide
information about the specific role of the 6-bromo substituent required for PAM action at the
42 nACh receptors.

Scheme 10. Synthesis of compounds 86 and 87a

a

Reagents: (a) Formic acid, formaldehyde (37% v/v), H2O, reflux, 3 h; (b) Oxalic acid, CHCl3, 0
°C, 1.5 h, recrystallized from i-PrOH/Et2O; (c) iodomethane, i-PrOH, 0 °C to room temperature,
22 h, recrystallized from MeOH/i-PrOH.

Synthesis of the homotryptamine analog (i.e., 89) and the 3-position des-methyl gramine side
chain analog (i.e., 88) (Figure 16) was attempted. The instability of the des-methyl gramine
analog 88 was a major issue, the product could not be isolated and, thus, the compound was not
pursued any further. It was found that compound 86 (Scheme 10) was active (see discussion
below) and thus, to see the effect of shortening of the tryptamine chain, compound 102 was
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synthesized. Gramines (indole-3-yl-N,N-dimethylmethylamines) are stable and can be
synthesized to obtain substitution on the indole nucleus. Similarly, to understand the role of
extension of the tryptamine side chain, compound 103 was considered, which is a des-bromo
analog of 89. This particular compound was considered based on the knowledge that the 6bromo substituent in dFBr (32) is required for potency, but not PAM action. Compound 104 was
considered instead of 90 (Figure 16) based on the data that the primary amine (40) is only half as
potent as dFBr (32) (see Table 3) and also because of the ease of synthesis of 104 compared to
90.

Compound 102 was synthesized by Dr. German. Scheme 11 summarizes the synthesis of
compound 103. Indole-3-propionic acid (105) was treated with methyl chloroformate and then
with methylamine hydrochloride to yield the known N-methyl-3-(1H-indol-3-yl)propanamide
(106)190 which was further reduced with LiAlH4 to yield N-methyl-3-(1H-indol-3yl)propanamine (107).191 The amine was protected by di-tert-butyl dicarbonate in the presence of
Et3N to yield tert-butyl-3-(indol-3-yl)propyl-N-methylcarbamate (108). Upon further treatment
of 107 with freshly prepared prenyl-9-BBN in the presence of tert-butyl hypochlorite and Et3N,
the reaction yielded tert-butyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-N-methylcarbamate
(109), which was deprotected and converted to an oxalate salt to yield N-methyl-3-(2-(1,179

dimethylallyl)-indol-1H-yl)propanamine oxalate (103). Although homogeneous in thin-layer
chromatographic analysis (Rf = 0.4 in CH2Cl2/MeOH/NH3 10:1:01), elemental analysis for 103
was not within the permissible range of 0.4% (Anal. Calcd for (C17H24N2·C2H2O4) C, 65.87; H,
7.56; N, 8.09. Found: C, 62.95; H, 7.12; N, 7.62). The oxalate salt can exist in different ratios
with the free base (e.g., 1 mol of free base and 1 mol of oxalate or 1 mol of free base and 0.5 mol
of oxalate). The 1H NMR spectrum didn’t indicate the presence of water in the sample. The MS
of 103 revealed a molecular base peak of 257.15 (the same as the M+1 of the free base of 103).
The mass peak of the oxalate ion will not be seen in the MS because the salt is ionic and at high
temperature will be converted to CO2. Thus, on the basis of a constant melting point on repeated
recrystallization with i-PrOH, the molecular base peak in the mass spectrum (all the hydrogen
atoms in the molecular structure accounted for in the NMR spectrum) it was concluded that 103
had been obtained.
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Scheme 11. Synthesis of compound 103a

a

Reagents: (a) (1) methyl chloroformate, Et3N, THF, 0 °C, 30 min; (2) methylamine HCl, 0 °C,
1.5 h; (b) LiAlH4, dioxane, reflux, overnight; (c) di-tert-butyl dicarbonate, Et3N, CH2Cl2, room
temperature, 19 h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN,
THF, room temperature, 2 h; (3) NaOH, H2O2, 1 h; (e) oxalic acid, Et2O, recrystallized from iPrOH.

Scheme 12 summarizes the synthesis of compound 104. 6-Bromo-1H-indole-3-carboxaldehyde
(110) underwent a Henry reaction in the presence of nitroethane and ammonium acetate as a
weak base to yield 3-[(E)-2-nitroprop-1-en-1-yl]-6-bromo-1H-indole (111).176 Further reduction
with NaBH4 in the presence of a Lewis acid yielded the corresponding -methyltryptamine
(112), which was Boc-protected to yield tert-butyl-1-(6-bromo-1H-indol-3-yl)propyl-2carbamate (113). The 2-dimethylallyl substituent was introduced by a prenylation reaction to
yield

tert-butyl-1-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-2-carbamate
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(114)

which, on acidic deprotection, yielded 1-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propan2-amine hydrochloride (104).

Scheme 12. Synthesis of compound 104a

a

Reagents: (a) Nitroethane, NH4Ac, reflux, 7 h; (b) NaBH4, BF3·Et2O, THF, reflux, 4 h; (c) ditert-butyl dicarbonate, Et3N, CH2Cl2, room temperature, 24 h; (d) (1) tert-butyl hypochlorite,
Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 3 h; (3) NaOH, H2O2, 1
h; (e) HCl, Et2O, 0 °C, 24 h, recrystallized from i-PrOH/Et2O.
Scheme 13 summarizes the synthesis of compounds 91 and 92. The N-alkyl analogs of dFBr (32)
were synthesized following a similar route where oxalyl chloride was reacted with 6bromoindole to yield the glyoxylyl chloride, which was further treated with the appropriate
amine, iso-propylamine and benzylamine, respectively, to yield the corresponding glyoxylamides
(115, 116) which, on reduction with borane dimethylsulfide complex, yielded the respective
tryptamines (117, 118). Further treatment of 117 and 118 with di-tert-butyl dicarbonate in the
presence of Et3N to yielded the Boc-protected tryptamines (119, 120) which were treated with
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freshly prepared prenyl-9-BBN in the presence of tert-butyl hypochlorite and Et3N to yield the
tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-isopropylcarbamate

(121)

and tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-benzylcarbamate (122),
respectively. Compound 121 was deprotected and converted to an HCl salt to yield N-iso-propyl6-bromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (91), while 122 was deprotected by
using

TFA

and converted into a oxalate salt

to

yield

N-benzyl-6-bromo-2-(1,1-

dimethylallyl)tryptamine hydrogen oxalate (92). It was observed that the bulkier N-alkyl
substituent, benzyl group compared to the isopropyl group, lowered the yield of the various
reactions involved in the reaction scheme.
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Scheme 13. Synthesis of compounds 91 and 92a

a

Reagents: Compound 91 (a) (1) oxalyl chloride, Et2O, -15 °C, 15 min, room temperature, 2 h;
(2) iso-propylamine, room temperature, overnight; (b) BH3·S(CH3)2, THF, reflux, 5 h; (c) di-tertbutyl dicarbonate, Et3N, DMF, room temperature, overnight; (d) (1) tert-butyl hypochlorite,
Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 4 h; (3) NaOH, H2O2, 1
h; (e) HCl, EtOAc, 0 °C, 24 h, recrystallized from MeOH.
Compound 92 (a) (1) oxalyl chloride, Et2O, -10 °C, 5 min, room temperature, 2 h; (2)
benzylamine, room temperature, 3 h; (b) BH3·S(CH3)2, THF, reflux, 6 h; (c) di-tert-butyl
dicarbonate, Et3N, DMF, room temperature, 24 h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78
°C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 6 h; (3) NaOH, H2O2, 1 h; (f) (1) TFA,
anhydrous CH2Cl2, room temperature 6 h; (2) oxalic acid, Et2O, recrystallized from i-PrOH.
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Scheme 14 summarizes the synthesis of compounds 93 and 94 where oxalyl chloride was reacted
with 6-bromoindole (46) to yield the glyoxylyl chloride, which was further treated with
methylamine to yield N-methyl-6-bromo-1H-indol-3-glyoxylamide (123). This, on reduction
with a borane dimethylsulfide complex, yielded N-methyl-6-bromotryptamine (35). Further
treatment with di-tert-butyl dicarbonate in the presence of Et3N to yielded tert-butyl-2-(6-bromo1H-indol-3-yl)ethyl-N-methylcarbamate (61) which was treated with freshly prepared prenyl 9BBN177 in the presence of tert-butyl hypochlorite and Et3N to yield tert-butyl-2-(6-bromo-2-(1,1dimethylallyl)-1H-indol-3-yl)ethyl-N-methylcarbamate

(124).

This

product

was

further

methylated at the indole 1-position with iodomethane in the presence of NaH to yield tert-butyl2-(6-bromo-1-methyl-2-(1,1-dimethylallyl)-indol-3-yl)ethyl-N-methylcarbamate (125), which
was deprotected and converted to an HCl salt to yield N-methyl-6-bromo-1-methyl-2-(1,1dimethylallyl)tryptamine hydrochloride (93). In a similar manner, 124 was alkylated with benzyl
bromide in the presence of NaH to yield tert-butyl-2-(6-bromo-1-benzyl-2-(1,1-dimethylallyl)indol-3-yl)ethyl-N-methylcarbamate (126), which was deprotected by TFA and converted to an
oxalate salt to yield N-methyl-6-bromo-1-benzyl-2-(1,1-dimethylallyl)tryptamine hydrogen
oxalate (94).
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Scheme 14. Synthesis of compound 93 and 94a

a

Reagents: (a) (1) oxalyl chloride, Et2O, 0 °C, 2 h; (2) methylamine, room temperature, 2 h; (b)
BH3·S(CH3)2, THF, reflux, 6 h; (c) di-tert-butyl dicarbonate, Et3N, DMF, room temperature, 24
h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room
temperature, 2 h; (3) NaOH, H2O2, 1 h; (e) (1) NaH, DMF, 0 °C, 30 min; (2) CH3I, 1.5 h; (f)
HCl, EtOAc, 0 °C, 7 h, recrystallized from MeOH; (g) (1) NaH, DMF, 0 °C, 45 min; (2)
benzylbromide, room temperature, 5.5 h; (h) (1) TFA, CH2Cl2, 0 °C, 2.5 h; (2) oxalic acid, Et2O,
recrystallized from i-PrOH.

Various unsuccessful attempts were made to synthesize compound 95 (Figure 17). The problem
reaction was the attachment of the 2-position dimethylallyl group in the presence of the 186

position substitution or vice versa. Various conditions were tried but none yielded the Nmethylethanamine side chain at the 1-position of the indole ring. While attempting the synthesis
of 95, biological results for compound 86 were obtained (Table 4) which showed that the N,Ndimethyl analog of 40 was active (see discussion); thus compound 127 was proposed. On similar
lines, compound 96 was modified to its N,N-dimethyl analog, 129. Scheme 15 summarizes the
synthesis of compound 127.

5-Bromoindole (129) was brominated in presence of bromine to yield 3,5-dibromoindole
(130),192 which was further treated with freshly prepared prenyl 9-BBN in the presence of Et3N
to yield 5-bromo-2-(1,1-dimethylallyl)-1H-indole (131)179,193 Compound 131 was alkylated at
the 1-position by N,N-dimethylaminoethyl chloride hydrochloride in the presence of NaH
followed by salt formation to yield N,N-dimethyl-5-bromo-2-(1,1-dimethylallyl)isotryptamine
hydrogen oxalate (127).
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Scheme 15. Synthesis of compound 127a

a

Reagent: (a) Br2, DMF, light protected, room temperature, 12 h; (b) prenyl-9-BBN, Et3N, THF,
room temperature, 4 h; (c) (1) NaH, DMF, 0 °C, 30 min; (2) N,N-dimethylaminoethyl chloride
hydrochloride, KtBuO, KI, reflux, 17 h; (3) oxalic acid, Et2O, recrystallized from MeOH/Et2O.
Scheme 16 summarizes the unsuccessful attempt to synthesize the benzimidazole analog 128.
Various unsuccessful attempts were made to attach the N,N-dimethylethanmine side chain to the
5-bromo-2-(1,1-dimethtylallyl)-benzo[d]imidazole moiety. Scheme 16, however, provided a
route for the synthesis of 5-bromo-2-(1,1-dimethtylallyl)-benzo[d]imidazole (136). The synthesis
of the benzimidazole analog (136) was discontinued when it was found that the N-H of the
indole was important towards the potency at the nACh receptors (see discussion below)
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Scheme 16. Attempted synthesis of compound 130a

a

Reagent: (a) LDE, THF, dimethyl sulphate, -78°C to 0°C, 1.5 h; (b) oxalyl chloride, CH2Cl2,
DMF, room temperature, 16 h; (c) DCC, DMAP, CH2Cl2, reflux, 19 h; (d) Fe, HOAc, reflux, 7 h.

Based on the results obtained for compound 102 (see discussion below) two more compounds;
137 and 138, were synthesized to develop pairs of molecules in different classes of compounds
(e.g., 33 and 137; 38 and 138).
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Scheme 17 summarizes the synthesis of compound 137. The indole (139) was brominated in the
presence of bromine to yield 3-bromoindole (140) which was further treated with freshly
prepared prenyl-9-BBN in the presence of Et3N which undergoes a nucleophile substitution
reaction where the 3-bromo substituent activates the 2-postion of the indole ring to yield 2-(1,1dimethylallyl)-1H-indole (141). Compound 141 was further treated with dimethylamine and
formaldehyde in a Mannich fashion to yield the corresponding gramine that was converted to the
oxalate salt to yield 2-(1,1-dimethylallyl)gramine oxalate (137).

Scheme 17. Synthesis of compound 137a

a

Reagents: (a) Liquid Br2, DMF, room temperature, 24 h; (b) prenyl-9-BBN, THF, Et3N room
temperature, 5 h; (c) (1) dimethylamine, HCHO, room temperature, overnight; (2) oxalic acid,
Et2O, recrystallized from i-PrOH.
Scheme 18 summarizes the synthesis of compound 138. The synthetic route was similar to
Scheme 8 which yielded compounds 37 and 39. Sonagashira coupling was performed in the
presence of the corresponding alkyne and ligand-based palladium catalysts provided 5-bromo-2(1-pentynyl)aniline (142). The corresponding alkyne was treated with ZnI2 to effect cyclization
to yield 6-bromo-2-propyl-1H-indole (143). Compound 143 was treated with dimethylamine and
formaldehyde in the presence of ZnI2 to undergo a Mannich reaction to yield the corresponding
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gramine, which was converted to an oxalate salt to yield 6-bromo-2-propylgramine hydrogen
oxalate (138).

Scheme 18. Synthesis of compound 138a

a

Reagents: (a) 1-pentyne, CuI, PdCl2(PPh3)2, Et3N, THF, room temperature, overnight; (b) ZnI2,
Toluene, reflux, 2.5 h; (c) (1) Formic acid, dimethylamine, ZnI2, EtOH, room temperature, 24 h;
(2) oxalic acid, Et2O, recrystallized from i-PrOH.

Based on the results obtained for compound 98 (see discussion below), compound 144 was
prepared. Scheme 19 summarizes the synthesis of compound 144. Parsons; et al.194 in 2011,
published a method to synthesize 5,6-dibromo indoles as an important building block for the
synthesis of various alkaloids. We were able to replicate the two-step reaction where the
commercially available methyl-1H-indole-3-carboxylate (145) was brominated using bromine
and HOAc as the solvent to obtain methyl-5,6-dibromo-1H-indole-3-carboxylate (146) with a
melting point matching the literature.194 This was one of the few reactions ever reported to
synthesize a 5,6-dibrominated indoles. Decarboxylation was achieved by performing a
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microwave-assisted reaction to obtain 5,6-dibromo-1H-indole (147).194 Oxalyl chloride was
reacted with 5,6-dibromo-1H-indole to yield the glyoxylyl chloride, which was further treated
with

methylamine

to

yield

N-methyl-5,6-bromo-1H-indol-3-glyoxylamide

(148).

This

compound, upon reduction with a borane dimethylsulfide complex, yielded N-methyl-5,6dibromotryptamine (149). Further treatment with di-tert-butyl dicarbonate in the presence of
Et3N yielded tert-butyl-2-(5,6-dibromo-1H-indol-3-yl)ethyl-N-methylcarbamate (150), which
was treated with freshly prepared prenyl 9-BBN in the presence of tert-butyl hypochlorite and
Et3N

to

yield

tert-butyl-2-(5,6-dibromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-

methylcarbamate (151). Compound 151 was deprotected and converted to an HCl salt to yield Nmethyl-5,6-dibromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (144).
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Scheme 19. Synthesis of compound 144a

a

Reagents: (a) Liquid Br2, HOAc, room temperature, 16 h; (b) KOH, MeOH, H2O, THF, MW
100 W, 150 °C, 1 h; (c) (1) oxalyl chloride, Et2O, -5 °C 15 min, reflux 5 h; (2) methylamine,
room temperature, overnight; (d) BH3·S(CH3)2, THF, reflux, 7 h; (e) di-tert-butyl dicarbonate,
Et3N, DMF, room temperature, 24 h; (f) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 1.5 h; (2)
prenyl-9-BBN, THF, room temperature, 6 h; (3) NaOH, H2O2, 2 h; (g) HCl, EtOAc, 0 °C, 24 h,
recrystallized from i-PrOH.
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B. Pharmacology
Function data for dFBr (32) analogs are provided in Table 5.

Table 5. Effect of dFBr (32) and its elaborated analogs on the action (potentiation or
antagonism) of ACh action at the human 42 nACh receptors.
Half maximum
potentiation
concentration (EC50)
(M) ( SEM)
0.33  0.52

Half maximum inhibition
concentration (IC50) (M)
( SEM)

Compound

Potentiation

Inhibition

dFBr (32)

+

+

86

+

-

9.7 (2.3-17.1)b

146.5 (15.9-280)b

87

-

+

-

2.48 (1.6-3.3)b

91

DAa

DA

92

DA

DA

4.30  1.4

35.0  2.0

DA

DA

93

+

+

94

150  0.2

97

+

+

7.40  0.1

14.0  .8

98

+

+

0.90  0.5

32.0  0.6

99

+

-

2.40  0.2

25.0  21.0

100

+

-

0.90  0.1

19.5  0.9

102

-

+

-

1.8  0.7

103

DA

DA

104

DA

DA

127

+

+

11.2  0.5

71.0  1.0

137

-

+

-

17.9 (3.1-32.6)b

138

-

+

-

17.8 (3.1-32.6)b

DA

DA

144
a

DA = Data currently unavailable, b95% confidence limits, n = 4. Note: where both potentiation
and inhibition was observed, inhibitory potencies (IC50 values) are only estimates.
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C. Discussion
Compounds 86-100, 102-104, 127, 137, 138 and 144 represent elaborated analogs of dFBr (32)
(Table 5; Figure 16 and 17); that is, they possess substituents uncommon to dFBr (32).
Comparing dFBr (32) with 86 (Figure 18; EC50 = 9.7 M), it is evident that the N,N-dimethyl
tertiary amine 86 is around 30-fold less potent than the secondary amine of dFBr (32). This
suggests that either the tertiary amine or steric bulk at the terminal amine may cause the decrease
in potency compared to dFBr (32). Interestingly with respect to effect, 86 enhanced the action of
ACh at 42 nACh receptors by 300% (Figure 18). This is similar to what was found for dFBr
(32) itself.9 Hence, N-methylation of dFBr (32) decreased its potency, but had no effect on its
efficacy.

Figure 18. Biphasic dose-response curve for compound 86 co-applied with 100 M ACh on
human 42 nACh receptors.

Compounds 91, which has an N-iso-propyl substituent, and 92, which is an N-benzyl analog, will
help answer questions regarding the tolerance of steric bulk at the amine region of dFBr (32).
Data have not yet been obtained for compounds 91 and 92.
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The 42 nACh receptors are ion channel in nature with ACh being the endogenous ligand. ACh
is a quaternary amine; thus, it was worthwhile to check the effect of a quaternary amine analog
of dFBr (i.e., 87) on the activity of ACh at the 42 nACh receptors. It was found that
compound 87 failed to potentiate the action of ACh, but was a relatively potent antagonist (Table
5; IC50 = 2.5 M).

Figure 19. Initial elaboration of dFBr (32). Data are from Table 5. Certain analogs did not
potentiate the effect of ACh at nACh receptors, but blocked the effect of ACh.
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Given its unusually high potency as an inhibitor, coupled with its quaternary nature, 87 might be
a competitive antagonist. Its affinity at 42 nACh receptors remains to be measured.
The gramine analog of dFBr (102) also showed no potentiation of action, but inhibited ACh
action (Table 5, Figure 19; IC50 = 1.8 M). It might be proposed that the binding modes of dFBr
(32) and 102 can be different and that 102 might be a member of an altogether different
mechanistic class of compounds. Compound 102 was also further studied to see what
substituents can be tolerated and yet retain the inhibition profile of the gramine analog of dFBr
(32). The two series; 32 and 102 were studied to bring about a parallel structural change. A
parallel change in structure should result in a parallel change in potency if the two series are
behaving in the same manner. Figure 20 summarizes the compounds that were examined to
rationally understand the effect of substituents on the action of ACh. It is rather interesting that
gramine 102 is an antagonist that lacks the PAM action of dFBr (32). Apparently, the 6-bromo
group is neither a requirement for PAM action (comparing 33 with 32) nor a requirement for
blocking action (comparing 137 with 102) (Figure 20). But, whereas the gem-dimethyl groups
appear required for PAM action of 32, they are not required for the blocking action (i.e., both 38
and 138 behaved only as blockers with no action as PAMs).
It might be concluded that shortening the tryptamine chain of dFBr-like compounds and not the
presence of the N,N-dimethylamine accounts for the elimination of PAM action, because the
N,N-dimethyl counterpart of dFBr (32), i.e., 86, retains such action. Likewise, comparing the
des-bromo analog 33 with des-bromo gramine analog 137, it is apparent that the 6-bromo
substituent is not required for potency as an inhibitor for dFBr-like compounds, whereas the lack
of a 6-bromo substituent as in the des-bromogramine analog 137 decreases potency as an
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inhibitor of ACh action. The tryptamine series and the gramine series appear to act very
differently (i.e., some tryptamines lack PAM action, whereas all gramines examined lacked this
action) and the SAR for their actions appear independent. Gramine analogs should be further
explored to optimize this structurally diverse class of compounds behaving as blockers (potential
NAMs?) at the 42 nACh receptors.

Figure 20. Comparison of the two series of analogs; dFBr (32) and 102. Data for 32, 33, and 38
are from Table 4; data for 102, 137, 138 are from Table 5.

Comparing compounds 97, which has a piperidine substituent at the 3-position, 102, which is a
gramine analog, and 103, which is a homotryptamine analog of dFBr (32), will help us
understand the effect of changing tryptamine chain length. Comparing dFBr (32) with compound
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97 (Table 5; EC50 = 7.4 M), it can be hypothesized that the 20-fold decrease in potency could
be attributed to the slight elongation of the distance between the terminal amine and the indole
nucleus (2-carbon length for dFBr vs the 2.5-carbon length for the piperidine moiety), or the substitution on the tryptamine chain. Thus, compound 103, which is the homotryptamine analog,
and 104, which is a -methyl substituted analog, respectively, will be able to address each
question individually to provide insight into the chain length and -substitution tolerance on the
dFBr (32) and potency.
It is known that the 6-bromo substituent of dFBr (32) makes a substantial contribution to activity.
To further understand whether the effect of the 6-bromo substituent is due to a steric or
electronic effect, compounds 99, which is a 6-methyl analog, and 100, which is a 6trifluoromethyl analog, were synthesized. Comparing 32, 99 and 100 (Figure 21) it is unclear
whether an electronic or steric effect is predominant for activity. Additional compounds will be
required to conduct a thorough QSAR study.
Compound 98 in which the position of the bromo substituent was changed, did not substantially
affect potency (Figure 21; Table 5; EC50 = 0.9 M). This suggests that there could be
steric/electronic properties of the 5-position substituent that can be explored. The similarity in
potency could be attributed to either steric or electronic properties of the bromo substituent. Also
the 5- and 6-bromo compounds can be binding differently to produce their action as a PAM.
Data for compound 144 will help answer the question of bulk tolerance at the 5- and 6-position
of dFBr (32). It will also help understand if the 5- and 6-bromo analogs bind similarly at the
receptor site. The 5-bromo analog 98 is an early example of exploration of the positions on the
indolic ring that can be tolerated. Also with the 6-bromo and the 5-bromo analog being almost
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equipotent (Table 5; 32; EC50 = 0.33 M, 98; EC50 = 0.87 M), by having both substituents in
one compound (146), an increase in potency might be seen. Data for compound 144 has not yet
been obtained.
The importance of the N-H of the indole nucleus was addressed. Compound 93 (Table 5; EC50 =
4.3 M), N1-methyl dFBr, was almost 13-fold less potent than dFBr (Table 5; 32; EC50 = 0.33
M) suggesting that the N-H of the indole might be involved as a hydrogen-bond donor making
an important hydrogen bond interaction with the amino acids in the receptor. This hypothesis
was further strengthened when compound 127 (Table 5; EC50 = 11.2 M) was found to be almost
34 times less potent than dFBr (32). However, the lower potency of compound 127 could also be
due to the translocation of the indolic nitrogen atom and/or the presence of a substitution on the
tertiary amine. However, the potency of 127 was similar to that of N-methyl dFBr (86; EC50 =
9.7 M). The comparison of compounds 32, 93 and 127 helps us understand that a hydrogen
bond donor might be important for the potency of dFBr (32) (Figure 21).
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Figure 21. Elaborated analogs of dFBr (32). Data are from Table 5. Certain analogs did not
potentiate the effect of ACh at ACh receptors.

Radiolabelled dFBr
Compound 40 was used as an intermediate and submitted for commercial tritiation to obtain
[3H]dFBr (in Dr. Jonathan B. Cohen’s laboratory at Harvard Medical School).195 The tritiated
dFBr (152) is the first radiolabelled positive allosteric modulator at 42 nACh receptors. All
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the studies performed on dFBr (32) involved only the CNS 42 nACh receptors, while the
peripheral muscle type receptor was not characterized. At the muscle type 42 ACh receptor,
it was found that dFBr (32) does not activate nor potentiate the ACh response when expressed in
Xenopus oocytes. Instead it was found to be a potent inhibitor (IC50 = 1 M). dFBr (32) was also
found to reversibly inhibit the binding of [3H]phencyclidine (IC50 = 4 M) with higher affinity
in the desensitized state than in the resting state ([3H]ACh, IC50 = 1 mM).195 Photolabeling
studies performed with [3H]dFBr (152) highlight certain amino acids in the ion channel (M2
helix): in the ACh binding orthosteric site on the -subunit (Tyr93, Tyr190 and Tyr198) as well
to a site near the orthosteric ACh binding site on the  subunit (Tyr105, Tyr111 and Tyr117) in
the presence and absence of ACh. This data shows dFBr as a potent inhibitor of muscle-type
42 ACh receptor that acts as a channel blocker by binding in the channel pore. Studies are
underway to identify possible binding site(s) for the PAM at 42 nACh receptor.
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D. Antagonism of the ACh response
In biological studies dFBr (32) produces a biphasic dose-response curve (Figure 8). The biphasic
response provides information about the potentiation (EC50) as well as inhibition (IC50) of ACh’s
effect. The biphasic dose-response curve has an overlay between the potentiation and inhibition
profile and sometimes it is relatively difficult to define the two regions. Ideally, the biphasic
dose-response curve should have a wide concentration range and a broad plateau to allow a
definite demarcation of the potentiation and inhibition profile. Some analogs that were tested did
not allow for an accurate estimation of the potentiation and inhibition profile. A more accurate
IC50 value can be obtained for those compounds that only produced an antagonist effect. For
purpose of establishing a preliminary SAR for the antagonistic action of dFBr (32), a high
standard deviation was accepted and the IC50 values were compared. The aim of examining
structural analogs of dFBr (32) was to determine similarities and differences for agonist vs
antagonist SAR. Figure 22 summarizes dFBr (32) and its analogs. Comparing dFBr (32) with 37,
which has a 2-methylpropyl substituent, and 36, with a 2-propenyl substituent, it is evident that
the gem-dimethyl groups are not required for the antagonist action at 42 nACh receptors. In
fact, compound 38 (lacking the methyl group of 37) was as potent as 37 as an antagonist.
Removal of the 6-bromo group of dFBr (i.e., 33) resulted in almost a 12-fold increase in
inhibitory action. The removal of the 6-bromo group of 37 (i.e., 44) seems to be tolerated and the
resulting compound is 3-fold more potent than 37 as an inhibitor. N-Methyl dFBr (86) showed no
change in potency compared to dFBr (32) while the gramine analog 102 was almost 80-fold
more potent as an inhibitor. Thus, the gramine analog 102 attributes its relative potency as an
antagonist to the shortening of the tryptamine side chain rather than to the N,N-dimethyl amine
103

found in 86. In the gramine series (compounds 102, 137 and 138), it can be concluded that the
removal of the 6-bromo group is tolerated and is not required for action. Similarly the gemdimethyl groups are not essential for potency as an antagonist (comparing 137 and 138).

Figure 22. Analogs of dFBr (32) comparing the inhibition of the ACh-induced response. Each
arrow symbolizes a structural change. Data are from Tables 4 and 5.
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As seen in Figure 22, comparing dFBr (32) and quaternary amine 87, it is seen that the 60-fold
increase in potency of 87 is due to the quaternary amine, suggesting that the electronic nature of
the amine is important towards the activity (inhibition), along with greater bulk at the amine
region. An observation that needs to be further explored. The 1-methyl analog of dFBr (93) was
shown to have a 10-fold decrease in PAM potency (Table 6; EC50 = 4.3 M), but an improved
inhibition potency by almost 4-fold (Table 6; IC50 = 35 M). So it can be predicted that the steric
bulk at the N1-position is not favored for potentiation but it is tolerated for inhibition of ACh
action at 42 nACh receptors. Comparing dFBr (32) and the 1-methyl analog (93), it can also
be concluded that the hydrogen bond donor property of the indolic N-H might be important for
potentiation, while the hydrogen bond acceptor property of the substituted N1-position of the
indole could be favoring the inhibition of the ACh-induced action at the 42 nACh receptors.
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Table 6. Effect of dFBr (32) and its analogs on inhibition of ACh action at the human 42
nACh receptors.

dFBr (32)

+

+

Half maximum
potentiation
concentration (EC50)
(M)
0.33  0.52*

86

+

+

9.70 (2.3-17.1)

146.5 (15.9-280)

87

-

+

NPa

2.48 (1.6-3.3)

93

+

+

4.30  1.4*

35.0  2.0*

97

+

+

7.40  0.1*

14.0  0.8*

102

-

+

NP

1.8  0.7*

137

-

+

NP

17.9 (3.1-32.6)

138

-

+

NP

17.8 (3.1-32.6)

Compound Potentiation Inhibition

a

Half maximum
inhibition concentration
(IC50) (M)
150  0.2*

NP = No potentiation of the action of ACh; * = SEM;  = 95% confidence limits; n = 4.

It can be concluded that the structural features required for potentiation action and inhibition
action are not identical, as summarized in Table 7. Nevertheless, it is realized that the
‘inhibitory’ effect is in need of further study. That is, the nature of ‘inhibition’ is unknown at this
time. Several dramatic structural changes have been made (e.g., tryptamine vs quaternary amine
vs gramine). Certain compounds might produce their inhibitory effect like dFBr (32), presumably
by acting as a channel blocker; others might represent NAMs, or perhaps competitive antagonists
that bind at the orthosteric site. This needs to be investigated.
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Table 7. Summary of structural requirements for potentiation/inhibition of the ACh response at
the 42 nACh receptors.
Substituent

Potentiators

Inhibitors

6-Bromo

Required for potency but not

Not required for potency or

action

action

gem-Dimethyl

Required for action

Not required

3-Position carbon chain

2-Carbon (tryptamine)

1-Carbon (gramine)
Quaternary amine might be

N-Substituent

Secondary amine optimal

optimal
Secondary and tertiary amine
are equipotent

N1-Substitution

Indolic NH required for

Bulk tolerated at the indolic

activity

NH

The results shown in Table 7 can be a good starting point to develop functionally different series
of analogs as potentiators or inhibitors of the ACh response at the 42 nACh receptors.
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VI. Conclusions

des-Formylflustrabromine (dFBr, 32) has been identified as a positive allosteric modulator
(PAM) at α4β2 nACh receptors that potentiates the actions of the neurotransmitter ACh. It was
isolated in small quantities from a marine organism: Flustra foliacea. The present investigation
was to identify what structural features of dFBr (32) are required for the action of dFBr as a
PAM. The ‘deconstruction-reconstruction-elaboration’ approach also identified a possible
pharmacophore for a positive allosteric modulator action at 42 nACh receptors.
It is worth mentioning that the in vitro studies were performed on oocytes. The
electrophysiological data obtained from the oocytes studies should be thoroughly examined and
various factors such as temperature, experimental conditions, and functioning of the oocytes
should be considered. Also the data obtained from electrophysiology should be used as a good
starting point for performing in vivo studies which has a better correlation with how the drug
behaves in humans.
One of the aims of this study was to identify critical structural features of dFBr for potentiation
of ACh at 42 nACh receptors. Figure 23 summarizes the structural features required for
action/potency. The ‘deconstructed’ analogs of the 2-position showed that double bond
saturation (i.e., 34) is tolerated. This provides a synthetic advantage for future dFBr (32) analogs.
The gem-dimethyl groups are required along with a quaternary carbon at the 2-position (i.e., 39)
for potency. The amine region was investigated and it was shown that the secondary amine of
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dFBr (32) was optimal. The primary amine counterpart 40 was half as potent as the parent
analog. The N,N-dimethyl tertiary amine analog 86 was almost 30 times less potent than dFBr
(32). This might be attributed to the basicity of the amine or the steric bulk at the amine region.
The quaternary amine 87 was studied to see if the quaternary amine and its cation- interaction
similar to the interaction of ACh would have any effect. It was shown to be an antagonist, and
was relatively potent. The antagonistic action of the analog can be because of a different mode of
binding. The tryptamine side chain was examined and it was found that shortening of the chain
abolishes potentiation of action of ACh, but the compound retains action as an antagonist. A
possible explanation could be a different mode of binding. The development of the gramine
analogs (i.e., 102, 137, and 138) provides some preliminary information on the structural
requirements for their antagonist action (Figure 24). Additional gramine analogs should be
explored for the antagonist action at 42 nACh receptors.
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Figure 23. SAR for dFBr (32) at 42 nACh receptors.

Figure 24. Preliminary SAR for antagonist action of dFBr (32) analogs at 42 nACh receptors.
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The piperidine analog 97 was synthesized to examine a constrained side chain. The piperidine
analog 97 possesses two features of interest; the distance of the amine from the indole nucleus,
and branching of the 3-position tryptamine side chain. The secondary amines of dFBr (32) with
i-propyl (i.e., 91) and benzyl (i.e., 92) substituents were synthesized to explore the region for
steric bulk tolerance. The indolic N-H was investigated and it was seen that the hydrogen-bond
donor is required at the receptor site, shown by the almost 10-fold decreased potency of 93
compared to 32. The 1-methyl substitution of 93 provided information about the indolic N-H and
steric bulk. Although a methyl substituent is not too bulky in volume, a benzyl substituent (i.e.,
94) was synthesized which might provide information about any region for bulk tolerance at the
indolic N-H region. The isotryptamine analog 127 was similar in potency compared to N-methyl
dFBr (86), which supports data for compound 93 suggesting that the N-H of the indole is optimal
for potency. The 6-bromo substituent of dFBr (32) was investigated. Removal of the 6-bromo
group was a major synthetic advantage for synthesis of 2-position substituted analogs of dFBr
(32), although removal of the 6-bromo group reduced the activity by 20-fold; thus, the 6-bromo
group is required for potency but not for action. The steric and electronic properties of the 6bromo substituent were further explored. The 6-methyl analog (i.e., 99) and the 6-trifluoromethyl
analog (i.e., 100) explored the importance of the 6-bromo group, and comparing them, it is still
unclear whether electronic or steric properties are important for the potentiation of the AChinduced response. Additional analogs are required for developing a QSAR for studying the
electronic and steric effect for PAM action. The 5-position of dFBr (32), which is para- to the
indolic N-H, was also examined and it was found that a 5-bromo substituent is tolerated; thus,
compound 144 can possibly have a synergistic/additive effect towards the potency by having 5,6111

dibromo substituents. Compound 152 will be a useful tool to perform binding experiments to
understand the binding sites. In conclusion a pharmacophore of dFBr (32) was developed.

Figure 25. Minimal structural features required for the PAM action of dFBr (32). This simplified
structure might represent a pharmacophore for such action.

There is growing interest in the discovery of PAMs which are selective for 4-, 2, or 2
containing subunits, and one such compound; NS9283 (153) has been found to be selective for
the 2- and 4- containing nACh receptors. Compound 153 is a potent PAM at the (2)3(2)2,
(2)3(4)2, and (4)3(2)2 nACh receptors (EC50 = 1.3 M, EC50 = 1.7 M, EC50 = 3.3 M
respectively).196 Attaining subunit selectivity and progressing towards subtype selectivity is the
need of the hour for understanding the role of various subtypes of the nACh receptors.

Binding experiments with tritiated dFBr will further help understand the binding of dFBr (32)like ligands at the 42 nACh receptors. Compound 152, being a radiolabeled ligand, can be
used for high-throughput screening to identify other allosteric modulators for the 42 nACh
receptors thus further helping in identification of possible new leads.
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VII. Experimental

A. Synthesis
Melting points (mp) were measured on a Thomas-Hoover melting point apparatus using a glass
capillary tube and are uncorrected. 1H NMR spectra were recorded on a Varian 400 MHz
spectrometer using tetramethylsilane (TMS) as an internal standard. Peak positions are given in
parts per million (). UHPLC-MS were recorded on a Perkin Elmer Flexar UHLPC with AxION
2 Time of Flight (TOF) Mass Spectrometer and the molecular weight of the compounds was
within 0.05% of calculated values. Elemental analysis was performed by Atlantic Microlab Inc.
(Norcross, GA) for the elements indicated and the results are within 0.4% of calculated values.
Infrared spectra were obtained on a Thermo Nicolet iS10 FT-IR.

Flash chromatography was

performed on CombiFlash Companion/TS (Telodyne Isco Inc., Lincoln, NE) using packed silica
gel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase Silica Flash Column,
Teledyne Isco Inc., Lincoln, NE). All reactions were monitored by thin-layer chromatography
(TLC) on silica gel GHLF plates (250 , 2.5 x 10 cm; Analtech Inc., Newark, DE).
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N-Methyl-6-bromotryptamine (35). Compound 35 was prepared as described.9 Borane
dimethylsulfide (10.1M in THF, 3.63 mL) was added in a dropwise manner at 60 °C to a stirred
solution of N-methyl-6-bromo-1H-indol-3-gloxylamide (123) (3.4 g, 12 mmol) in anhydrous
THF (35 mL). The reaction mixture was heated at reflux for 3 h, cooled to room temperature,
quenched with HCl (2N, to pH 1), and extracted with EtOAc (2 x 30 mL). The aqueous portion
was basified with NaOH (3M, to pH 8) and extracted with CH2Cl2 (3 x 40 mL). The combined
organic portion was washed with H2O (2 x 50 mL), brine (50 mL), dried (Na2SO4), and
evaporated under reduced pressure to yield 1.4 g (49%) of 35 as an off-white colored solid: mp
108-110 °C (lit.9 mp 112-114 °C); 1H NMR (CDCl3) δ 2.38 (s, 3H, CH3), 2.85 (m, 4H, CH2),
6.95-7.41 (m, 4H, Ar), 8.0 (s, 1H, indolic NH).

N-Methyl-6-Bromo-2-sec-butyltryptamine Hydrogen Oxalate (37). Compound 37 was
prepared using a literature procedure for a similar compound.178 Borane dimethylsulfide (10.1M
in THF, 0.4 mL, 4.5 mmol) was added in a dropwise manner at 60 °C to a stirred solution of Nmethyl-6-bromo-2-sec-butyl-1H-indol-3-glyoxylamide (66) (0.5 g, 1.5 mmol) in anhydrous THF
(15 mL). The reaction mixture was allowed to stir at reflux overnight, cooled to 0 °C, quenched
with H2O (4 mL), acidified with HCl (2N, to pH 1), and heated at reflux for 30 min. The THF
was evaporated under reduced pressure and the remaining aqueous portion was diluted with H2O
(50 mL) and basified with NaOH (3M, to pH 14) and extracted with CH2Cl2 (2 x 20 mL). The
combined organic portion was washed with H2O (2 x 15 mL), dried (Na2SO4), and solvent was
evaporated under reduced pressure to yield 0.2 g (50%) of the free base of 37 as a yellow oil.
Oxalic acid (0.1 g, 0.8 mmol) was added to the solution of free base of 37 in CHCl3 (3 mL) and
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the reaction mixture was allowed to stir at room temperature for 30 min. The precipitate was
collected by filtration to yield a white-colored solid which upon recrystallization from i-PrOH
afforded 0.1 g (43%) of 37 as a white solid: mp 126-129 ºC; 1H NMR (DMSO-d6) δ 0.70 (t, 3H,
CH3), 0.85-0.87 (m, 3H, CH3), 1.42-1.50 (m, 2H, CH2), 2.42 (s, 3H, CH3), 2.76-2.81 (m, 5H, 2 x
CH2, CH), 6.92 (d, 1H, Ar), 7.24-7.28 (m, 2H, Ar), 10.78 (s, 1H, COOH). Anal. Calcd.
(C15H21BrN2·C2H2O4·0.5H2O) C, 50.01; H, 5.92; N, 6.86. Found: C, 49.90; H, 5.73; N, 6.68.

N-Methyl-6-Bromo-2-tert-butyltryptamine Hydrochloride (39). Compound 39 was prepared
using a literature procedure for a similar compound.178 Borane dimethylsulfide (10.1M in THF,
0.3 mL, 2.5 mmol) was added in a dropwise manner at 60 °C to a stirred solution of N-methyl-6bromo-2-tert-butyl-1H-indol-3-glyoxylamide (72) (0.3 g, 0.8 mmol) in anhydrous THF (15 mL).
The reaction mixture was allowed to stir at reflux for 6 h, cooled to 0 °C, quenched with H 2O (4
mL), acidified with HCl (2N, to pH 1), and heated at reflux for 1 h. The THF was evaporated
under reduced pressure and the remaining aqueous portion was diluted with H2O (50 mL) and
extracted with Et2O (2 x 25 mL). The aqueous portion was basified with NaOH (3M, to pH 9)
and extracted with CH2Cl2 (3 x 30 mL). The combined organic portion was washed with H2O (3
x 70 mL), dried (Na2SO4), and solvent was evaporated under reduced pressure to yield 0.2 g
(78%) of the free base of 39 as a yellow oil. The oil was dissolved in anhydrous Et2O (15 mL)
and cooled to 0 °C. HCl/Et2O (10 mL) was added and the reaction mixture was allowed to stir
overnight. The solvent was evaporated to yield a white solid which was recrystallized from iPrOH to yield 0.05 g (17%) of 39 as a white solid: mp 246-248 °C; 1H NMR (DMSO-d6) δ 1.44
(s, 9H, (CH3)3), 2.61 (s, 3H, CH3), 2.94-2.98 (m, 2H, CH2), 3.16-3.19 (m, 2H, CH2), 7.09-7.12
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(dd, J = 8.4, 1.7 Hz, 1H, Ar), 7.46 (d, J = 1.7 Hz, 1H, Ar), 7.52-7.54 (d, J = 8.4 Hz, 1H, Ar), 8.87
(br s, 2H, NH2+ aliphatic), 10.76 (s, 1H, indolic NH). Anal. Calcd for (C15H21BrN2·HCl) C,
52.11; H, 6.41; N, 8.10. Found: C, 52.28; H, 6.42; N, 8.01.

6-Bromo-2-(1,1-dimethylallyl)tryptamine Hydrochloride (40). Gaseous HCl was bubbled into
a solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (50) (90
mg, 0.22 mmol) in anhydrous EtOAc (10 mL) at 0 °C. The reaction mixture was allowed to stir
at room temperature for 24 h and the solvent was evaporated to yield a white solid which was
recrystallized from EtOAc/MeOH to yield 25 mg (33%) of 40 as white crystals: mp 256-258 °C;
1

H NMR (DMSO-d6) δ 1.49 (s, 6H, (CH3)2), 2.85 (t, 2H, CH2), 3.05 (t, 2H, CH2), 5.08 (m, 2H,

CH), 6.14 (m, 1H, CH), 7.12 (dd, 1H, Ar), 7.50 (m, 2H, Ar), 7.98 (s, 3H, NH3+ aliphatic), 10.76
(s, 1H, indolic NH). Anal. Calcd for (C15H19BrN2∙HCl∙0.25H2O) C, 51.74; H, 5.93; N, 8.05.
Found: C, 51.90; H, 5.87; N, 8.00.

N-Methyl-2-tert-butyltryptamine Hydrogen Oxalate (43). Compound 43 was prepared using a
literature procedure for a similar compound.197 Lithium aluminum hydride (0.3 g, 6.5 mmol) was
suspended in dioxane (10 mL) and heated at reflux. A solution of N-methyl-2-tert-butyl-1Hindol-3-glyoxylamide (58) (0.2 g, 0.7 mmol) was added, and the reaction mixture was allowed to
reflux overnight. The reaction mixture was cooled to room temperature, diluted with THF (10
mL) and quenched with MeOH (3 mL) and NaOH (3M, 3 mL). The reaction mixture was filtered
and the filtrate was diluted with THF (15 mL) and further heated at reflux for 30 min, the organic
solvent was evaporated under reduced pressure to yield a yellow oil. The residue was purified by
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column chromatography (silica gel; CH2Cl2/MeOH 100:1 to 10:1) to afford 0.05 g (33%) of the
free base as a yellow oil. A solution of the free base in anhydrous THF (2 mL) and anhydrous
Et2O (5 mL) was cooled to 0 °C. Saturated oxalic acid solution in anhydrous Et2O (5 mL) was
added and the reaction mixture was allowed to warm to room temperature and stirred overnight.
The precipitate was collected by filtration to yield a white-colored solid which upon
recrystallization from i-PrOH afford 0.03 g (56%) of 43 as white flakes: mp 194-195 °C; 1H
NMR (DMSO-d6) δ 1.43 (s, 9H, (CH3)3), 2.64 (s, 3H, CH3), 2.94 (d, 2H, CH2), 3.15 (d, 2H,
CH2),

6.96-7.51

(m,

4H,

Ar),

10.55

(s,

1H,

indolic

NH).

Anal.

Calcd

for

(C18H30N2O·C2H2O4·C3H8O) C, 63.14; H, 8.49; N, 7.19. Found: C, 62.81; H, 8.46; N, 7.18.

3-[(E)-2-Nitroethenyl]-6-bromo-1H-indole (47). Compound 47 was prepared as described.176
In a 2-neck flask, 1-dimethylamino-2-nitroethylene (1.2 g, 10.2 mmol) was added to a solution of
6-bromoindole (46) (2.0 g, 10.2 mmol) in anhydrous CH2Cl2 (10 mL) under a N2 atmosphere.
Trifluoroacetic acid (1 mL) was added and the reaction mixture was allowed to stir at room
temperature for 1 h, quenched carefully with a saturated aqueous solution of NaHCO3 and the
residue was collected by filtration and dried to yield 2.4 g (88%) of 47 as a yellow solid: mp 193195 °C (decomp) (lit.176 mp not reported); 1H NMR (CDCl3) δ 7.37 (dd, J = 8.64, 1.56 Hz, 1H,
Ar), 7.58 (m, 3H, Ar), 7.66 (d, J = 13.5 Hz, 1H, CH), 8.17 (d, J = 13.5 Hz, 1H, CH), 8.67 (s, 1H,
indolic NH).

6-Bromotryptamine (48). Compound 48 was prepared as described.176 To a round bottom flask
cooled to 0 °C (ice bath), NaBH4 (0.8 g, 21 mmol) was added followed by addition of anhydrous
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THF (18 mL) and BF3·Et2O (5.65 mL, 23 mmol). The ice bath was removed and the contents
were allowed to stir at room temperature for 15 min. A solution of 3-[(E)-2-nitroethenyl]-6bromo-1H-indole (47) (1.0 g, 4 mmol) in anhydrous THF (11 mL) was added in a dropwise
manner over 10 min, and the reaction mixture was heated at reflux for 2 h, cooled to room
temperature and quenched with careful addition of ice. The mixture was acidified with HCl (2N,
to pH 2) and heated at 80-85 °C for 2 h. After cooling, the acidic solution was extracted with
Et2O (2 x 25 mL). The aqueous portion was basified with NaOH (3M, to pH 10) to liberate the
amine. NaCl (10 g) was added and the product was extracted with Et2O (3 x 30 mL). The
combined organic portion was washed with H2O (3 x 50 mL), brine (50 mL), dried (Na2SO4),
and evaporated to dryness under reduced pressure to yield 0.33 g (40%) of 48 as a brown oil: 1H
NMR (CDCl3) δ 2.81 (t, 2H, CH2), 2.95 (t, 2H, CH2), 6.93 (s, 1H, Ar), 7.14 (dd, J = 8.4, 1.6 Hz,
1H, Ar), 7.39 (d, J = 8.4 Hz, 1H, Ar), 7.43 (s, J = 1.5 Hz, 1H, Ar), 8.2 (s, 1H, indolic NH).

tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethylcarbamate (49). Compound 49 was prepared as
described.9 Di-tert-butyl dicarbonate (0.3 g, 1.3 mmol) and Et3N (0.2 mL, 1.3 mmol) were added
to an anhydrous DMF (15 mL) solution of 6-bromotryptamine (48) (0.3 g, 1.3 mmol) and the
reaction mixture was allowed to stir at room temperature for 24 h. The reaction mixture was
quenched with ice-cold H2O (100 mL) and extracted with EtOAc (3 x 40 mL). The combined
organic portion was washed with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4), and
evaporated to dryness under reduced pressure to afford 0.26 g (60%) of 49 as a white foam
which solidified on drying: mp 100-102 °C (lit.178 mp not reported); 1H NMR (CDCl3) δ 1.36 (s,
9H, (CH3)3), 2.85 (t, 2H, CH2), 3.37 (t, 2H, CH2), 4.51 (s, 1H, NH aliphatic), 6.95 (s, 1H, Ar),
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7.15 (dd, J = 8.5, 1.6 Hz, 1H, Ar), 7.39 (d, J = 8.4 Hz, 1H, Ar), 7.45 (s, J = 1.5 Hz, 1H, Ar), 7.94
(s, 1H, indolic NH).

tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (50). Compound
50 was prepared using a literature procedure for a similar compound.198 tert-Butyl hypochlorite
(0.10 g, 0.9 mmol) was added to a solution of tert-butyl-2-(6-bromo-1H-indol-3yl)ethylcarbamate (49) (0.25 g, 0.7 mmol) and Et3N (0.90 g, 0.9 mmol) in anhydrous THF (10
mL) at -78 °C and allowed to stir for 45 min. Freshly prepared prenyl 9-BBN179 (1.5 mmol) was
added in a dropwise manner over 20 min while maintaining the temperature below -78 °C. The
reaction mixture was allowed to warm to room temperature and stirred for an additional 2 h.
NaOH (3M, 3 mL) and H2O2 (30% v/v, 3 mL) were added dropwise and stirring was continued
for another 1 h at room temperature. The reaction mixture was diluted with Et2O (100 mL), the
organic layer was separated and washed with H2O (3 x 30 mL), brine (40 mL) and dried
(Na2SO4). The solvent was evaporated under reduced pressure to yield a crude residue which
was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 10:1) to afford 0.1
g (33%) of 50 as a white foam: 1H NMR (CDCl3) δ 1.37 (s, 9H, (CH3)3), 1.48 (s, 6H, (CH3)2),
2.93 (t, 2H, CH2), 3.29 (t, 2H, CH2), 5.08 (m, 2H, CH), 6.03 (m, 1H, CH), 7.10 (dd, 1H, Ar),
7.35 (m, 2H, Ar), 7.78 (s, 1H, indolic NH). Compound 50 was used for the preparation of
compound 40.

2,2-Dimethyl-N-(o-tolyl)propionamide (52). Compound 52 was prepared as described.180 A
solution of trimethylacetyl chloride (4.6 mL, 37 mmol) in anhydrous CH2Cl2 (10 mL) was added
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to a solution of o-toludine (51) (4.01 mL, 37.3 mol) and Et3N (5.2 mL, 37.3 mol) in anhydrous
CH2Cl (30 mL) which was previously cooled to 0 °C. The reaction mixture was allowed to warm
to room temperature and stirred for 2 h. The reaction was quenched with H2O (50 mL). The
organic layer was washed with H2O (3 x 50 mL), dried (Na2SO4) and evaporated to dryness
under reduced pressure to yield a crude white solid which upon recrystallization from
CH2Cl2/hexanes yielded 5.95 g (83%) of 52 as a white solid: mp 109-111 °C (lit.180 mp 109-111
°C); 1H NMR (CDCl3) δ 1.36 (s, 9H, (CH3)3), 2.28 (s, 3H, CH3), 7.0-7.5 (m, 4H, Ar).

2-tert-Butyl-1H-indole (55). Compound 55 was prepared as described.181 n-Butyllithium (1.6 M
in hexane, 19.6 mL, 31 mmol) was added in a dropwise manner at 0 °C to a stirred solution of
2,2-dimethyl-N-(o-tolyl)propionamide (52) (3 g, 16 mmol) in anhydrous THF (20 mL). The
reaction mixture was allowed to stir at 0 °C for 1 h, at room temperature for 8 h and heated at
reflux for 2 h. The reaction was cooled to room temperature, diluted with EtOAc (35 mL), and
quenched with saturated NH4Cl (20 mL). The organic layer was separated, washed with H2O (2
x 50 mL), dried (Na2SO4) and evaporated to dryness to yield a crude brown oil which on
crystallization with MeOH/H2O yielded 2.0 g (74%) of 55 as a light brown solid: mp 73-75 °C
(lit.181 mp 77 °C); 1H NMR (CDCl3) δ 1.46 (s, 9H, (CH3)3), 6.32 (s, 1H, CH), 7.15-7.61 (m, 4H,
Ar), 7.99 (s, 1H, indolic NH).

N-Methyl-2-tert-Butyl-1H-indol-3-glyoxylamide (58). Compound 58 was prepared using a
literature procedure for a similar compound.199 A solution of 2-tert-butyl-1H-indole (55) (0.2 g, 1
mmol) in anhydrous Et2O (10 mL) in a 2-neck flask was chilled to -5 °C and N2 was bubbled in
120

for 5 min. Oxalyl chloride (0.2 mL, 2 mmol) was added in a dropwise manner and the reaction
mixture was allowed to stir at 0 °C for 6 h. The organic solvent was evaporated under reduced
pressure and to the precipitate was added methylamine (40% in H2O, 5 mL) and the solution was
allowed to stir at room temperature overnight. The precipitate was collected by filtration, washed
with H2O (3 x 50 mL), dried and recrystallized from MeOH to yield 0.2 g (56%) of 58 as a
brown solid: mp 190-191 °C; 1H NMR (CDCl3) δ 1.46 (s, 9H, (CH3)3), 3.1 (s, 3H, CH3), 6.77 (s,
1H, NH aliphatic), 7.07-7.45 (m, 4H, Ar), 7.76 (s, 1H, indolic NH). Compound 58 was employed
in synthesis of 43.

tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-methylcarbamate (61). Compound 61 was
prepared as described.9 Di-tert-butyl dicarbonate (0.9 g, 4 mmol) and Et3N (0.5 g, 4 mmol) were
added to an anhydrous DMF (15 mL) solution of N-methyl-6-bromotryptamine (35) (1.0 g, 4
mmol) and allowed to stir at room temperature for 24 h. The reaction mixture was quenched with
H2O (40 mL) and extracted with EtOAc (3 x 40 mL). The combined organic portion was washed
with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4) and evaporated to dryness to afford 1.3 g
(94%) of 61 as a white foam: mp 124-126 °C (lit.9 mp 120-124 °C). The product was used
without further purification in the attempted synthesis of 62.

1-(3-Bromophenyl)-2-(3-methylpentan-2-ylidene)hydrazine (64). Compound 64 was prepared
according to a literature procedure for a similar compound.200 To a solution of 3-methylpentan2-one (0.1 mL, 0.9 mmol) in MeOH (10 mL) was added 3-bromophenylhydrazine (63) (0.2 g,
0.9 mmol) along with few drops of gl. HOAc and the reaction mixture was allowed to stir at
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room temperature for 2 h. The solvent was removed under reduced pressure and the residue was
dried to afford 0.23 g (95%) of 64 as a yellow-colored oil: 1H NMR (CDCl3)  0.54 (t, 3H, CH3),
0.98 (d, 3H, CH3), 1.45-1.47 (m, 2H, CH2), 1.56-1.58 (m, 1H, CH), 2.04 (s, 3H, CH3), 6.69 (d,
1H, Ar), 6.94-6.96 (m, 2H, Ar), 7.30 (m, 1H, Ar). The product was used without further
purification in the attempted preparation of 65.

6-Bromo-2-sec-butyl-1H-indole (65). Compound 64 was prepared according to a literature
procedure for similar compound.184 A solution of sec-butyl magnesium chloride in THF (2.0 M,
5 mL) was added in a dropwise manner to a solution of 1-(2-amino-4-bromophenyl)-2chloroethan-1-one (75) (1.0 g, 4.0 mmol) in anhydrous THF (20 mL) at -10 °C and allowed to
stir in an ice bath for 15 min. The reaction mixture was allowed to warm to room temperature,
and quenched with aqueous saturated NH4Cl (10 mL), extracted with MTBE (2 x 30 mL) and
washed with brine (10 mL). The organic portion was combined, dried (Na2SO4) and the solvent
was removed under reduced pressure. The oily residue was purified by column chromatography
(silica gel) using hexanes/EtOAc (9:1) to afford 0.64 g (38%) of 65 as a yellow solid: mp 37-38
°C; 1H NMR (CDCl3) δ 0.83 (t, 3H, CH3), 1.25 (d, 3H, CH3), 1.6-1.65 (m, 2H, CH2), 2.72-2.75
(m, 1H, CH), 6.14 (s, 1H, ArH), 7.07 (d, J = 8.0 Hz, 1H, ArH), 7.29 (s, 1H, ArH), 7.35 (s, 1H,
ArH), 7.78 (br s, 1H, indolic NH).

N-Methyl-6-bromo-2-sec-butyl-1H-indol-3-glyoxylamide (66). Compound 66 was prepared
using a literature procedure for a similar compound.201 A solution of 6-bromo-2-sec-butyl-1Hindole-3-glyoxylchloride (81) (0.6 g, 1.9 mmol) in anhydrous THF (2 mL) was added to
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methylamine (40% in H2O, 25 mL) cooled to °C. The reaction mixture was allowed to warm to
room temperature and stirred overnight. The reaction mixture was diluted with H2O (100 mL)
and the residue was collected by filtration, washed with H2O (3 x 50 mL) and dried to yield 0.5 g
(82%) of 66 as a buff-colored solid: The compound was impure even after repeated attempts at
crystallization with various solvents. Compound 66 was used without any further purification in
the preparation of compound 37.

4-Bromo-2-nitrotoluene (68). Compound 68 was prepared as described.202 A solution of 4methyl-3-nitroaniline (67) (10.0 g, 65.7 mmol) in H2O (25 mL) was added to conc. H2SO4 (25
mL) in H2O (150 mL) in a flask. The mixture was heated until all the starting material was
dissolved. On cooling the solid crystals were collected by filtration, washed with cold H2O (3 x
50 mL) to give the sulfonic acid salt as dark-yellow crystals (A) which was dissolved in H2O (70
mL) and HBr (62%, 17.5 mL) and the temperature was maintained at -5 °C. In a separate flask, a
solution of NaNO2 (8.2 g, 118.3 mmol) in H2O (26 mL) was added slowly to the above solution
while maintaining the temperature below 0 °C (B). In a 3-neck flask, CuBr (9.5 g, 65.7 mmol)
was dissolved in HBr (62%, 12.5 mL) and the mixture was heated to reflux. To this heated
solution, solution B was added slowly over 15 min and stirring was continued at reflux for 1.5 h.
The reaction mixture was allowed to cool to room temperature and extracted with MTBE (3 x 50
mL). The combined organic portion was washed with H2O (2 x 100 mL), 5% NH4OH (2 x 150
mL), brine (150 mL), dried (MgSO4) and the solvent was removed under reduced pressure to
afford 7.1 g (50%) of 68 as yellow, needle-shaped crystals: mp 42-44 °C (lit.202 mp 43-45 °C), 1H
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NMR (CDCl3)  2.55 (s, 3H, CH3), 7.32 (d, J = 8.2 Hz, 1H, Ar), 7.72 (dd, J = 8.2, 1.9 Hz, 1H,
Ar), 8.22 (d, J = 1.9 Hz, 1H, Ar).

(E/Z)-1-(4-Bromo-2-nitrostyryl)pyrrolidine (69). Compound 69 was prepared as described.203
A solution of 4-bromo-2-nitrotoluene (68) (1 g, 4.6 mmol), DMF-DMA (0.8 mL, 5.6 mmol) and
pyrrolidine (0.5 mL, 5.6 mmol) in DMF (10 mL) was heated to 110 °C until the TLC analysis
showed consumption of 68. The dark red solution was allowed to cool to room temperature,
diluted with Et2O (30 mL) and washed with H2O (3 x 50 mL). The combined H2O portion was
further extracted with Et2O (2 x 25 mL) and the combined organic portion was washed with H2O
(3 x 50 mL), brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure
to afford 1 g (70%) of 69 as a red-colored crystals: mp 61-63 °C (lit.176 mp not reported) 1H
NMR (CDCl3)  1.92-1.96 (m, 4H, CH2), 3.32-3.36 (m, 4H, CH2), 5.80 (d, J = 13.4 Hz, 1H, CH),
7.28 (d, J = 13.3 Hz, 1H, CH), 7.34 (d, J = 8.3 Hz, 1H, Ar), 7.58 (d, J = 1.8 Hz, 1H, Ar), 8.12
(dd, J = 8.2, 1.9 Hz, 1H, Ar). Compound 69 was used in the attempted synthesis of 70.

6-Bromo-2-tert-butyl-1H-indole (71). Compound 71 was prepared using a literature procedure
for a similar compound.188 Zinc iodide (0.2 g, 0.6 mmol) was added in one portion to a solution
of 5-bromo-2-(3,3-dimethylbut-1-yn-1-yl)aniline (80) (2.9 g, 11.5 mmol) in anhydrous toluene
(40 mL) and the reaction mixture was heated at reflux for 41 h. The reaction mixture was
allowed to cool to room temperature and washed with H2O (3 x 50 mL). The aqueous portion
was extracted with CH2Cl2 (3 x 50 mL) and the combined organic portion was washed with H2O
(3 x 70 mL), dried (Na2SO4) and the solvent was evaporated under reduced pressure to yield a
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crude product which upon recrystallization from hexanes afforded 1.5 g (51%) of 71 as buffcolored flakes: mp 110-111 °C; 1H NMR (CDCl3) δ 1.39 (s, 9H, (CH3)3), 6.24 (s, 1H, Ar), 7.157.18 (dd, J = 8.4, 1.2 Hz, 1H, Ar), 7.37-7.40 (d, J = 9 Hz, 1H, Ar), 7.46 (d, J = 1.2 Hz, 1H, Ar),
7.94 (br s, 1H, indolic NH).

N-Methyl-6-bromo-2-tert-butyl-1H-indol-3-glyoxylamide (72). Compound 72 was prepared
using a literature procedure for a similar compound.201 A solution of 6-bromo-2-tert-butyl-1Hindole (71) (1.3 g, 5 mmol) in anhydrous Et2O (25 mL) in a 2-neck flask was chilled to -5 °C and
N2 was bubbled in for 5 min. Oxalyl chloride (0.9 mL, 10 mmol) was added in a dropwise
manner and the reaction mixture was heated at reflux overnight. The Et2O was evaporated and
the precipitate was dissolved in THF (5 mL) to which was added methylamine (40% in H2O, 25
mL) and the solution was allowed to stir at room temperature for 15 h. The reaction mixture was
diluted with H2O (100 mL) and the residue was collected by filtration, washed with H2O (3 x 50
mL), hexanes (3 x 50 mL) and dried to yield 1.4 g (77%) of 72 as a buff-colored solid: mp 190193 °C (decomp); 1H NMR (CDCl3) δ 1.53 (s, 9H, (CH3)3), 3.04 (s, 3H, CH3), 6.85 (br s, 1H,
NH), 7.28-7.29 (dd, J = 8.4, 1.4 Hz, 1H, Ar), 7.50 (d, J = 1.4 Hz, 1H, Ar), 7.54-7.57 (d, J = 8.4
Hz, 1H, Ar), 8.66 (br s, 1H, indolic NH). Compound 72 was used in the preparation of
compound 39.

1-(2-Amino-4-bromophenyl)-2-chloroethan-1-one (75). Compound 75 was prepared according
to a literature procedure for a similar compound.184 3-Bromoaniline (74) (5.0 g, 29 mmol) and
chloroacetonitrile (4.6 mL, 73 mmol) were added sequentially to a mixture of AlCl3 (4.6 g, 35
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mmol) and BCl3 solution (1.0 M in CH2Cl2, 35 mL, 35 mmol) in CH2Cl2 (30 mL) in an ice bath
and the cloudy solution was allowed to stir for 5 h at room temperature and heated at reflux
overnight. The reaction mixture was cooled in an ice bath, quenched with 2 N HCl 150 mL,
heated at reflux for 20 min, allowed to cool to room temperature, and extracted with CH2Cl2 (3 x
50 mL). The combined organic portion was washed with H2O (3 x 50 mL), brine (50 mL), dried
(Na2SO4) and the solvent was removed under reduced pressure to afford 6.0 g (69%) of 75 as a
yellow solid: mp 139-141 °C; 1H NMR (CDCl3)  4.54 (s, 2H, CH2), 6.28 (br s, 2H, NH2), 6.70
(dd, J = 8.68, 1.84 Hz, 1H, Ar), 6.81 (d, J = 1.84 Hz ,1H, Ar), 7.40 (d, J = 8.68 Hz, 1H, Ar). The
product was used without further purification in the attempted synthesis of 71. It was also used in
the preparation of compound 65.

4-Bromo-2-nitroaniline (77). Compound 77 was prepared as described.185 N-Bromosuccinimde
(12.9 g, 72 mmol) was added slowly over 10 min to a solution of commercially available 2nitroaniline (77) (10.0 g, 72 mmol) in gl. HOAc (30 mL) and the solution was heated to 55 °C.
The reaction mixture was allowed to stir at 40-50 °C for 5 h, upon which it was poured into icewater (100 mL). The product was collected by filtration, washed with cold H2O (3 x 50 mL),
dried and recrystallized from EtOH to afford 12.4 g (79%) of 77 as orange, needle-shaped
crystals: mp 110-111 °C (lit.185 mp 111-112 °C); 1H NMR (CDCl3) δ 6.01 (br s, 2H, NH2), 6.65
(d, J = 8.9 Hz, 1H, Ar), 7.36 (dd, J = 8.8, 2.3 Hz, 1H, Ar), 8.20 (d, J = 2.3 Hz, 1H, Ar).

4-Bromo-2-nitroiodobenzene (78). Compound 78 prepared as described.186 A solution of 4bromo-2-nitroaniline (77) (7.3 g, 34 mmol) in anhydrous THF (50 mL) was added in a dropwise
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manner to BF3·Et2O (15.7 mL, 125 mmol) at -30 °C. The reaction mixture was allowed to stir for
10 min and then a solution of t-BuONO (13.3 mL, 111 mmol) in anhydrous THF (40 mL) was
added in a dropwise manner. The reaction mixture was allowed to warm to -10 °C, diluted with
Et2O (100 mL), and stirring was continued at room temperature for 1 h until a pale-yellow solid
precipitate was formed. The solid was collected by filtration and washed with Et2O (50 mL) to
afford a pale-yellow solid, which was then slowly added to a mixture of KI (7.1 g, 43 mmol) and
I2 (5.4 g, 21 mmol) in MeCN (100 mL). The reaction mixture was allowed to stir at room
temperature for 1 h. A saturated aqueous solution of Na2S2O3 (250 mL) was added and the
reaction mixture was extracted with CH2Cl2 (2 x 90 mL). The combined organic portion was
washed with H2O (2 x 100 mL), dried (Na2SO4) and the solvent was removed under reduced
pressure to afford 9.3 g (84%) of 78 as a yellow powder: mp 86-88 °C ( lit.186 mp 87-89 °C ); 1H
NMR (CDCl3) δ 7.40 (dd, J = 8.4, 2.2 Hz, 1H, Ar), 7.89 (d, J = 8.4 Hz, 1H, Ar), 8.0 (d, J = 2.2
Hz, 1H, Ar).

5-Bromo-2-iodoaniline (79). Compound 79 was prepared as described.187 A mixture of 4bromo-2-nitroiodobenzene (78) (8.4 g, 26 mmol), Fe powder (6.1 g, 110 mmol) in gl. HOAc (45
mL) and absolute EtOH (40 mL) was heated at reflux for 1.5 h. The reaction mixture was
allowed to cool to room temperature and a saturated aqueous solution of NaHCO3 (200 mL) was
added. The mixture was extracted with Et2O (4 x 50 mL) and the combined organic portion was
washed with H2O (3 x 100 mL), brine (100 mL), dried (Na2SO4) and the solvent was evaporated
under reduced pressure to yield a crude residue. The crude product was purified by column
chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:5) to afford 4.6 g (60%) of 79 as a
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cream-colored solid: mp 54-55 °C (lit.187 mp 55 °C); 1H NMR (CDCl3) δ 4.14 (br s, 2H, NH2),
6.60 (dd, J = 8.4, 2.2 Hz, 1H, Ar), 6.88 (d, J = 2.2 Hz, 1H, Ar), 7.45 (d, J = 8.4 Hz, 1H, Ar).

5-Bromo-2-(3,3-dimethylbut-1-yn-1-yl)aniline (80). Compound 80 was prepared using a
literature procedure for a similar compound.204 A mixture of 5-bromo-2-iodoaniline (79) (4.0 g,
13.4 mmol), CuI (0.1 g, 0.7 mmol) and PdCl2(PPh3)2 (0.5 g, 0.7 mmol) was suspended in
anhydrous THF (50 mL). Et3N (5.6 mL, 40.3 mmol) and 3,3-dimethylbut-1-yne (2.2 mL, 17.5
mmol) were added successively and the reaction mixture was allowed to stir at room temperature
for 5 h. The reaction mixture was diluted with Et2O (100 mL), filtered through Celite, and the
organic portion was washed sequentially with H2O (3 x 100 mL), a saturated aqueous solution of
NH4Cl (50 mL), brine (50 mL), dried (Na2SO4) and the solvent was evaporated under reduced
pressure to yield a crude residue. The crude product was purified by column chromatography
(silica gel; hexanes/EtOAc 100:1 to 75:1) to afford 2.9 g (86%) of 80 as a light-yellow oil: 1H
NMR (CDCl3) δ 1.34 (s, 9H, (CH3)3), 4.19 (br s, 2H, NH2), 6.75-6.79 (dd, J = 8.4, 1.9 Hz, 1H,
Ar), 6.84 (d, J = 1.9 Hz, 1H, Ar), 7.06-7.08 (d, J = 8.1 Hz, 1H, Ar). Compound 80 was used in
the preparation of compound 71.

6-Bromo-2-sec-butyl-1H-indol-3-glyoxylchloride (81). Compound 81 was prepared using a
literature procedure for a similar compound.201 A solution of 6-bromo-2-sec-butyl-1H-indole
(65) (0.5 g, 1.98 mmol) in anhydrous Et2O (20 mL) in a 2-neck flask was chilled to -5 °C and N2
was bubbled in for 5 min. Oxalyl chloride (0.2 mL, 2.40 mmol) was added in a dropwise manner
and allowed to stir for 30 min at 0 °C. The Et2O was evaporated and the residue was washed
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with Et2O (2 x 5 mL) to remove excess oxalyl chloride to afford 0.6 g (94%) of 81 as a yellow
colored oil. The product was used without any further purification for the synthesis of compound
66.

2-(1,1-Dimethylallyl)tryptamine Hydrochloride (82). Gaseous HCl was bubbled into a
solution of tert-butyl-2-(2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (85) (0.4 g) in
anhydrous Et2O (20 mL) at 0 °C. The reaction mixture was allowed to stir for 24 h and the
solvent was evaporated to yield a purple solid which was recrystallized from i-PrOH/Et2O to
yield 0.1 g (28%) of 82 as brown crystals: mp 231-232 °C; 1H NMR (DMSO-d6) δ 1.50 (s, 6H,
CH3), 2.86 (t, 2H, CH2), 3.07 (t, 2H, CH2), 5.06-5.11 (m, 2H, CH2), 6.12-6.18 (m, 1H, CH),
6.95-7.06 (m, 2H, Ar), 7.34 (d, J = 7.9 Hz, 1H, Ar), 7.51 (d, J = 7.8 Hz, 1H, Ar), 8.05 (br s, 3H,
NH3+ aliphatic), 10.59 (br s, 1H, indolic NH). Anal. Calcd for (C15H20N2·HCl) C, 68.04; H, 7.99;
N, 10.58. Found: C, 67.89; H, 7.99; N, 10.46.

tert-Butyl-2-(1H-indol-3-yl)ethylcarbamate (84). Compound 84 was prepared as described.189
Triethylamine (0.9 g, 8.5 mmol) and di-tert-butyl dicarbonate (1.9 g, 8.5 mmol) were added to a
solution of tryptamine (83) (1.4 g, 8.5 mmol) in anhydrous DMF (30 mL) and allowed to stir for
20 h at room temperature. The reaction mixture was quenched with ice and H2O (80 mL) and
extracted with EtOAc (3 x 40 mL). The combined organic portion was washed with H2O (3 x 40
mL), brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to
yield a crude oil. The crude product was purified by column chromatography (silica gel;
hexanes/EtOAc; 100:1 to 4:1) to afford 2.0 g (91%) of 84 as a white solid: mp 92-94 °C (lit.189
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mp 96 °C); 1H NMR (CDCl3) δ 1.37 (s, 9H, CH3), 2.96 (t, 2H, CH2), 3.32 (m, 2H, CH2), 4.55 (br
s, 1H, NH aliphatic), 6.98-7.08 (m, 3H, Ar), 7.21 (d, J = 8.0 Hz, 1H, Ar), 7.48 (d, J = 7.8 Hz, 1H,
Ar), 7.79 (br s, 1H, indolic NH).

tert-Butyl-2-(2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (85). Compound 85 was
prepared using a literature procedure for a similar compound.198 tert-Butyl hypochlorite (0.5 g,
4.6 mmol) was added to a solution of tert-butyl-2-(1H-indol-3-yl)ethylcarbamate (84) (1.0 g, 3.8
mmol) and Et3N (0.5 g, 4.6 mmol) in anhydrous THF (25 mL) at -78 °C and the solution was
allowed to stir for 45 min. Freshly prepared prenyl 9-BBN179 (7.7 mmol) was added in a
dropwise manner over 15 min while maintaining the temperature at -55 °C. The reaction mixture
was allowed to warm to room temperature and was stirred for an additional 3 h. Sodium
hydroxide (3M, 10 mL) and H2O2 (30% v/v, 10 mL) were added in a dropwise manner and the
reaction mixture was allowed to stir for 1 h at room temperature. The reaction was diluted with
Et2O (100 mL), the organic layer was separated and washed with H2O (3 x 60 mL), brine (80
mL) and dried (Na2SO4). The solvent was evaporated under reduced pressure to yield a crude
residue which was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 5:1)
to afford 0.5 g (36%) of 85 as a white foam: 1H NMR (CDCl3) δ 1.37 (s, 9H, CH3), 1.47 (s, 6H,
CH3), 2.96 (t, 2H, CH2), 3.32 (m, 2H, CH2), 4.53 (br s, 1H, NH aliphatic), 5.06-5.11 (m, 2H,
CH2), 6.01-6.08 (m, 1H, CH), 6.98-7.08 (m, 2H, Ar), 7.21 (d, J = 8.0 Hz, 1H, Ar), 7.48 (d, J =
7.8 Hz, 1H, Ar), 7.79 (br s, 1H, indolic NH). Compound 85 was used in the preparation of
compound 82.
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N,N-Dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Hydrogen Oxalate (86). A solution
of N,N-dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine (101) (0.05 g) in anhydrous CHCl3 (3
mL) was allowed to stir at 0 °C for 1.5 h. The precipitate was collected by filtration and the
white solid obtained was recrystallized from i-PrOH/Et2O to yield 0.02 g (36%) of 86 as a white
crystals: mp 172-173 °C; NMR (DMSO-d6) δ 1.58 (s, 6H, (CH3)2), 2.73 (s, 6H, N(CH3)2), 4.39
(m, 4H CH2), 5.25-5.29 (m, 2H, CH2), 6.31-6.38 (m, 1H, CH), 7.25 (dd, J = 8.4, 1H, Ar), 7.59
(d, J = 1.6 Hz, 1H, Ar), 7.70 (d, J = 8.4, 1.5 Hz, 1H, Ar), 11.27 (s, 1H, COOH). Anal. Calcd for
(C17H23BrN2·C2H2O4) C, 53.40; H, 6.36; N, 6.55. Found: C, 53.39; H, 6.06; N, 6.50.

N,N,N-Trimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Methiodide (87). A solution of
N,N-dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine (101) (0.05g, 0.2 mmol) in anhydrous iPrOH (4 mL) was cooled to 0 °C (ice-bath). Iodomethane (0.06 g, 0.5 mmol) was added and the
reaction mixture was allowed to stir for 22 h at room temperature under a N2 atmosphere. The
precipitate was collected by filtration and washed with anhydrous Et2O (3 x 15 mL), air dried
and crystallized from MeOH/i-PrOH to afford 0.02 g (30%) of 87 as yellow crystals: mp 208210 °C; 1H NMR (CD3CN) δ 1.54 (s, 6H, (CH3)2), 3.15 (s, 9H, N(CH3)3), 3.22-3.38 (m, 4H
CH2), 5.25 (m, 2H, CH2), 6.22 (m, 1H, CH), 7.22 (dd, J = 8.4, 1.7 Hz, 1H, Ar), 7.46 (d, J = 8.5
Hz, 1H, Ar), 7.59 (d, J = 1.5 Hz, 1H, Ar), 9.35 (br s, 1H, indolic NH). Anal. Calcd for
(C18H26BrIN2·C3H8O) C, 46.94; H, 6.38; N, 5.21. Found: C, 46.73; H, 6.29; N, 5.25.

N-iso-Propyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Hydrochloride (91). HCl gas was
bubbled into a 0 °C solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl131

N-iso-propylcarbamate (121) (0.4 g) in dry anhydrous EtOAc (10 mL). The reaction mixture was
allowed to stir for 24 h and the solvent was evaporated to yield a white solid which was
recrystallized from MeOH to yield 0.1g, (29%) of 91 as white crystals: mp 295-299 °C; 1HNMR
(DMSO-d6) δ 1.25 (d, 6H, CH3), 1.50 (s, 6H, CH3), 2.88-2.92 (m, 2H, CH2), 3.09-3.14 (t, 2H,
CH2), 5.09-5.13 (d, 2H CH2), 6.12-6.19 (m, 1H, CH), 7.11-7.14 (d, J = 8.4, 1.8 Hz, 1H, Ar), 7.49
(d, J = 1.7 Hz, 1H, Ar), 7.53-7.55 (d, J = 8.4 Hz, 1H, Ar), 8.86 (br s, 2H, NH2+ aliphatic), 10.78
(s, IH, indolic NH). Anal. Calcd for (C18H25BrN2·HCl) C, 56.04; H, 6.79; N, 7.26. Found: C,
56.02; H, 6.75; N, 7.32.

N-Benzyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Hydrogen Oxalate (92). Trifluoroacetic
acid (0.05 mL) was added into a 0 °C solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)1H-indol-3-yl)ethyl-N-benzylcarbamate (122) (0.05 g) in anhydrous CH2Cl2 (5 mL), and the
reaction mixture was allowed to stir for 6 h at room temperature. The reaction was quenched
with H2O (25 mL) and the organic portion was separated. The aqueous portion was further
extracted with CH2Cl2 (2 x 15 mL) and the combined organic portion was washed with NaOH
(3M, 3 x 25 mL), H2O (3 x 50 mL), dried (Na2SO4) and evaporated under reduced pressure to
yield a yellow oil. The free base was dissolved in anhydrous Et2O (15 mL) and converted to the
oxalate salt by addition of saturated oxalic acid solution in Et2O (4 ml). The precipitate was
collected by filtration, dried and recrystallized from i-PrOH to yield 0.02g (51%) of 92 as a white
powder: mp 244-245 °C; 1HNMR (DMSO-d6) δ 1.47 (s, 6H, (CH3)2), 2.99 (br s, 2H, CH2), 3.07
(br s, 2H, CH2), 4.15 (s, 2H, CH2), 4.99-5.04 (d, 2H CH2), 6.03-6.10 (m, 1H, CH), 7.09 (d, J =
8.6 Hz, 1H, Ar), 7.38-7.50 (m, 7H, Ar), 10.72 (s, IH, indolic NH). Anal. Calcd
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(C22H25BrN2·C2H2O4) C, 59.14; H, 5.58; N, 5.75. Found: C, 56.02; H, 6.75; N, 7.32. UHPLCMS; [M+1] calculated for C22H25BrN2 397.1, found 397.1.

N-Methyl-6-bromo-1-methyl-2-(1,1-dimethylallyl)tryptamine Hydrochloride (93). Gaseous
HCl was bubbled into a 0 °C solution of tert-butyl-2-(6-bromo-1-methyl-2-(1,1-dimethylallyl)indol-3-yl)ethyl-N-methylcarbamate (125) (100 mg) in anhydrous EtOAc (10 mL). The reaction
mixture was allowed to stir at room temperature for 7 h and the solvent was evaporated under
reduced pressure to yield a white solid which was recrystallized from MeOH to yield 35 mg
(41%) of 93 as white crystals: mp 251-252 °C; 1H NMR (DMSO-d6) δ 1.52 (s, 6H, (CH3)2), 2.53
(s, 3H NHCH3), 2.87 (t, 2H, CH2), 3.2 (t, 2H, CH2), 3.6 (s, 3H, NCH3), 4. 88 (d, 1H CH2), 5.05
(d, 1H, CH2), 6.15 (m, 1H, CH), 7.12 (d. 1H, Ar), 7.54 (m, 2H, Ar), 8.78 (s, 2H, NH2+ aliphatic).
Anal. Calcd for (C17H23BrN2·HCl) C, 54.93; H, 6.51; N, 7.54. Found: C, 55.21; H, 6.70; N, 7.27.

N-Methyl-6-bromo-1-benzyl-2-(1,1-dimethylallyl)tryptamine

Hydrogen

Oxalate

(94).

Gaseous HCl was bubbled into a 0 °C solution of tert-butyl-2-(6-bromo-1-benzyl-2-(1,1dimethylallyl)-indol-3-yl)ethyl-N-methylcarbamate (126) (100 mg) in anhydrous EtOAc (10
mL). The reaction mixture was allowed to stir at room temperature for 7 h and the solvent was
evaporated under reduced pressure to yield a sticky yellow solid which was converted to an
oxalate salt which upon recrystallization from i-PrOH yielded 50 mg (60%) of 94 as a yellow
solid: mp 184-186 °C; 1H NMR (DMSO-d6) δ 1.52 (s, 6H, (CH3)2), 2.53 (s, 3H NHCH3), 2.87 (t,
2H, CH2), 3.2 (t, 2H, CH2), 3.6 (s, 3H, NCH3), 4. 88 (d, 1H CH2), 5.05 (d, 1H, CH2), 6.15 (m,
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1H, CH), 7.12 (d. 1H, Ar), 7.54 (m, 2H, Ar), 8.78 (s, 2H, NH2+ aliphatic). UHPLC-MS; [M+1]
calculated for C23H27BrN2 410.13, found 410.13.

N,N-Dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine (101). Compound 101 was prepared
using a literature procedure for a similar compound.205 An aqueous mixture (3N NaOH to pH 10)
of 6-bromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (40) (0.06 g, 0.2 mmol) was extracted
with CH2Cl2 (3 x 10 mL). The combined organic portion was washed with H2O (3 x 15 mL),
brine (30 mL), dried (Na2SO4) and the solvent was evaporated under reduced pressure to yield 6bromo-2-(1,1-dimethylallyl)tryptamine (40, free base). Formic acid (0.04 g, 0.8 mmol),
formaldehyde (37%, 0.02 g, 0.5 mmol) and H2O (3 mL) were added and the reaction mixture
was heated at reflux for 3 h. The reaction mixture was allowed to cool to room temperature, H2O
(5 mL) was added, and the reaction mixture was basified with NaOH (3M, to pH 10). The
aqueous portion was extracted with EtOAc (3 x 20 mL) and the combined organic portion was
washed with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4) and the solvent was removed
under reduced pressure to yield 0.05g (91%) of 101 as a crude product which was used for
further reaction without purification in the preparation of compound 86 and 87.

N-Methyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-yl)propanamine Hydrogen Oxalate (103).
Gaseous HCl was bubbled into a solution of tert-butyl-3-(2-(1,1-dimethylallyl)-1H-indol-3yl)propyl-N-methylcarbamate (109) (0.1 g, 0.3 mmol) in anhydrous EtOAc (10 mL) at 0 °C. The
reaction mixture was allowed to stir at room temperature overnight. The solvent was evaporated
under reduced pressure to yield a brown solid which was converted to the oxalate salt and
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recrystallized from i-PrOH to yield 0.03 g (28%) of 103 as a yellow solid: mp 135-138 °C; 1H
NMR (DMSO-d6) δ 1.49 (s, 6H, (CH3)2), 1.83 (m, 2H, CH2), 2.55 (s, 3H, CH3), 2.76 (t, 2H,
CH2), 2.94 (t, 2H, CH2), 5.09 (m, 2H, CH2), 6.16 (m, 1H, CH), 6.95 (t, 1H, Ar), 7.21 (t, 1H, Ar),
7.32 (d, J = 8.0 Hz, 1H, Ar), 7.44 (d, J = 7.8 Hz, 1H, Ar), 10.47 (s, 1H, COOH). Anal. Calcd for
(C17H24N2·C2H2O4) C, 63.04; H, 7.18; N, 7.50. Found: C, 65.87; H, 7.56; N, 8.09; UHPLC-MS;
[M+1] calculated for C17H24N2 257.15, found 257.15.

1-(6-Bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propan-2-amine

Hydrochloride

(104).

Gaseous HCl was bubbled into a solution of tert-butyl-1-(6-bromo-2-(1,1-dimethylallyl)-1Hindol-3-yl)propyl-2-carbamate (114) (300 mg, 0.2 mmol) in anhydrous Et2O (20 mL) at 0 °C.
The reaction mixture was allowed to stir at room temperature for 24 h and the solvent was
evaporated to yield a white solid which was recrystallized from i-PrOH/Et2O to yield 60 mg
(27%) of 104 as white crystals: mp 229-230 °C; 1H NMR (DMSO-d6) δ 1.09 (d, 3H, CH3), 1.51
(d, 6H, (CH3)2), 2.95-3.14 (m, 2H, CH2), 3.43 (m, 1H, CH), 5.08-5.15 (m, 2H, CH), 6.14-6.21
(m, 1H, CH), 7.14 (dd, 1H, Ar), 7.51 (m, 2H, Ar), 8.07 (br s, 3H, NH3+ aliphatic), 10.86 (br s,
1H, indolic NH). Anal. Calcd for (C16H21BrN2·HCl) C, 53.72; H, 6.20; N, 7.83. Found: C, 53.55;
H, 6.25; N, 7.82.

N-Methyl-3-(1H-indol-3-yl)propanamide (106). Compound 106 was prepared as described.190
Indole-3-propionic acid (105) (1 g, 5.3 mmol) and Et3N (2.1 g, 21.1 mmol) were dissolved in
anhydrous THF (40 mL). The solution was cooled to 0 °C in an ice bath to which was added
methyl chloroformate (0.5 mL, 6.3 mmol) in a dropwise manner over 10 min. Stirring was
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continued at 0 °C for an additional 30 min. Methylamine hydrochloride (5.5 g, 81.4 mmol) was
added and the reaction was allowed to stir further at 0 °C for 90 min upon which the precipitate
was removed by filtration and the filtrate was evaporated under reduced pressure to yield a crude
yellow oil. The crude product was purified by column chromatography (silica gel;
hexanes/EtOAc; 100:1 to 5:1) to afford 0.8 g (76%) of 106 as a cream-colored solid: mp 99-100
°C (lit.190 mp 99-101 °C); 1H NMR (CDCl3) δ 2.49 (t, 2H, CH2), 2.66 (d, 3H, CH3), 3.05 (t, 2H,
CH2), 6.94 (s, 1H, Ar), 7.03-7.06 (dt, 1H, Ar), 7.10-7.14 (dt, 1H, Ar), 7.28 (d, J = 8.0 Hz, 1H,
Ar), 7.52 (d, J = 7.6 Hz, 1H, Ar), 7.95 (br s, 1H, indolic NH).

N-Methyl-(1H-indol-3-yl)propanamine (107). Compound 107 was prepared as described.191
Lithium aluminum hydride (1.1 g, 27.7 mmol) was suspended in anhydrous dioxane (12 mL) and
a solution of 3-(1H-indol-3-yl)-N-methylpropanamide (106) (0.2 g, 0.65 mmol) was added, and
the reaction mixture was heated at reflux overnight. The reaction mixture was allowed to cool to
room temperature and diluted with Et2O (50 mL), H2O (1 mL), NaOH (15%, 1 mL) and EtOH (2
mL). The reaction mixture was further stirred at room temperature for 2 h and dried (Na2SO4).
The organic portion was evaporated under reduced pressure to afford 0.5 g (67%) of 107 as a
yellow oil which was used without purification for the next step.

tert-Butyl-3-(1H-indol-3-yl)propyl-N-methylcarbamate (108). Compound 108 was prepared
using a literature procedure for a similar compound.9 Triethylamine (0.4 mL, 2.6 mmol) and ditert-butyl dicarbonate (0.6 g, 2.6 mmol) were added to a CH2Cl2 (15 mL) solution of indol-3-ylN-methylpropanamine (107) (0.5 g, 2.6 mmol) and allowed to stir at room temperature for 19 h.
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The reaction mixture was quenched with H2O (50 mL) and extracted with CH2Cl2 (2 x 30 mL).
The combined organic portion was washed with H2O (3 x 50 mL), dried (Na2SO4) and
evaporated under reduced pressure to obtain a yellow oil. The crude product was purified by
column chromatography (silica gel; hexanes/EtOAc; 100:1 to 25:1) to afford 0.4 g (58%) of 108
as a white foam: 1H NMR (CDCl3) δ 1.37 (s, 9H, (CH3)3), 1.83-1.90 (m, 2H, CH2), 2.68 (t, 2H,
CH2), 2.78 (s, 3H, CH3), 3.24 (m, 2H, CH2), 6.93 (s, 1H, Ar), 7.01-7.03 (dt, 1H, Ar), 7.09-7.13
(dt, 1H, Ar), 7.28 (d, J = 8.0 Hz, 1H, Ar), 7.52 (d, J = 7.8 Hz, 1H, Ar), 7.86 (br s, 1H, indolic
NH).

tert-Butyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-N-methylcarbamate

(109).

Compound 109 was prepared using a literature procedure for a similar compound.198 tert-Butyl
hypochlorite (0.2 g, 1.7 mmol) was added to a solution of tert-butyl-3-(indol-3-yl)propyl-Nmethylcarbamate (108) (0.4 g, 1.4 mmol) and Et3N (0.2 g, 1.7 mmol) in THF (15 mL) at -78 °C
and allowed to stir for 45 min. Freshly prepared prenyl-9-BBN179 (2.8 mmol) was added in a
dropwise manner over 10 min while maintaining temperature at -78 °C. The reaction mixture
was allowed to warm to room temperature and stirred for additional 2 h. Sodium hydroxide (3M,
5 mL) and H2O2 (30% v/v, 5 mL) were added in a dropwise manner and the solution was stirred
for 1 h and diluted with Et2O (100 mL). The organic layer was washed with H2O (3 x 60 mL),
brine (80 mL), dried (Na2SO4), and evaporated under reduced pressure to yield a yellow oil
which was subjected to purification by column chromatography (silica gel; hexanes/EtOAc;
100:1 to 25:1) to afford 0.2 g (40%) of 109 as a glassy solid: mp 116-118 °C; 1H NMR (CDCl3)
δ 1.38 (s, 9H, (CH3)3), 1.45 (m, 8H, CH2, CH3), 2.72 (t, 2H, CH2), 2.81 (s, 3H, CH3), 3.25 (m,
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2H, CH2), 5.05-5.10 (m, 2H, CH2), 6.01-6.08 (m, 1H, CH), 6.97-7.06 m, 2H, Ar), 7.20 (d, J = 7.8
Hz, 1H, Ar), 7.41 (d, J = 7.6 Hz, 1H, Ar), 7.74 (br s, 1H, indolic NH). Compound 109 was used
in the preparation of compound 103.

3-[(E)-2-Nitroprop-1-en-1-yl]-6-bromo-1H-indole (111). Compound 111 was prepared as
described.176 Ammonium acetate (1.2 g, 15 mmol) was added to a solution of 6-bromo-1Hindole-3-carboxaldehyde (110) (4.0 g, 17.9 mmol) in nitroethane (25 mL) in a 2-neck flask under
an N2 atmosphere and the solution was then allowed to stir at reflux for 7 h. The reaction mixture
was allowed to cool to room temperature and the precipitate was collected by filtration, washed
with H2O (30 mL), nitroethane (2 x 15 mL) and dried to yield 3.7 g (74%) of 111 as a yellow
solid: mp 219-220 °C (lit.176 mp not reported); 1H NMR (CDCl3) δ 2.53 (d, 3H, CH3), 7.39-7.42
(dd, J = 8.48, 1.68 Hz, 1H, Ar), 7.54 (d, J = 2.8 Hz, 1H, Ar), 7.63 (d, J = 1.4 Hz, 1H, CH), 7.68
(d, J = 8.52 Hz, 1H, Ar), 8.43 (s, 1H, Ar), 8.65 (br s, 1H, indolic NH).

1-(6-Bromo-1H-indol-3-yl)propan-2-amine (112). Compound 112 was prepared using a
literature procedure for a similar compound.176 Sodium borohydride (2.8 g, 73 mmol) was added
to a solution of anhydrous THF (40 mL) and BF3·Et2O (10 mL, 79 mmol) at 0 °C, and the
resulting suspension was stirred for 15 min while maintaining the temperature at 0 °C. 3-[(E)-2Nitroprop-1-en-1-yl)-6-bromo-1H-indole (111) (3.7 g, 13 mmol) was then added, and the
reaction mixture was allowed to stir at reflux for 4 h, cooled in an ice bath and quenched by the
careful addition of H2O (2 mL). The mixture was acidified with HCl (2N, to pH 1) and heated at
reflux for a further 2 h. After cooling, the acidic solution was extracted with Et2O (2 x 25 mL).
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The aqueous portion was basified with NaOH (3M, to pH 10) and extracted with Et2O (3 x 50
mL). The combined organic portion was washed with H2O (3 x 100 mL), brine (50 mL), dried
(Na2SO4), and the solvent was evaporated under reduced pressure to yield 1.5 g (44%) of 112 as
a white foam which was used for next step without purification.

tert-Butyl-1-(6-bromo-1H-indol-3-yl)propyl-2-carbamate (113). Compound 113 was prepared
using a literature procedure for a similar compound.9 Di-tert-butyl dicarbonate (1.3 g, 5.8 mmol)
and Et3N (0.6 g, 5.8 mmol) were added to a solution of 1-(6-bromo-1H-indol-3-yl)propan-2amine (112) (1.5 g, 1.3 mmol) in anhydrous DMF (20 mL) and the reaction mixture was allowed
to stir for 24 h. The reaction mixture was poured into H2O with ice (100 mL) and extracted with
EtOAc (3 x 40 mL). The combined organic portion was washed with H2O (3 x 40 mL), brine (50
mL), dried (Na2SO4), and evaporated under reduced pressure to yield the crude product. The
crude residue was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 3:1)
to afford 1.5 g (75%) of 113 as a white foam: 1H NMR (CDCl3) δ 1.04 (d, 3H, CH3), 1.36 (s,
9H, (CH3)3), 2.72-2.89 (m, 2H, CH2), 3.92 (m, 1H, CH), 4.34 (s, 1H, NH aliphatic), 6.93 (s, J =
2.1 Hz, 1H, Ar), 7.14 (dd, J = 8.4, 1.6 Hz, 1H, Ar), 7.43 (m, 2H, Ar), 7.95 (s, 1H, indolic NH).

tert-Butyl-1-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-2-carbamate

(114).

Compound 114 was prepared using a literature procedure for a similar compound.198 tert-Butyl
hypochlorite (0.4 g, 3.3 mmol) was added to a solution of tert-butyl-3-(6-bromo-1H-indol-3yl)propyl-2-carbamate (113) (0.9 g, 2.5 mmol) and Et3N (0.3 g, 3.3 mmol) in anhydrous THF
(30 mL) at -78 °C and the solution was allowed to stir for 45 min. Freshly prepared prenyl-9139

BBN179 (5.1 mmol) was added in a dropwise manner over 20 min while maintaining the
temperature at -55 °C. The reaction mixture was allowed to warm to room temperature and was
stirred for an additional 3 h. Aqueous NaOH (3M, 7 mL) and H2O2 (30% v/v, 7 mL) were added
in a dropwise manner and stirring was continued for another 1 h. The reaction mixture was
diluted with Et2O (100 mL), the organic layer was separated and washed with H2O (3 x 100 mL),
brine (80 mL), dried (Na2SO4) and evaporated under reduced pressure to yield a crude residue
which was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:8) to
afford 0.5 g (45%) of 114 as a white foam: 1H NMR (CDCl3) δ 1.09 (d, 3H, CH3), 1.36 (s, 9H,
(CH3)3), 1.51 (d, 6H, (CH3)2), 2.95-3.14 (m, 2H, CH2), 3.43 (m, 1H, CH), 4.34 (s, 1H, NH
aliphatic), 5.08-5.15 (m, 2H, CH), 6.14-6.21 (m, 1H, CH), 7.14 (dd, 1H, Ar), 7.51 (m, 2H, Ar),
7.95 (s, 1H, indolic NH). Compound 114 was employed in the preparation of compound 104.

N-iso-Propyl-6-bromo-1H-indol-3-glyoxylamide (115). Compound 115 was prepared using a
literature procedure for a similar compound.201,206 In a 2-neck flask a solution of 6-bromoindole
(46) (4.0 g, 20.4 mmol) in anhydrous Et2O (25 mL) was chilled to -15 oC and N2 was bubbled for
5 min. Oxalyl chloride (3.6 mL, 40.8 mol) was added in a dropwise manner with continued
stirring for 2 h, after which the precipitate was collected by filtration, washed with Et 2O (2 x 25
mL) and dried over vacuum. The solid was dissolved in THF (10 mL) and cooled to 0 °C. isoPropylamine (3 mL) was added in a dropwise manner and the reaction mixture was allowed to
stir at room temperature overnight. The organic portion was evaporated and the residue was
washed with H2O (100 mL), Et2O (3 x 35 mL) to afford 2.7 g (69%) of 115 as a white solid: mp
268-269 °C; 1H NMR (DMSO-d6) δ 1.16-1.18 (d, 6H, CH3), 4.00-4.06 (sep, 1H, CH), 7.40-7.42
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(dd, J = 8.4, 1.8 Hz, 1H, Ar), 7.44 (d, J = 1.8 Hz, 1H, Ar), 8.14-8.16 (d, J = 8.5 Hz, 1H, Ar),
8.53-8.55 (d, J = 8.2 Hz, 1H, Ar), 8.74 (s, 1H, NH aliphatic), 12.27 (br s, 1H, indolic NH).

N-Benzyl-6-bromo-1H-indol-3-glyoxylamide (116). Compound 116 was prepared using a
literature procedure for a similar compound.201,206 In a 2-neck flask a solution of 6-bromoindole
(46) (1.7 g, 8.7 mmol) in anhydrous Et2O (25 mL) was chilled to -10 °C and N2 was bubbled for
5 min. Oxalyl chloride (1.5 mL, 17.4 mmol) was added in a dropwise manner and the stirring
was continued for 2 h. The glyoxyl chloride formed was collected by filtration, washed with
Et2O (2 x 25 mL), dried under reduced pressure, dissolved in anhydrous THF (18 mL), and the
solution cooled to 0 °C. Benzylamine (1.4 mL, 13.1 mmol) was added in a dropwise manner and
the reaction was allowed to stir at room temperature for 3 h. The precipitate was collected by
filtration and washed with H2O (100 mL). The crude product was recrystallized from MeOH to
afford 1.6 g (51%) of 116 as buff-colored, needle-shaped crystals: mp 232-233 °C; 1H NMR
(DMSO-d6) δ 4.42-4.44 (d, 2H, CH2), 7.26-7.28 (m, 1H, Ar), 7.33-7.35 (m, 4H, Ar), 7.40-7.43
(dd, J = 8.5, 1.8 Hz, 1H, Ar), 8.16-8.18 (d, J = 8.4 Hz, 1H, Ar), 8.78 (s, 1H, Ar), 9.30-9.33 (t,
1H, NH aliphatic), 12.30 (br s, 1H, indolic NH).

N-iso-Propyl-6-bromotryptamine (117). Compound 117 was prepared using a literature
procedure for a similar compound.178 Borane dimethylsulfide (10.1M in THF, 1.4 mL) was
added in a dropwise manner at 60 °C to a stirred solution of N-iso-propyl-6-bromo-1H-indol-3glyoxylamide (115) (1.5 g, 4.9 mol) in dry THF (35 mL). The reaction mixture was heated at
reflux for 5 h, cooled to room temperature and quenched with HCl (2N, to pH 1). The THF was
141

evaporated under reduced pressure and the remaining aqueous portion was diluted with H2O
(100 mL), basified with NaOH (3M, to pH 9) and extracted with CH2Cl2 (3 x 50 mL). The
combined organic portions were washed with H2O (2 x 50 mL), dried (Na2SO4), and solvent was
evaporated under reduced pressure to yield 1.2 g (89%) of 117 as a yellow foam: 1H NMR
(CDCl3) δ 1.07-1.09 (d, 6H, CH3), 2.86-2.90 (m, 2H, CH2), 3.21-3.23 (t, 2H, CH2), 6.91 (s, 1H,
Ar), 7.13-7.15 (d, 1H, Ar), 7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). Compound 117 was used
without further purification in the synthesis of compound 119.

N-Benzyl-6-bromotryptamine (118). Compound 118 was prepared using a literature procedure
for a similar compound.178 Borane dimethylsulfide (10.1M in THF, 1.3 mL) was added in a
dropwise manner at 60 °C to a stirred solution of N-benzyl-6-bromo-1H-indol-3-glyoxylamide
(116) (1.5 g, 4.2 mmol) in anhydrous THF (35 mL). The reaction mixture was heated at reflux
for 5.5 h, cooled to room temperature and quenched with HCl (2N, to pH 1). The organic solvent
was evaporated under reduced pressure and the remaining aqueous mixture was diluted with H2O
(100 mL), basified with NaOH (3M, to pH 9) and extracted with CH2Cl2 (3 x 50 mL). The
combined organic portion was washed with H2O (2 x 50 mL), dried (Na2SO4), and solvent was
evaporated under reduced pressure to yield 1.4 g (61%) of 118 as a yellow foam. Compound 118
was used without further purification for synthesis of compound 120.

tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-iso-propylcarbamate (119). Compound 119
was prepared using a literature procedure for a similar compound.9 Triethylamine (0.60 mL, 4.3
mmol) and di-tert-butyl dicarbonate (0.93 g, 4.3 mmol) were added to a CH2Cl2 (20 mL) solution
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of N-iso-propyl-6-bromotryptamine (117) (1.20 g, 4.3 mmol) and allowed to stir overnight. The
reaction mixture was diluted with CH2Cl2 (30 mL) and washed with H2O (3 x 40 mL), dried
(Na2SO4), and evaporated to yield a crude residue. The residue was purified by column
chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:24) to afford 1.04 g (64%) of 119 as
white foam: 1H NMR (CDCl3) δ 1.07-1.09 (d, 6H, CH3), 1.43 (s, 9H, CH3), 2.86-2.90 (m, 2H,
CH2), 3.21-3.23 (t, 2H, CH2), 4.04-4.06 (sep, 1H, CH), 6.91 (s, 1H, Ar), 7.13-7.15 (d, 1H, Ar),
7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH).

tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-benzylcarbamate (120). Compound 120 was
prepared using a literature procedure for a similar compound.9 Triethylamine (0.3 g, 2.6 mmol)
and di-tert-butyl dicarbonate (0.6 g, 2.6 mmol) were added to an anhydrous CH2Cl2 (15 mL)
solution of N-benzyl-6-bromotryptamine (118) (0.8 g, 2.6 mmol) and allowed to stir at room
temperature for 24 h. The reaction mixture was diluted with CH2Cl2 (30 mL) and washed with
H2O (3 x 40 mL), dried (Na2SO4), and evaporated to yield a crude residue. The residue was
purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:24) to afford 0.6 g
(50%) of 120 as a white foam: 1H NMR (CDCl3) δ 1.38 (s, 9H, (CH3)3), 2.83 (br s, 2H, CH2),
3.36 (br s, 2H, CH2), 4.31 (s, 2H, CH2), 6.84 (br s, 1H, Ar), 7.10-7.30 (m, 8H, Ar), 7.91 (br s, IH,
indolic NH).

tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-iso-propyl

carbamate

(121). Compound 121 was prepared using a literature procedure for a similar compound.198 tertButyl hypochlorite (0.24 g, 2.2 mmol) was added to a solution of tert-butyl-2-(6-bromo-1H143

indol-3-yl)ethyl-N-iso-propylcarbamate (119) (0.70 g, 1.8 mmol) and Et3N (0.22 g, 2.2 mmol) in
THF (15 mL) at -65 oC and allowed to stir for 45 min. Freshly prepared prenyl 9-BBN179 (3.7
mmol) was added in a dropwise manner over 30 min while maintaining the temperature at -50
o

C. The reaction mixture was allowed to warm to room temperature and stirred for an additional

4 h. Sodium hydroxide (3M, 7 mL) and H2O2 (30%, 7 mL) were added in a dropwise manner and
stirring was continued for 1 h. The reaction mixture was diluted with Et2O (50 mL), and the
organic layer was washed with H2O (3 x 60 mL), brine (80 mL), dried (Na2SO4), and evaporated
to yield a crude residue. The residue was purified by column chromatography (silica gel;
hexanes/EtOAc; 100:1 to 10:1) to afford 0.5 g (62%) of 121 as a white foam: 1HNMR (CDCl3) δ
1.25 (d, 6H, CH3), 1.43 (s, 9H, CH3), 1.50 (s, 6H, CH3), 2.86-2.90 (m, 2H, CH2), 3.21-3.23 (t,
2H, CH2), 5.09-5.13 (d, 2H CH2), 6.12-6.19 (m, 1H, CH), 7.13-7.15 (d, J = 8.4, 1.8 Hz, 1H, Ar),
7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). Compound 121 was used in preparation of 91.

tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-benzylcarbamate

(122).

Compound 122 was prepared using a literature procedure for a similar compound.198 tert-Butyl
hypochlorite (0.09 g, 0.8 mmol) was added to a solution of tert-butyl-2-(6-bromo-1H-indol-3yl)ethyl-N-benzylcarbamate (120) (0.30 g, 0.7 mmol) and Et3N (0.08 g, 0.8 mmol) in anhydrous
THF (10 mL) at -65 °C and allowed to stir for 45 min. Freshly prepared prenyl 9-BBN179 (1.4
mmol) was added in a dropwise manner over 10 min while maintaining the temperature at -50
°C. The reaction mixture was allowed to warm to room temperature and stirred for an additional
5.5 h. Sodium hydroxide (3M, 3 mL) and H2O2 (30%, 3 mL) were added in a dropwise manner
and stirring was continued for 1 h. The reaction mixture was diluted with Et 2O (50 mL), and the
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organic layer was washed with H2O (3 x 30 mL), brine (50 mL), dried (Na2SO4), and evaporated
to yield a crude residue. The residue was purified by column chromatography (silica gel;
hexanes/EtOAc; 100:1 to 10:1) to afford 0.06 g (17%) of 122 as a white foam: 1H NMR
(CDCl3) δ 1.37 (s, 9H, (CH3)3), 1.43 (s, 6H, (CH3)2), 2.84 (br s, 2H, CH2), 3.36 (br s, 2H, CH2),
4.31 (s, 2H, CH2), 4.99-5.03 (d, 2H CH2), 6.02-6.08 (m, 1H, CH), 6.84 (d, J = 8.4 Hz, 1H, Ar),
7.10-7.30 (m, 7H, Ar), 7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). This compound was employed
in the preparation of compound 92.

N-Methyl-6-bromo-1H-indol-3-glyoxylamide (123). Compound 123 was prepared as
described.201 In a 2-neck flask a solution of 6-bromoindole (46) (4.0 g, 20 mmol) in anhydrous
Et2O (20 mL) was chilled to -5 °C and N2 was bubbled for 5 min. Oxalyl chloride (3.6 mL, 41
mmol) was added in a dropwise manner with continued stirring and the reaction was stirred at 0
°C for 2 h, after which the solvent was evaporated, the residue was washed with cold Et2O (25
mL) and dried under vacuum. The solid was added to cold aqueous methylamine (40%, 35 mL)
and was allowed to stir at room temperature for 2 h after which the precipitate was collected by
filtration to yield a brown solid which, upon recrystallization from MeOH, yielded 4.3 g (73%)
of 123 as a white solid: mp 252-253 °C (lit.9 mp 249-252 °C); 1H NMR (DMSO-d6) δ 2.75 (s,
3H, CH3), 7.4 (d, J = 8.48 Hz, 1H, Ar), 7.73 (s, 1H, Ar), 8.15 (d, J = 8.48 Hz, 1H, Ar), 8.68 (s,
1H, NH aliphatic), 8.79 (s, 1H, Ar), 12.26 (s, 1H, indolic NH). Compound 123 was used in the
preparation of compound 35.
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tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-methylcarbamate (124).
Compound 124 was prepared as described.198 tert-Butyl hypochlorite (0.5 g, 4.1 mmol) was
added to a solution of tert-butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-methylcarbamate (61) (1.2 g,
3.4 mmol) and Et3N (0.4 g, 4.1 mmol) in anhydrous THF (15 mL) at -78 °C and allowed to stir
for 45 min. Freshly prepared prenyl 9-BBN179 (6.8 mmol) was added in a dropwise manner over
30 min while maintaining the temperature at -78 °C. The reaction mixture was allowed to warm
to room temperature and stirred for 2 h. Sodium hydroxide (3M, 5 mL) and H2O2 (30% v/v, 5
mL) were added in a dropwise manner and stirring was continued for 1 h. The reaction mixture
was diluted with Et2O (100 mL), and the organic layer was washed with H2O (3 x 60 mL), brine
(80 mL), dried (Na2SO4), and evaporated to yield a crude residue which was purified by column
chromatography (silica gel; hexanes/EtOAc 100:1 to 10:1) to afford 0.4 g (27%) of 124 as a
white foam: 1H NMR (CDCl3) δ 1.40 (s, 9H, (CH3)3), 1.54 (s, 6H, (CH3)2), 2.78 (t, 3H, CH3),
2.92 (t, 2H, CH2), 3.32 (t, 2H, CH2), 5.09 (m, 2H, CH2), 6.03 (m, 1H, CH), 7.10-7.35 (m, 3H,
Ar), 7.77 (s, 1H, indolic NH).

tert-Butyl-2-(6-bromo-1-methyl-2-(1,1-dimethylallyl)-indol-3-yl)ethyl-N-methyl carbamate
(125). Compound 125 was prepared according to a literature procedure for a similar
compound.207,208 In a dry, round-bottom flask NaH (60% oil dispersion) (0.04 g, 0.9 mmol) was
allowed to stir with anhydrous toluene at 0 °C (ice bath) for 10 min. After removal of the
toluene,

a

solution

of

tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-

methylcarbamate (124) (0.3 g, 0.7 mmol) in anhydrous DMF (5 mL) was added and stirring
continued at 0 °C (ice bath) for 30 min. Iodomethane (0.15 g, 1.1 mmol) was added to the cold
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solution and the reaction mixture was allowed to stir at room temperature for 1.5 h. The reaction
was quenched with H2O (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic
portions were washed with H2O (3 x 25 mL) and brine (40 mL), dried (Na2SO4) and evaporated
to dryness under reduced pressure to yield a crude, yellow-colored oil which was purified by
column chromatography (silica gel; hexanes/EtOAc 100:1 to 10:1) to afford 0.2 g (79%) of 125
as a light-yellow oil: 1H NMR (CDCl3) δ 1.41 (s, 9H, (CH3)3), 1.56 (s, 6H, (CH3)2), 1.97-2.11
(m, 2H, CH2), 2.51 (br s, 5H, NCH3, CH2), 5.18-5.26 (m, 2H, CH2), 6.28-6.35 (m, 1H, CH), 6.77
(d, 2H, ArCH2), 7.13-7.18 (m. 7H, Ar), 7.72 (s, 1H, Ar). The product was used in the preparation
of compound 93.

tert-Butyl-2-(6-bromo-1-benzyl-2-(1,1-dimethylallyl)-indol-3-yl)ethyl-N-methyl

carbamate

(126). Compound 126 was prepared according to a literature procedure for a similar
compound.207,208 In a dry, round-bottom flask NaH (60% oil dispersion) (0.02 g, 0.6 mmol) was
allowed to stir with anhydrous toluene at 0 °C (ice bath) for 10 min. After removal of the
toluene,

a

solution

of

tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-

methylcarbamate (124) (0.2 g, 0.5 mmol) in anhydrous DMF (2 mL) was added and stirring
continued at 0 °C (ice bath) for 45 min. Benzyl bromide (0.09 g, 0.6 mmol) was added to the
cold solution and the reaction mixture was allowed to stir at room temperature for 5.5 h. The
reaction was quenched with H2O (30 mL) and extracted with EtOAc (3 x 20 mL). The combined
organic portions were washed with H2O (3 x 25 mL) and brine (40 mL), dried (Na2SO4) and
evaporated to dryness under reduced pressure to yield a crude, yellow-colored oil which was
purified by column chromatography (silica gel; hexanes/EtOAc 100:1 to 100:5) to afford 0.13 g
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(55%) of 126 as a white foam: 1H NMR (CDCl3) δ 1.31 (s, 9H, (CH3)3), 1.47 (s, 6H, (CH3)2),
1.97-2.11 (m, 2H, CH2), 2.51 (br s, 5H, NCH3, CH2), 5.18-5.26 (m, 2H, CH2), 6.28-6.35 (m, 1H,
CH), 6.7 (s, 2H, CH2), 7.1-7.2 (m, 7H, Ar), 7.37 (s, 1H, Ar). Compound 126 was used in the
preparation of compound 94.

N,N-Dimethyl-5-bromo-2-(1,1-dimethylallyl)isotryptamine

Hydrogen

Oxalate

(127).

Compound 127 was prepared according to a literature procedure for a similar compound.207,208 In
a dry, round-bottom flask NaH (60% oil dispersion) (0.06 g, 1.4 mmol) was allowed to stir with
anhydrous toluene in an ice bath for 10 min. After removal of the toluene, a solution of 5-bromo2-(1,1-dimethylallyl)-1H-indole (131) (0.15 g, 0.6 mmol) in anhydrous DMF (5 mL) was added
and stirring continued in an ice bath (0 °C) for another 20 min. In a separate beaker a solution of
N,N-dimethylaminoethyl chloride hydrochloride (0.2 g, 1.1 mmol), KtBuO (0.2 g, 1.4 mmol) and
KI (0.08 g, 0.6 mmol) in cold anhydrous DMF (3 mL) was then added to the round-bottom flask
and the reaction mixture was heated at reflux for 17 h. The reaction mixture was quenched with
H2O (20 mL) and extracted with EtOAc (2 x 25 mL) and CH2Cl2 (2 x 25 mL). The combined
organic portions were washed with H2O (2 x 50 mL), brine (50 mL), dried (Na2SO4) and
evaporated to dryness to yield 0.1 g (63%) of free base as a brown-colored oil. Saturated oxalic
acid solution in anhydrous Et2O (5 mL) was added to a solution of the free base (0.1 g) in
anhydrous Et2O (5 mL) at 0 °C and allowed to stir overnight. The precipitate formed was
collected by filtration and recrystallized from MeOH/Et2O to afford 0.04 g (32%) of 127 as white
flakes: mp 185-188 °C [The compound was prepared as previously described by D. Kim
(postdoctoral fellow in Dr. Glennons lab) as JSK-087 (mp 191-194 °C)]; 1H NMR (DMSO-d6) δ
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1.49 (s, 6H, (CH3)2), 2.69 (s, 6H N(CH3)2), 3.03 (t, 2H, CH2), 4.42 (t, 2H, CH2), 5.17 (m, 2H,
CH2), 6.09 (m, 1H, CH), 6.37 (s,1H, CH), 7.25 (d, 1H, J = 8.7 Hz, Ar), 7.43 (s, 1H, J = 8.7 Hz,
Ar), 7.70 (d, 1H, Ar).

3,5-Dibromo-1H-indole (130). Compound 130 prepared as described.192 A solution of liquid Br2
(0.2 mL, 4 mmol) in anhydrous DMF (5 mL) was added in a dropwise manner to a solution of 5bromoindole (129) (1.0 g, 4 mmol) in anhydrous DMF (5 mL). The light-protected mixture was
allowed to stir at room temperature for 12 h and then poured into water and ice (100 mL)
containing NH4OH (2 mL) and saturated aqueous NaS2O3 (0.3 mL). The product was collected
by filtration and was washed with water, dried under reduced pressure to yield 0.6 g (41%) of
130 as a brown solid: mp 90-92 °C (decomp) (lit.192 mp 94 °C); 1H NMR (DMSOd6) δ 7.41 (dd,
1H, Ar), 7.29 (dd, 1H, Ar), 7.62 (s, 1H, Ar), 7.53 (s, 1H, Ar), 11.69 (br s, 1H, indolic NH).

5-Bromo-2-(1,1-dimethylallyl)-1H-indole (131). Compound 131 was prepared as described.193
3,5-Dibromo-1H-indole (130) (0.5 g, 1.8 mmol) was added in one portion to a freshly prepared
prenyl 9-BBN177 (5.4 mmol) and Et3N (0.9 mL, 6.3 mmol) in anhydrous THF (10 mL) at room
temperature. The reaction mixture was allowed to stir at room temperature for 4 h and then
quenched with a saturated solution of NaHCO3 (20 mL). The organic layer was separated and the
aqueous portion was extracted with Et2O (2 x 20 mL). The combined organic portion was
washed with H2O (2 x 30 mL), brine (30 mL), dried (Na2SO4) evaporated to dryness under
reduced pressure to yield a crude, dark-yellow oil. The residue was purified by column
chromatography (silica gel; hexanes/EtOAc 100:1 to 30:1) to afford 0.3 g (78%) of 131 as a
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yellow oil: 1H NMR (CDCl3) δ 1.47 (s, 6H, CH3), 5.10 (m, 2H, CH2), 6.01 (m, 1H, CH), 6.24 (s,
1H, Ar), 7.20 (dd, 2H, Ar), 7.89 (br s, 1H, indolic NH). Compound 131 was used in the
preparation of 127.

2,2-Dimethylbut-3-enoic acid (133). Compound 133 was prepared as described.209 nButyllithium (2.5 M in hexane, 4.6 mL, 11.5 mmol) was added to a 3-neck flask and the solvent
was evaporated to dryness under N2. Anhydrous THF (5 mL) was added and the resulting
solution was cooled to -78 °C. Diethylamine (1.1 mL, 10.9 mmol) was added and the solution
was stirred for 15 min at 0 °C and cooled to -78 °C after which a solution of 2-methylbut-2-enoic
acid (132) (0.5 g, 4.9 mmol) in THF (3 mL) was added over 5 min with continuous stirring and
stirred additionally for 0.5 h at 0 °C. The solution was cooled again to -78 °C and dimethyl
sulfate (0.5 mL, 4.9 mmol) in THF (5 mL) was added over 5 min and stirring was continued for
0.5 h at the temperature, and then for additional 1.5 h at room temperature. The reaction mixture
was quenched with H2O (10 mL) and the mixture was washed with Et2O (3 x 15 mL). The
aqueous portion was acidified with conc. HCl (to pH 1) and extracted with EtOAc (3 x 10 mL).
The combined organic portion was washed with H2O (3 x 25 mL), brine (30 mL), dried (Na2SO4)
and evaporated to dryness to afford 0.35 g (61%) of 133 as a colorless oil: bp 184-187 °C (lit.209
bp not reported); 1H NMR (CDCl3) δ 1.27 (s, 6H, (CH3)2), 5.03-5.11 (m, 2H, CH2), 5.95-6.02
(m, 1H, CH), 6.93 (s, 1H, COOH).

2,2-Dimethylbut-3-enoyl chloride (134). Compound 134 was prepared as described.210 Oxalyl
chloride (0.3 mL, 2.9 mmol) was added dropwise to a solution of 2,2-dimethylbut-3-enoic acid
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(133) (0.3 g, 2.6 mmol) in anhydrous CH2Cl2 (5 mL) and few drops of DMF at 0 °C and stirred
for 16 h at room temperature. On completion the reaction mixture was evaporated to dryness
under reduced pressure to afford 0.3 g (90%) of 134 as a colorless oil. The material was used
without further purification for synthesis of compound 135.

N-(4-Bromo-2-nitrophenyl)-2,2-dimethylbut-3-enamide (135). Compound 135 was prepared
according to a literature procedure for a similar compound.211 A solution of 2-butyl-2-methylbut3-enoyl chloride (134) (0.3 g, 2.4 mmol) in CH2Cl2 (30 mL) was cooled to 0 °C to which DMAP
(0.1 g, 0.8 mmol), 4-bromo-2-nitroaniline (77) (0.3 g, 1.5 mmol) and DCC (0.3 g, 1.5 mmol) was
added sequentially, stirred for 10 min at 0 °C and heated at reflux for 19 h. The reaction mixture
was allowed to cool to room temperature and washed with HCl (2M, 3 x 30 mL), saturated
NaHCO3 (40 mL), brine (40 mL), dried (Na2SO4) and the solvent was removed under reduced
pressure to yield a crude, yellow oil. The residue was purified by column chromatography (silica
gel; hexanes/EtOAc; 100:1 to 100:15) to afford 0.2 g (52%) of 135 as a yellow solid: mp 98-99
°C; 1H NMR (CDCl3)  1.35 (s, 6H, (CH3)2), 5.33-5.37 (m, 2H, CH2), 5.98-6.06 (m, 1H, CH),
7.65 (dd, J = 9.1, 2.4 Hz, 1H, Ar), 8.28 (d, J = 2.4 Hz, 1H, Ar), 8.68 (d, J = 9.1 Hz, 1H, Ar),
10.51 (br s, 1H, NH). ); IR (Diamond): 1698 cm-1 (C=O).

5-Bromo-2-(1,1-dimethtylallyl)-benzo[d]imidazole (136). Compound 136 was prepared
according to a literature procedure for a similar compound.212 Iron (0.07 g, 1.3 mmol) was added
to a solution of N-(4-bromo-2-nitrophenyl)-2,2-dimethylbut-3-enamide (135) (0.2 g, 0.6 mmol)
in gl. HOAc (4 mL) and the reaction mixture was heated at reflux for 5 h. The reaction mixture
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was allowed to cool to room temperature and diluted with H2O (25 mL). The aqueous mixture
was washed with EtOAc (2 x 25 mL) and basified with NaOH (3M, to pH 8). The basified
aqueous portion was extracted with EtOAc (3 x 30 mL), and the combined organic portions were
washed with H2O (2 x 30 mL), brine (30 mL), dried (Na2SO4) and the solvent was removed
under reduced pressure to yield 0.15 g (86%) of 136 as a cream-colored solid: mp 231-233 °C;
1

H NMR (CDCl3)  1.52 (s, 6H, (CH3)2), 5.15-5.20 (m, 2H, CH2), 6.04-6.11 (m, 1H, CH), 7.44

(d, J = 1.8 Hz, 1H, Ar), 7.55 (dd, J = 8.5, 1.8 Hz, 1H, Ar), 7.82 (d, J = 8.6 Hz, 1H, Ar), 8.73 (br
s, 1H, NH).

2-(1,1-Dimethylallyl)gramine Hydrogen Oxalate (137). Compound 137 was prepared
following a literature procedure for a similar compound.213 Dimethylamine (40%, 0.1 mL, 0.8
mmol) and HCHO (37%, 0.7 mL, 0.8 mmol) were added to a solution of 2-(1,1-dimethylallyl)1H-indole (141) (0.10 g, 0.5 mmol) in gl. HOAc (3 mL) maintained at 5 °C. When the vapors
ceased, MeOH (4 mL) was added to make a clear solution and the reaction mixture was allowed
to stir overnight at room temperature. The organic solvent was removed by evaporation under
reduced pressure and the solution was basified with NaOH (3M, to pH 10). The aqueous portion
was extracted with Et2O (3 x 30 mL) and the combined organic portion was washed with H2O (3
x 50 mL), brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to
yield the gramine as a free base which was converted to an oxalate salt by addition of a saturated
oxalic acid solution in anhydrous Et2O (5 mL) to a solution of crude 2-(1,1dimethylallyl)gramine in anhydrous Et2O (5 mL) at 0 °C. The precipitate was collected by
filtration, dried and recrystallized from i-PrOH to afford 0.04 g (22%) of 137 as white crystals:
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mp 155-158 °C; 1H NMR (DMSO-d6) δ 1.54 (s, 6H, (CH3)2), 2.72 (s, 6H, N(CH3)2), 4.39 (s, 2H,
CH2), 5.22 (m, 2H, CH2), 6.33 (m, 1H, CH), 7.04-7.68 (m, 4H, Ar), 11.13 (br s, 1H, COOH).
Anal. Calcd for (C16H22N2·C2H2O4·0.5 H2O) C, 63.33; H, 7.38; N, 8.21. Found: C, 63.09; H,
7.40; N, 8.42.

6-Bromo-2-propylgramine Hydrogen Oxalate (138). Compound 138 was prepared following a
literature procedure for a similar compound.213 Dimethylamine (40% in H2O, 0.12 mL, 1.0
mmol), formaldehyde (37%, 0.07 mL, 0.9 mmol) and zinc iodide (0.30 g, 1.0 mmol) were added
to a solution of 6-bromo-2-propyl-1H-indole (143) (0.15 g, 0.6 mmol) in absolute EtOH (20 mL)
and allowed to stir at room temperature for 24 h. The organic solvent was evaporated under
reduced pressure, and the aqueous portion was extracted with CH2Cl2 (2 x 40 mL). The
combined organic portions were washed with H2O (3 x 50 mL), dried (Na2SO4) and evaporated
under reduced pressure to yield the free base as a yellow oil. Saturated oxalic acid solution in
anhydrous Et2O (5 mL) was added to a solution of crude 6-bromo-2-propylgramine (0.1 g) in
anhydrous Et2O (5 mL) at 0 °C and allowed to stir overnight. The precipitate formed was
collected by filtration and recrystallized from i-PrOH to afford 0.05 g (21%) of 138 as white
crystals: mp 181-183 °C; 1H NMR (DMSO-d6) δ 0.93 (s, 3H, CH3), 1.69 (m, 2H, CH2), 2.74 (s,
6H, CH3), 2.79 (t, 2H, CH2), 4.39 (s, 2H, CH2), 7.20 (dd, J = 8.4, 1.8 Hz, 1H, Ar), 7.50 (d, J =
1.6 Hz, 1H, Ar), 7.65 (d, J = 8.4 Hz, 1H, Ar), 9.17 (br s, 1H, indolic NH), 11.47 (s, 1H, COOH).
Anal. Calcd for (C14H19BrN2·C2H2O4) C, 49.88; H, 5.49; N, 7.27. Found: C, 49.85; H, 5.44; N,
7.26.
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3-Bromo-1H-indole (140). Compound 140 was prepared as described.192,214 A solution of liquid
Br2 (0.7 mL, 14 mmol) in anhydrous DMF (20 mL) was added in a dropwise manner to a
solution of indole (139) (2.0 g, 17 mmol) in anhydrous DMF (20 mL). The light-protected
mixture was allowed to stir at room temperature for 24 h and then poured into water and ice (100
mL) containing NH4OH (2 mL) and a saturated aqueous solution of Na2S2O3 (0.5 mL). The
aqueous portion was extracted with EtOAc (3 x 40 mL). The combined organic portion was
washed with 5% aqueous LiCl (3 x 40 mL), brine (50 mL), dried (Na2SO4) and the solvent was
removed under reduced pressure to yield a crude product which upon recrystallization from
petroleum ether/Et2O yield 1.6 g (48%) of 140 as an off-white solid: mp 66-67 °C (decomp)
(lit.214 mp 65 °C).

2-(1,1-Dimethylallyl)-1H-indole (141). Compound 141 was prepared as described.215 3-Bromo1H-indole (140) (0.3 g, 1.3 mmol) was added in one portion to freshly prepared prenyl 9-BBN177
(3.8 mmol) and Et3N (0.6 mL, 4.5 mmol) in anhydrous THF (10 mL) at room temperature. The
reaction mixture was allowed to stir at room temperature for 5 h and then quenched with
saturated NaHCO3 (20 mL). The organic layer was separated and the aqueous portion was
extracted with Et2O (3 x 40 mL). The combined organic portion was washed with H2O (2 x 30
mL), brine (30 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to
yield a crude, yellow oil. The residue was purified by column chromatography (silica gel;
hexanes/EtOAc; 50:1 to 10:1) to afford 0.2 g (85%) of 141 as a yellow oil: 1H NMR (CDCl3) δ
1.41 (s, 6H, (CH3)2), 5.05 (m, 2H, CH2), 5.97 (m, 1H, CH), 6.24 (s, 1H, Ar), 6.97-7.48 (m, 4H,
Ar), 7.8 (br s, 1H, indolic NH). Compound 141 was used in the preparation of compound 137.
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5-Bromo-2-(1-pentynyl)aniline (142). Compound 142 was prepared following a literature
procedure for a similar compound.204 A mixture of 5-bromo-2-iodoaniline (79) (1.0 g, 3.4
mmol), CuI (0.03 g, 0.2 mmol) and PdCl2(PPh3)2 (0.12 g, 0.2 mmol) were suspended in
anhydrous THF (30 mL). Et3N (1.4 mL, 10.1 mmol) and 1-pentyne (0.4 mL, 4.4 mmol) were
added successively and the reaction mixture was allowed to stir at room temperature overnight.
The reaction mixture was diluted with Et2O (100 mL), filtered through Celite, and the organic
portion was washed sequentially with H2O (3 x 100 mL), a saturated aqueous solution of NH4Cl
(50 mL), brine (50 mL), dried (Na2SO4) and the solvent was evaporated under reduced pressure
to yield a crude residue. The crude product was purified by column chromatography (silica gel;
hexanes/EtOAc 100:1 to 75:1) to afford 1.4 g (88%) of 142 as a light-yellow oil: 1H NMR
(CDCl3) δ 0.98 (t, 3H, CH3), 1.57 (m, 2H, CH2), 2.36 (t, 2H, CH2), 4.14 (br s, 2H, NH2), 6.70
(dd, J = 8.2, 1.9 Hz, 1H, Ar), 6.76 (d, J = 1.9 Hz, 1H, Ar), 7.01 (d, J = 8.2 Hz, 1H, Ar).

6-Bromo-2-propyl-1H-indole (143). Compound 143 was prepared following a literature
procedure for a similar compound.188 Zinc iodide (0.9 g, 0.3 mmol) was added in one portion to a
solution of 5-bromo-2-(1-pentynyl)aniline (142) (1.4 g, 5.9 mmol) in anhydrous toluene (20 mL)
and the reaction mixture was heated at reflux for 3 h. The reaction mixture was allowed to cool
to room temperature, quenched with H2O (100 mL) and extracted with CH2Cl2 (3 X 50 mL). The
combined organic portion was washed with H2O (3 x 70 mL), dried (Na2SO4) and the solvent
was evaporated under reduced pressure to afford a crude product which after recrystallization
from hexanes yielded 1.2 g (87%) of 143 as yellow crystals: mp 85-86 °C; 1H NMR (CDCl3) δ
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0.93 (t, 3H, CH3), 1.67 (m, 2H, CH2), 2.64 (t, 2H, CH2), 6.14 (s, 1H, Ar), 7.09 (dd, J = 8.4, 1.7
Hz, 1H, Ar), 7.29 (d, J = 8.4 Hz, 1H, Ar), 7.36 (s, 1H, Ar), 7.77 (br s, 1H, indolic NH).
Compound 143 was employed in preparation of compound 138.

N-Methyl-5,6-Dibromo-2-(1,1-dimethylallyl)tryptamine Hydrochloride (144). Gaseous HCl
was bubbled through a solution of tert-butyl-2-(5,6-dibromo-2-(1,1-dimethylallyl)-1H-indol-3yl)ethyl-N-methylcarbamate (151) (280 mg) in dry anhydrous EtOAc (10 mL) at 0 °C. The
reaction mixture was allowed to stir for 24 h and the solvent was evaporated to yield a white
solid which upon recrystallization from i-PrOH, yielded 60 mg (25%) of 144 as white crystals:
mp 238-239 °C; 1H NMR (DMSO-d6) δ 1.52 (s, 6H, CH3), 2.62 (s, 3H NH(CH3), 2.95 (t, 2H,
CH2), 3.09 (t, 2H, CH2), 5.10-5.16 (m, 2H, CH2), 6.12-6.19 (m, 1H, CH), 7.71 (s, 1H, Ar), 8.03
(s, 1H, Ar), 8.81 (br s, 1H, NH+ aliphatic), 10.98 (s, 1H, indolic NH). Anal. Calcd for
(C16H20Br2N2·HCl) C, 44.01; H, 4.85; N, 6.35. Found: C, 43.99; H, 4.74; N, 6.35.

Methyl-5,6-dibromo-1H-indolyl-3-carboxylate (146). Compound 146 was prepared as
described.194 Liquid Br2 (3.9 mL, 75 mmol) was added to a suspension of commercially available
methyl-1H-indolyl-3-carboxylate (145) (6 g, 34 mmol) in HOAc (45 mL) and the reaction
mixture was allowed to stir at room temperature for 16 h. The reaction mixture was filtered and
the precipitate was collected and washed with EtOH (2 x 50 mL) and petroleum ether (50 mL),
and dried in air to yield 7.7 g (68%) of 146 as a grey powder: mp 246-252 °C (lit.194 mp 237-242
°C); 1H NMR (CDCl3) δ 3.85 (s, 3H, CH3), 7.65 (s, 1H, Ar), 7.83 (s, 1H, Ar), 8.39 (s, 1H, Ar),
8.45 (br s, 1H, indolic NH).
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5,6-Dibromo-1H-indole (147). Compound 146 was prepared as described.194 Methyl-5,6dibromo-1H-indolyl-3-carboxylate (146) (5 g, 15 mmol), KOH (3 g, 54 mmol), MeOH (9 mL),
THF (9 mL) and H2O (4 mL) was added to a 50 mL glass tube. The solution was microwave
(100 W, 150 °C, 1 h) irradiated. The reaction mixture was diluted with CH2Cl2 (50 mL) and the
organic phase was separated and washed with H2O (2 x 50 mL), and dried (Na2SO4) to obtain a
crude brown solid which, on recrystallization with toluene/hexanes, yielded 3.2 g (68%) of 147
as buff-colored flakes: mp 150-152 °C (lit.192 mp 150-151°C); 1H NMR (CDCl3) δ 6.41 (m, 1H,
Ar), 7.14 (t, 1H, Ar), 7.63 (s, 1H, Ar), 7.84 (s, 1H, Ar), 8.09 (br s, 1H, indolic NH).

N-Methyl-5,6-dibromo-1H-indol-3-glyoxylamide (148). Compound

148 was prepared

according to a literature procedure for a similar compound.201 A solution of 5,6-dibromo-1Hindole (147) (1.8 g, 6.6 mmol) in anhydrous Et2O (20 mL) in a 2-neck flask was chilled to -5 °C
and N2 was bubbled in for 5 min. Oxalyl chloride (1.2 mL, 13.1 mmol) was added in a dropwise
manner and the reaction mixture was heated at reflux for 5 h. The reaction mixture was filtered
and the precipitate was washed with cold Et2O (2 x 10 mL) and air dried. The solid was added to
cold methylamine (40% in H2O, 25 mL) and the solution was allowed to stir at room temperature
overnight. The reaction mixture was diluted with H2O (100 mL) and the residue was collected by
filtration and air dried to yield 1.8 g (76%) of 148 as a buff-colored solid: mp 263-264 °C
(decomp); 1H NMR (DMSOd6) δ 2.75 (s, 3H, CH3), 7.14 (s, 1H, Ar), 7.63 (s, 1H, Ar), 7.84 (s,
1H, Ar), 8.09 (br s, 1H, indolic NH).
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N-Methyl-5,6-Dibromotryptamine (149). Borane dimethylsulfide (10.1M in THF, 1.4 mL, 14
mmol) was added in a dropwise manner at 60 °C to a stirred solution of N-methyl-5,6-dibromo1H-indol-3-glyoxylamide (148) (1.7 g, 5 mmol) in dry THF (35 mL). The reaction mixture was
allowed to stir at reflux for 7 h, cooled to 0 °C, quenched with H2O (4 mL), acidified with HCl
(2N, to pH 1), and heated at reflux for 1 h. The THF was evaporated under reduced pressure and
the remaining aqueous portion was diluted with H2O (100 mL), basified with NaOH (3M, to pH
9) and extracted with CH2Cl2 (3 x 50 mL). The combined organic portions were washed with
H2O (2 x 50 mL), dried (Na2SO4), and solvent was evaporated under reduced pressure to yield
1.5 g (96%) of 149 as a white solid: mp 107-111 °C; 1H NMR (CDCl3) δ 2.30 (s, 3H, NHCH3),
2.71 (t, 2H, CH2), 2.76 (t, 2H, CH2), 7.25 (s, 1H, Ar), 7.73 (s, 1H, Ar), 7.91 (s, 1H, Ar), 11.09 (br
s, 1H, indolic NH). The material was used without further purification for synthesis of compound
150.

tert-Butyl-2-(5,6-dibromo-1H-indol-3-yl)ethyl-N-methylcarbamate (150). Compound 150
was prepared based on a literature procedure for similar compound.9 Triethylamine (0.5 g, 4.5
mmol) and di-tert-butyl dicarbonate (1.0 g, 4.5 mmol) were added to a solution of 5,6-dibromo1H-indol-3-yl-N-methylethanamine (149) (1.5 g, 4.5 mmol) in DMF (20 mL) and the solution
was allowed to stir at room temperature for 24 h. The reaction mixture was quenched with H 2O
(40 mL) and extracted with EtOAc (3 x 40 mL). The combined organic portions were washed
with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4) and the solvent was evaporated under
reduced pressure to yield a crude residue. The residue was purified by column chromatography
(silica gel; hexanes/EtOAc; 100:1 to 3:1) to afford 1.2 g (60%) of 150 as a white foam: 1H NMR
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(CDCl3) δ 1.40 (s, 9H, CH3), 2.84 (s, 3H, NHCH3), 2.91 (t, 2H, CH2), 3.48 (t, 2H, CH2), 7.01 (s,
1H, Ar), 7.66 (s, 1H, Ar), 7.87 (s, 1H, Ar), 8.07 (br s, 1H, indolic NH).

tert-Butyl-2-(5,6-dibromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-methylcarbamate
(151). Compound 151 was prepared based on a literature procedure of a similar compound.198
tert-Butyl hypochlorite (0.3 g, 3.0 mmol) was added to a solution of tert-butyl-2-(5,6-dibromo1H-indol-3-yl)ethyl-N-methylcarbamate (150) (1.0 g, 2.3 mmol) and Et3N (0.3 g, 3 mmol) in
THF (25 mL) at -78 oC and the solution was allowed to stir for 90 min. Freshly prepared prenyl
9-BBN179 (4.6 mmol) was added in a dropwise manner over 20 min while maintaining the
temperature at -55 oC. The reaction mixture was allowed to warm to room temperature and
stirred for an additional 6 h. Sodium hydroxide (3M, 10 mL) and H2O2 (30%, 10 mL) were
added in a dropwise manner, and reaction mixture was stirred for an additional 2 h, and then
diluted with Et2O (100 mL). The organic layer was washed with H2O (3 x 60 mL), brine (80
mL), dried (Na2SO4), and evaporated under reduced pressure to yield a crude residue. The
residue was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 10:1) to
afford 0.4 g (33%) of 151 as a white foam: mp 55-57 °C; 1H NMR (CDCl3) δ 1.44 (s, 9H, CH3),
2.71-2.90 (m, 5H, CH2, CH3), 3.29 (m, 2H, CH2), 5.07-5.12 (m, 2H, CH2), 5.99-6.06 (m, 1H,
CH), 7.49 (s, 1H, Ar), 7.72 (s, 1H, Ar), 7.82 (br s, 1H, indolic NH). Compound 151 was
employed in the preparation of compound 144.
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B. Electrophysiology
The electrophysiological studies were performed in Dr. Shulte’s lab at the University of Alaska
(Fairbanks). The cDNA sequences for the human 4 (NCBI Reference Sequence:
NM_000744.5) and 2 (NCBI Reference Sequence: NM_000748.2) nACh receptors were used
for the synthesis of the cDNA for for each of the subunits (performed in Burlingame, CA). The
cDNA for the 2 subunit was inserted in the pcDNA3.1/Zero (+) expression vector and the 4
subunit was inserted in the pcDNA3.1/hygromyocin expression vector (both the vectors obtained
from Invitrogen, Carlsbad, CA). Ovarian lobes from the Xenopus laevis frogs were obtained by
surgically removing and washing twice with Barth’s buffer (Ca2+ free) (82.5 mM NaCl/2.5 mM
KCl/1 mM MgCl2/5 mM HEPES, pH 7.4). The oocytes were then shaken with collagenase (1.5
mg/mL, Sigma Type II obtained from Sigma-Aldrich) for 1 h at 20-25 °C. Stage IV oocytes were
selected for the microinjection and injected with 50 nL of the appropriate ratios of the synthetic
cRNA transcripts of 4 and 2 subunits (prepared using mMESSAGE mMACHINE High Yield
Capped RNA Transcription Kit obtained from Ambion, TX) at a concentration of 0.2 ng/mL.
Later the injected oocytes were incubated at 19 °C for 24-72 h before being used for the voltage
clamp experiments. The incubated oocytes were used for recordings were obtained using an
automated two-electrode voltage-clamp system incorporating an OC-725C oocyte amplifier
(obtained from Warner Instruments, CT) which was coupled to a computerized data acquisition
system; Datapac 2000 (obtained from RUN technologies) and an autoinjection system (Gilson)
for the injection of solution of test compounds. The electrodes used for recording and the one
providing the current (with a resistance of 1-4 M) were filled with 3 M KCl solution. The
oocytes were held in a vertical flow chamber of 200 L volume and perfused with ND-96 buffer
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(96 mM NaCl/ 2 mM KCl/ 1.8 mM CaCl2/ 1 mM MgCl2/5 mM HEPES; pH 7.4) at a rate of 20
mL/min. The test compound solution (using ND-96 buffer) were injected into the chamber (20
mL/min) using the autoinjection system. The test compounds were applied alone or co-applied
with 100 M (EC75) of ACh.9 All assays were performed at least in triplicate. The EC50 values
were calculated by fitting the dose-response curve by non-linear cruve fitting. Built-in algorithms
of GraphPad prism (San Diego, CA) was used for the calculation. For IC50 determination doseresponse curve data were fit to a single-site competition model. For compounds with the biphasic
dose-response curve the data were fit to a hormetic model which generates the EC50 and IC50
simultaneously. Data was expressed in  SEM or 95% confidence limits. All statistical
differences were tested using student’s t-test with the P values (P  0.05 representing significant
statistical difference).9,167,216
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